

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100

(43) International Publication Date  
28 March 2002 (28.03.2002)

PCT

(10) International Publication Number  
WO 02/24947 A2

(51) International Patent Classification<sup>7</sup>: C12Q 1/68,  
G01N 33/574, A61P 35/00, A61K 31/70

Allen, D. [CA/CA]; 1633 West 65th Avenue, Vancouver,  
British Columbia V6P 2R2 (CA).

(21) International Application Number: PCT/IB01/02237

(74) Agents: ROBINSON, Christopher, J. et al.; FETHER-  
STONHAUGH & CO, Suite 2200, 650 West Georgia  
Street, Box 11560, Vancouver, British Columbia V6B 4N8  
(CA).

(22) International Filing Date:  
20 September 2001 (20.09.2001)

(25) Filing Language: English

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,  
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,  
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,  
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,  
MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI,  
SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU,  
ZA, ZW.

(26) Publication Language: English

(30) Priority Data:  
60/233,999 20 September 2000 (20.09.2000) US  
60/237,423 2 October 2000 (02.10.2000) US  
60/237,419 2 October 2000 (02.10.2000) US  
60/238,558 4 October 2000 (04.10.2000) US  
60/290,555 10 May 2001 (10.05.2001) US

(84) Designated States (*regional*): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian  
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European  
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,  
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,  
CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD,  
TG).

(71) Applicants (*for all designated States except US*):  
KINETEK PHARMACEUTICALS, INC. [CA/CA];  
1200 West 73rd Avenue, Suite 850, Vancouver, British  
Columbia V6P 6G5 (CA). THE UNIVERSITY OF  
BRITISH COLUMBIA [CA/CA]; The UBC Univer-  
sity-Industry Liaison Office, IRC Room 331, 2194 Health  
Sciences Mail, Vancouver, British Columbia V6T 1Z3  
(CA).

Published:  
— without international search report and to be republished  
upon receipt of that report

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): YOGANATHAN,  
Thillainathan [CA/CA]; 7111 Lynnwood Drive - 5,  
Richmond, British Columbia V7C 5S9 (CA). DELANEY,

For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.

(54) Title: CANCER ASSOCIATED PROTEIN KINASES AND THEIR USES

(57) Abstract: Detection of expression of the provided protein kinase in cancers is useful as a diagnostic, for determining the effectiveness of drugs, and determining patient prognosis. The encoded polypeptides further provides a target for screening pharmaceutical agents effective in inhibiting the growth or metastasis of tumor cells.



WO 02/24947 A2

## CANCER ASSOCIATED PROTEIN KINASES AND THEIR USES

## INTRODUCTION

An accumulation of genetic changes underlies the development and progression of cancer, resulting in cells that differ from normal cells in their behavior, biochemistry, genetics, and microscopic appearance. Mutations in DNA that cause changes in the expression level of key proteins, or in the biological activity of proteins, are thought to be at the heart of cancer. For example, cancer can be triggered in part when genes that play a critical role in the regulation of cell division undergo mutations that lead to their over-expression. "Oncogenes" are involved in the dysregulation of growth that occurs in cancers.

Oncogene activity may involve protein kinases, enzymes that help regulate many cellular activities, particularly signaling from the cell membrane to the nucleus to initiate the cell's entrance into the cell cycle and to control other functions.

Oncogenes may be tumor susceptibility genes, which are typically up-regulated in tumor cells, or may be tumor suppressor genes, which are down-regulated or absent in tumor cells. Malignancies can arise when a tumor suppressor is lost and/or an oncogene is inappropriately activated. When such mutations occur in somatic cells, they result in the growth of sporadic tumors.

Hundreds of genes have been implicated in cancer, but in most cases relationships between these genes and their effects are poorly understood. Using massively parallel gene expression analysis, scientists can now begin to connect these genes into related pathways.

Phosphorylation is important in signal transduction mediated by receptors via extracellular biological signals such as growth factors or hormones. For example, many oncogenes are protein kinases, i.e. enzymes that catalyze protein phosphorylation reactions or are specifically regulated by phosphorylation. In addition, a kinase can have its activity regulated by one or more distinct protein kinases, resulting in specific signaling cascades.

Cloning procedures aided by homology searches of EST databases have accelerated the pace of discovery of new genes, but EST database searching remains an involved and onerous task. More than 1.6 million human EST sequences have been deposited in public databases, making it difficult to identify ESTs that represent new genes. Compounding the problems of scale are difficulties in detection associated with a high sequencing error rate and low sequence similarity between distant homologues.

Despite a long-felt need to understand and discover methods for regulating cells involved in various disease states, the complexity of signal transduction pathways has been a barrier to the development of products and processes for such regulation. Accordingly, there is a need in the art for improved methods for detecting and modulating the activity of such genes, and for treating diseases associated with the cancer and signal transduction pathway.

*Relevant Literature*

The use of genomic sequence in data mining for signaling proteins is discussed in Schultz et al. (2000) Nature Genetics 25:201. The MAPK protein family has been reviewed, for example by

Meskiene I, and Hirt, H. (2000) Plant Mol Biol 42(6):791-806. MAP3K has been discussed, for example, by Ing, Y.L. *et al.* (1994) Oncogene. 9: 1745-1750 and also by Courseaux, A. *et al.* (1996) Genomics, 37:354-365 Serine/threonine protein kinases have been reviewed, for example, by Cross TG, *et al.* (2000) Exp Cell Res. Apr 10;256(1):34-41.

5

#### SUMMARY OF THE INVENTION

The genetic sequences provided herein as SEQ ID NOS:1, 3, 5, 7, 9, 11 and 13 encode protein kinases that are herein shown to be over-expressed in cancer cells. Detection of expression in cancer cells is useful as a diagnostic; for determining the effectiveness and mechanism of action of therapeutic drug candidates, and for determining patient prognosis. These sequences further provides a target for screening pharmaceutical agents effective in inhibiting the growth or metastasis of tumor cells. In one embodiment of the invention, a complete nucleotide sequence of the human cDNA corresponding to the cancer associated protein kinase is provided.

10

15

#### BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 is a graph depicting the proliferation of Cos7 cells that were transfected with increasing concentrations of CaMK-X1 or vector plasmids in the presence of KCl.

Figure 2 is a graph depicting phosphorylation of CREBtide and Syntide 2 *in vitro* by CamKX1.

20

Figure 3 is a graph depicting activity of transcription factors in the presence of SGK2. AP1 and NF- $\kappa$ B activity was measured in HEK293 cells and in HEK293 cells stably transfected with SGK2.

Figure 4 is a graph depicting the activation of SGK2 (K 25 plasmid) by PDK1.

Figure 5 depicts the sequences of several DMPK isoforms.

25

#### DESCRIPTION OF THE SPECIFIC EMBODIMENTS

SEQ ID NOS:1, 3, 5, 7, 9, 11 and 13 encode protein kinases that are shown to be over-expressed in cancer cells. The encoded cancer associated protein kinases of the invention provide targets for drug screening or altering expression levels, and for determining other molecular targets in kinase signal transduction pathways involved in transformation and growth of tumor cells. Detection of over-expression in cancers provides a useful diagnostic for predicting patient prognosis and probability of drug effectiveness.

30

#### PROTEIN KINASES

35

*Mitogen Activated Protein Kinases.* The human gene sequence encoding MAP3K11, is provided as SEQ ID NO:1, and the encoded polypeptide product is provided as SEQ ID NO: 2. Dot blot analysis of probes prepared from mRNA of tumors showed that expression of MAP3K11 is consistently up-regulated in clinical samples of human tumors.

40

Many of the transduction pathways in mammalian cells that involve the sequential activation of a series of signaling proteins linking the cell surface with nuclear targets are mediated by mitogen-

activated protein kinases (MAPKs) (also called extracellular signal-regulated kinases or ERKs). In mammalian cells, three parallel MAPK pathways have been described. Generally, MAPKs are rapidly activated in response to ligand binding by both growth factor receptors that are tyrosine kinases (such as the EGF receptor) and receptors that are coupled to G proteins. Phosphorylation of tyrosine residues leads to generation of docking sites for SH2 (Src homology 2) and PTB (phosphotyrosine binding) domains of adaptor proteins. (see Lemmon *et al.* (1994) Trends Biochem Sci 19:459-63; and Pawson *et al.* (1997) Science 278:2075-80.

Mitogen-activated protein (MAP) kinases include extracellular signal-regulated protein kinase (ERK), c-Jun amino-terminal kinase (JNK), and p38 subgroups. These MAP kinase isoforms are activated by dual phosphorylation on threonine and tyrosine (Derijard *et al.* (1995) Science 267(5198):682-5). MAP3K11 is an isoform that has been described by Ing *et al.* (1994) Oncogene 9:1745-1750. It has been mapped via fluorescence in situ hybridization to 11q13.1-q13.3 (Courseaux *et al.* (1996) Genomics 37:354-365). MAP3K also shares homology, including an unusual leucine zipper-basic motif, with a family of protein kinases known as mixed lineage protein kinases.

Ing *et al.* (*supra.*) found that MAP3K contains an SH3 domain and has a long carboxy-terminal tail that exhibits proline rich motifs similar to known SH3 binding sites. SH3 domains play the role of a protein switch, which is turned on by a number of receptor-mediated signals to which it responds by changes in kinase activity and by changes in intracellular localization. It acts as part of an adapter molecule and recruits downstream proteins in a signaling pathway.

**Calmodulin Kinase.** The human gene sequence encoding CaMK-X1, which maps to chromosome 1q32.1-32.3, is provided as SEQ ID NO:3, and the encoded polypeptide product is provided as SEQ ID NO: 4. The open reading frame of the sequence is indicated in the seqlist of SEQ ID NO:3, and starts at position 70. Dot blot analysis of probes prepared from mRNA of tumors showed that expression of CaMK-X1 is consistently up-regulated in human tumor tissue.

Many of the intracellular physiological activities in mammalian cells that involve  $\text{Ca}^{++}$  as a second messenger are mediated by calmodulin (CaM). This ubiquitous  $\text{Ca}^{++}$ -binding protein has an ability to activate a variety of enzymes in a  $\text{Ca}^{++}$ -dependent manner. Among these enzymes are  $\text{Ca}^{++}$  and calmodulin-dependent cyclic-nucleotide phosphodiesterase (CaM-PDE) and the calmodulin-dependent kinases. Many of the CaM-kinases are activated by phosphorylation in addition to binding to CaM. The kinase may autophosphorylate, or be phosphorylated by another kinase as part of a "kinase cascade".

Each member of the CaM-kinase cascade has a catalytic domain adjacent to a regulatory region that contains an overlapping auto-inhibitory domain (AID) and the CaM-binding domain (CBD). An interaction between the AID and the catalytic domain maintains the kinase in an inactive conformation by preventing binding of protein substrate as well as  $\text{Mg}^{++}$ -ATP. Binding of  $\text{Ca}^{++}$ -CaM to the CBD alters the conformation of the overlapping AID such that it no longer interferes with substrate binding; the kinase is therefore active. As in the cases of other protein kinases, CaMKI has a catalytic cleft between its upper and lower lobes, which are responsible for binding  $\text{Mg}^{++}$ -ATP and

protein substrates, respectively. At the base of their catalytic clefts, many protein kinases, including CaMKI and CaMKIV, have an activation loop containing a threonine residue whose phosphorylation strongly augments kinase activity.

5           *Serum and Glucocorticoid-induced Protein Kinases (SGK)*. The human gene sequence encoding SGK2- $\alpha$  is provided as SEQ ID NO:5, and the encoded polypeptide product is provided as SEQ ID NO:6. Dot blot analysis of probes prepared from mRNA of tumors showed that expression of SGK2- $\alpha$  is consistently up-regulated in human tumor tissue.

10           SGKs actively shuttle between the nucleus and the cytoplasm in synchrony with the cell cycle. SGK was originally identified as a glucocorticoid and osmotic stress-responsive gene; two related isoforms have been termed SGK2 and SGK3. In addition, there are two splice variants of SGK2; specifically, SGK2 $\alpha$  and SGK2 $\beta$ . SGK2 $\alpha$  encodes a protein of 367 residues with a calculated molecular mass of 41.1 kDa. Although SGK 1, 2, and 3 share a high degree of sequence similarity, the mechanisms that regulate the level and activity of SGK2 and SGK3 differ significantly from those  
15           that regulate SGK1. SGK2 has a peptide specificity similar to that of protein kinase B, preferentially phosphorylating Ser and Thr residues that lie in Arg-Xaa-Arg-Xaa-Xaa-Ser/Thr motifs.

            The data provided herein demonstrate that SGK2 $\alpha$  is activated by protein dependent kinase 1. CDK1 is a catalytic subunit of a protein kinase complex, called the M-phase promoting factor, that induces entry into mitosis and is universal among eukaryotes. Lee *et al.* (1988) Nature 333: 676-679  
20           describe the regulated expression and phosphorylation of CDK1 in human and murine *in vitro* systems. Serum stimulation of human and mouse fibroblasts results in a marked increase in CDK1 transcription. Both the yeast and mammalian systems are regulated by phosphorylation of the gene product. In HeLa cells, CDK1 is the most abundant phosphotyrosine-containing protein and its phosphotyrosine content is subject to cell-cycle regulation (Draetta *et al.* (1988) Nature 336: 738-  
25           744). One site of CDK1 tyrosine phosphorylation *in vivo* is selectively phosphorylated *in vitro* by a product of the SRC gene. Taxol activates CDK1 kinase in MDA-MB-435 breast cancer cells, leading to cell cycle arrest at the G2/M phase and, subsequently, apoptosis. Chemical inhibitors of CDK1 block taxol-induced apoptosis in these cells (Yu *et al.* (1998) Molec. Cell 2:581-591). Interference in  
30           this pathway is of interest in the development of therapeutic agents that affect cell cycle arrest and apoptosis.

*G Protein coupled Receptor Kinase*. The human gene sequence encoding GRK5 is provided as SEQ ID NO:7, and the encoded polypeptide product is provided as SEQ ID NO:8. Dot blot analysis of probes prepared from mRNA of tumors showed that expression of GRK5 is consistently  
35           up-regulated in clinical samples of human tumors.

            GRKs are a family of serine/threonine kinases that induce receptor desensitization by the phosphorylation of agonist-occupied or -activated receptors. GRKs transduce the binding of extracellular ligands into intracellular signaling events. To date, seven members of the GRK family have been identified. Common features of these kinases include a centrally localized catalytic

domain of approximately 240 amino acids, which shares significant sequence identity between family members, an N-terminal domain of 161-197 amino acids, and a variable length C-terminal domain. All of the GRKs can directly interact with phospholipids either via covalent modifications such as farnesylation, palmitoylation, or via lipid binding domains such as the pleckstrin homology domain, or  
5 a polybasic domain.

GRK5 is a protein of approximately 67.7 kDa (see Kunapali and Benovic (1993) P.N.A.S. 90:5588-5592) and was identified by its homology with other members of the GRK family. It is expressed in a number of different tissues, including heart, placenta and lung. Autophosphorylation of GRK5 appears to activate the kinase (Pronin and Benovic (1997) P.N.A.S. 272:3806-3812).  
10 GRK5 is also phosphorylated by PKC, where the major sites of PKC phosphorylation are localized within the C-terminal 26 amino acids. PKC phosphorylation significantly inhibits GRK5 activity.

*Myotonic dystrophy protein kinase.* The human gene sequence encoding DM-PK, is provided as SEQ ID NO:9, and the encoded polypeptide product is provided as SEQ ID NO: 10. The  
15 sequence of additional isoforms is provided as SEQ ID NO:38 and SEQ ID NO:39. Dot blot analysis of probes prepared from mRNA of tumors showed that expression of DM-PK is consistently up-regulated in clinical samples of human tumors.

Human myotonic dystrophy protein kinase (DM-PK) is a member of a class of multidomain protein kinases that regulate cell size and shape in a variety of organisms (see Brook *et al.* (1992) Cell 68:799-808; and Fu *et al.* (1992) Science 255:1256-1258). DM-PK exhibits a novel catalytic  
20 activity similar to, but distinct from, related protein kinases such as protein kinase C and A, and the Rho kinases. Little is currently known about the general properties of DM-PK including domain function, substrate specificity, and potential mechanisms of regulation. Two forms of the kinase are expressed in muscle, where the larger form (the primary translation product) is proteolytically cleaved  
25 near the carboxy terminus to generate the smaller. Inhibitory activity of the full-length kinase has been mapped to a pseudosubstrate autoinhibitory domain at the extreme carboxy terminus of DM-PK (see Bush *et al.* (2000) Biochemistry 39:8480-90).

Shaw *et al.* (1993) Genomics 18:673-9 demonstrated that the DM-PK gene contains 15 exons distributed over about 13 kb of genomic DNA. It encodes a protein of 624 amino acids with an  
30 N-terminal domain highly homologous to cAMP-dependent serine-threonine protein kinases, an intermediate domain with a high alpha-helical content and weak similarity to various filamentous proteins, and a hydrophobic C-terminal segment. A CTG repeat is located in the 3' untranslated region of DM-PK mRNA. The unstable CTG motif is found uniquely in humans, although the flanking nucleotides are also present in mouse. The involvement of a protein kinase in myotonic dystrophy is  
35 consistent with the pivotal role of such enzymes in a wide range of biochemical and cellular pathways. The autosomal dominant nature of the disease is due to a dosage deficiency.

*Protein Kinase D2.* The human gene sequence encoding PKD2 is provided as SEQ ID NO:11, and the encoded polypeptide product is provided as SEQ ID NO:12. Dot blot analysis of

probes prepared from mRNA of tumors showed that expression of PKD2 is consistently up-regulated in clinical samples of human tumors.

PKD2 is a human serine threonine protein kinase gene (Genbank accession number NM\_016457; Sturany *et al.* (2001) *J. Biol. Chem.* 276:3310-3318). The protein sequence contains two cysteine-rich motifs at the N terminus, a pleckstrin homology domain, and a catalytic domain containing all the characteristic sequence motifs of serine protein kinases. It exhibits the strongest homology to the serine threonine protein kinases PKD/PKC $\mu$  and PKC, particularly in the duplex zinc finger-like cysteine-rich motif, in the pleckstrin homology domain and in the protein kinase domain. The mRNA of PKD2 is widely expressed in human and murine tissues. It encodes a protein with a molecular mass of 105 kDa in SDS-polyacrylamide gel electrophoresis, which is expressed in various human cell lines, including HL60 cells, which do not express PKC $\mu$ . In vivo phorbol ester binding studies demonstrated a concentration-dependent binding of [<sup>3</sup>H]phorbol 12,13-dibutyrate to PKD2. The addition of phorbol 12,13-dibutyrate in the presence of dioleoylphosphatidylserine stimulated the autophosphorylation of PKD2 in a synergistic fashion. Phorbol esters also stimulated autophosphorylation of PKD2 in intact cells. Phosphorylation of Ser876 of PKD2 correlated with the activation status of the kinase.

#### DIAGNOSTIC METHODS

Determination of the presence of any one of SEQ ID NOS:1, 3, 5, 7, 9, 11 and 13 is used in the diagnosis, typing and staging of tumors. Detection of the presence of the sequence is performed by the use of a specific binding pair member to quantitate the specific protein, DNA or RNA present in a patient sample. Generally the sample will be a biopsy or other cell sample from the tumor. Where the tumor has metastasized, blood samples may be analyzed.

#### SPECIFIC BINDING MEMBERS

In a typical assay, a tissue sample, e.g. biopsy, blood sample, *etc.* is assayed for the presence of a cancer associated kinase corresponding to SEQ ID NOS:1, 3, 5, 7, 9, 11 or 13 specific sequences by combining the sample with a SEQ ID NOS:1, 3, 5, 7, 9, 11 and 13 specific binding member, and detecting directly or indirectly the presence of the complex formed between the two members. The term "specific binding member" as used herein refers to a member of a specific binding pair, *i.e.* two molecules where one of the molecules through chemical or physical means specifically binds to the other molecule. One of the molecules will be a nucleic acid corresponding to SEQ ID NOS:1, 3, 5, 7, 9, 11 and 13 or a polypeptide encoded by the nucleic acid, which can include any protein substantially similar to the amino acid sequence provided in SEQ ID NOS:2, 4, 6, 8, 10, 12, 14, 38 or 39 or a fragment thereof; or any nucleic acid substantially similar to the nucleotide sequence provided in SEQ ID NOS:1, 3, 5, 7, 9, 11 and 13, or a fragment thereof. The complementary members of a specific binding pair are sometimes referred to as a ligand and receptor.

Binding pairs of interest include antigen and antibody specific binding pairs, peptide-MHC antigen and T cell receptor pairs; complementary nucleotide sequences (including nucleic acid

sequences used as probes and capture agents in DNA hybridization assays); kinase protein and substrate pairs; autologous monoclonal antibodies, and the like. The specific binding pairs may include analogs, derivatives and fragments of the original specific binding member. For example, an antibody directed to a protein antigen may also recognize peptide fragments, chemically synthesized peptidomimetics, labeled protein, derivatized protein, *etc.* so long as an epitope is present.

*Nucleic acid sequences.* In another embodiment of the invention, nucleic acids are used as a specific binding member. Sequences for detection are complementary to a one of the provided cancer associated kinase corresponding to SEQ ID NOS:1, 3, 5, 7, 9, 11 or 13. The nucleic acids of the invention include nucleic acids having a high degree of sequence similarity or sequence identity to one of SEQ ID NOS:1, 3, 5, 7, 9, 11 and 13. Sequence identity can be determined by hybridization under stringent conditions, for example, at 50°C or higher and 0.1XSSC (9 mM saline/0.9 mM sodium citrate). Hybridization methods and conditions are well known in the art, see, *e.g.*, U.S. patent 5,707,829. Nucleic acids that are substantially identical to the provided nucleic acid sequence, *e.g.* allelic variants, genetically altered versions of the gene, *etc.*, bind to SEQ ID NOS:1, 3, 5, 7, 9, 11 or 13 under stringent hybridization conditions.

The nucleic acids can be cDNAs or genomic DNAs, as well as fragments thereof. The term "cDNA" as used herein is intended to include all nucleic acids that share the arrangement of sequence elements found in native mature mRNA species, where sequence elements are exons and 3' and 5' non-coding regions. Normally mRNA species have contiguous exons, with the intervening introns, when present, being removed by nuclear RNA splicing, to create a continuous open reading frame encoding a polypeptide of the invention.

A genomic sequence of interest comprises the nucleic acid present between the initiation codon and the stop codon, as defined in the listed sequences, including all of the introns that are normally present in a native chromosome. It can further include the 3' and 5' untranslated regions found in the mature mRNA. It can further include specific transcriptional and translational regulatory sequences, such as promoters, enhancers, *etc.*, including about 1 kb, but possibly more, of flanking genomic DNA at either the 5' or 3' end of the transcribed region. The genomic DNA flanking the coding region, either 3' or 5', or internal regulatory sequences as sometimes found in introns, contains sequences required for proper tissue, stage-specific, or disease-state specific expression, and are useful for investigating the up-regulation of expression in tumor cells.

Probes specific to the nucleic acid of the invention can be generated using the nucleic acid sequence disclosed in SEQ ID NOS:1, 3, 5, 7, 9, 11 or 13. The probes are preferably at least about 18 nt, 25nt, 50 nt or more of the corresponding contiguous sequence of SEQ ID NOS:1, 3, 5, 7, 9, 11 or 13, and are usually less than about 2, 1, or 0.5 kb in length. Preferably, probes are designed based on a contiguous sequence that remains unmasked following application of a masking program for masking low complexity, *e.g.* BLASTX. Double or single stranded fragments can be obtained from the DNA sequence by chemically synthesizing oligonucleotides in accordance with conventional methods, by restriction enzyme digestion, by PCR amplification, *etc.* The probes can be labeled, for example, with a radioactive, biotinylated, or fluorescent tag.



The nucleic acids of the subject invention are isolated and obtained in substantial purity, generally as other than an intact chromosome. Usually, the nucleic acids, either as DNA or RNA, will be obtained substantially free of other naturally-occurring nucleic acid sequences, generally being at least about 50%, usually at least about 90% pure and are typically "recombinant," e.g., flanked by one or more nucleotides with which it is not normally associated on a naturally occurring chromosome.

The nucleic acids of the invention can be provided as a linear molecule or within a circular molecule, and can be provided within autonomously replicating molecules (vectors) or within molecules without replication sequences. Expression of the nucleic acids can be regulated by their own or by other regulatory sequences known in the art. The nucleic acids of the invention can be introduced into suitable host cells using a variety of techniques available in the art, such as transferrin polycation-mediated DNA transfer, transfection with naked or encapsulated nucleic acids, liposome-mediated DNA transfer, intracellular transportation of DNA-coated latex beads, protoplast fusion, viral infection, electroporation, gene gun, calcium phosphate-mediated transfection, and the like.

For use in amplification reactions, such as PCR, a pair of primers will be used. The exact composition of the primer sequences is not critical to the invention, but for most applications the primers will hybridize to the subject sequence under stringent conditions, as known in the art. It is preferable to choose a pair of primers that will generate an amplification product of at least about 50 nt, preferably at least about 100 nt. Algorithms for the selection of primer sequences are generally known, and are available in commercial software packages. Amplification primers hybridize to complementary strands of DNA, and will prime towards each other. For hybridization probes, it may be desirable to use nucleic acid analogs, in order to improve the stability and binding affinity. The term "nucleic acid" shall be understood to encompass such analogs.

**Antibodies.** The polypeptides of the invention may be used for the production of antibodies, where short fragments provide for antibodies specific for the particular polypeptide, and larger fragments or the entire protein allow for the production of antibodies over the surface of the polypeptide. As used herein, the term "antibodies" includes antibodies of any isotype, fragments of antibodies which retain specific binding to antigen, including, but not limited to, Fab, Fv, scFv, and Fd fragments, chimeric antibodies, humanized antibodies, single-chain antibodies, and fusion proteins comprising an antigen-binding portion of an antibody and a non-antibody protein. The antibodies may be detectably labeled, e.g., with a radioisotope, an enzyme which generates a detectable product, a green fluorescent protein, and the like. The antibodies may be further conjugated to other moieties, such as members of specific binding pairs, e.g., biotin (member of biotin-avidin specific binding pair), and the like. The antibodies may also be bound to a solid support, including, but not limited to, polystyrene plates or beads, and the like.

"Antibody specificity", in the context of antibody-antigen interactions, is a term well understood in the art, and indicates that a given antibody binds to a given antigen, wherein the binding can be inhibited by that antigen or an epitope thereof which is recognized by the antibody,

and does not substantially bind to unrelated antigens. Methods of determining specific antibody binding are well known to those skilled in the art, and can be used to determine the specificity of antibodies of the invention for a polypeptide, particularly a human polypeptide corresponding to SEQ ID NOS:2, 4, 6, 8, 10 or 12.

- 5           Antibodies are prepared in accordance with conventional ways, where the expressed polypeptide or protein is used as an immunogen, by itself or conjugated to known immunogenic carriers, e.g. KLH, pre-S HBsAg, other viral or eukaryotic proteins, or the like. Various adjuvants may be employed, with a series of injections, as appropriate. For monoclonal antibodies, after one or more booster injections, the spleen is isolated, the lymphocytes immortalized by cell fusion, and then  
10           screened for high affinity antibody binding. The immortalized cells, *i.e.* hybridomas, producing the desired antibodies may then be expanded. For further description, see *Monoclonal Antibodies: A Laboratory Manual*, Harlow and Lane eds., Cold Spring Harbor Laboratories, Cold Spring Harbor, New York, 1988. If desired, the mRNA encoding the heavy and light chains may be isolated and mutagenized by cloning in *E. coli*, and the heavy and light chains mixed to further enhance the  
15           affinity of the antibody. Alternatives to *in vivo* immunization as a method of raising antibodies include binding to phage display libraries, usually in conjunction with *in vitro* affinity maturation.

#### METHODS FOR QUANTITATION OF NUCLEIC ACIDS

- Nucleic acid reagents derived from the sequence of SEQ ID NOS:1, 3, 5, 7, 9, 11 or 13 are  
20           used to screen patient samples, e.g. biopsy-derived tumors, inflammatory samples such as arthritic synovium, *etc.*, for amplified DNA in the cell, or increased expression of the corresponding mRNA or protein. DNA-based reagents are also designed for evaluation of chromosomal loci implicated in certain diseases e.g. for use in loss-of-heterozygosity (LOH) studies, or design of primers based on coding sequences.

- 25           The polynucleotides of the invention can be used to detect differences in expression levels between two cells, e.g., as a method to identify abnormal or diseased tissue in a human. The tissue suspected of being abnormal or diseased can be derived from a different tissue type of the human, but preferably it is derived from the same tissue type; for example, an intestinal polyp or other abnormal growth should be compared with normal intestinal tissue. The normal tissue can be the  
30           same tissue as that of the test sample, or any normal tissue of the patient, especially those that express the polynucleotide-related gene of interest (e.g., brain, thymus, testis, heart, prostate, placenta, spleen, small intestine, skeletal muscle, pancreas, and the mucosal lining of the colon, etc.). A difference between the polynucleotide-related gene, mRNA, or protein in the two tissues which are compared, for example, in molecular weight, amino acid or nucleotide sequence, or  
35           relative abundance, indicates a change in the gene, or a gene which regulates it, in the tissue of the human that was suspected of being diseased.

- The subject nucleic acid and/or polypeptide compositions may be used to analyze a patient sample for the presence of polymorphisms associated with a disease state. Biochemical studies may be performed to determine whether a sequence polymorphism in a coding region or control  
40           regions is associated with disease, particularly cancers and other growth abnormalities. Diseases of

interest may also include other hyperproliferative disorders. Disease associated polymorphisms may include deletion or truncation of the gene, mutations that alter expression level, that affect the binding activity of the protein, the kinase activity domain, *etc.*

Changes in the promoter or enhancer sequence that may affect expression levels of can be compared to expression levels of the normal allele by various methods known in the art. Methods for determining promoter or enhancer strength include quantitation of the expressed natural protein; insertion of the variant control element into a vector with a reporter gene such as beta-galactosidase, luciferase, chloramphenicol acetyltransferase, *etc.* that provides for convenient quantitation; and the like.

A number of methods are available for analyzing nucleic acids for the presence of a specific sequence, *e.g.* upregulated expression. Cells that express SEQ ID NOS:1, 3, 5, 7, 9, 11 or 13 may be used as a source of mRNA, which may be assayed directly or reverse transcribed into cDNA for analysis. The nucleic acid may be amplified by conventional techniques, such as the polymerase chain reaction (PCR), to provide sufficient amounts for analysis. The use of the polymerase chain reaction is described in Saiki *et al.* (1985) Science 239:487, and a review of techniques may be found in Sambrook, *et al.* Molecular Cloning: A Laboratory Manual, CSH Press 1989, pp.14.2-14.33.

A detectable label may be included in an amplification reaction. Suitable labels include fluorochromes, *e.g.* fluorescein isothiocyanate (FITC), rhodamine, Texas Red, phycoerythrin, allophycocyanin, 6-carboxyfluorescein (6-FAM), 2,7-dimethoxy-4,5-dichloro-6-carboxyfluorescein (JOE), 6-carboxy-X-rhodamine (ROX), 6-carboxy-2,4,7,4,7-hexachlorofluorescein (HEX), 5-carboxyfluorescein (5-FAM) or N,N,N,N-tetramethyl-6-carboxyrhodamine (TAMRA), radioactive labels, *e.g.*  $^{32}\text{P}$ ,  $^{35}\text{S}$ ,  $^3\text{H}$ ; *etc.* The label may be a two stage system, where the amplified DNA is conjugated to biotin, haptens, *etc.* having a high affinity binding partner, *e.g.* avidin, specific antibodies, *etc.*, where the binding partner is conjugated to a detectable label. The label may be conjugated to one or both of the primers. Alternatively, the pool of nucleotides used in the amplification is labeled, so as to incorporate the label into the amplification product.

The sample nucleic acid, *e.g.* amplified or cloned fragment, is analyzed by one of a number of methods known in the art. Probes may be hybridized to northern or dot blots, or liquid hybridization reactions performed. The nucleic acid may be sequenced by dideoxy or other methods, and the sequence of bases compared to a wild-type sequence. Single strand conformational polymorphism (SSCP) analysis, denaturing gradient gel electrophoresis (DGGE), and heteroduplex analysis in gel matrices are used to detect conformational changes created by DNA sequence variation as alterations in electrophoretic mobility. Fractionation is performed by gel or capillary electrophoresis, particularly acrylamide or agarose gels.

Arrays provide a high throughput technique that can assay a large number of polynucleotides in a sample. In one aspect of the invention, an array is constructed comprising one or more of SEQ ID NOS:1, 3, 5, 7, 9, 11 and 13, preferably comprising all of these sequences, which array may further comprise other sequences known to be up- or down-regulated in tumor cells. This technology can be used as a tool to test for differential expression.

A variety of methods of producing arrays, as well as variations of these methods, are known in the art and contemplated for use in the invention. For example, arrays can be created by spotting polynucleotide probes onto a substrate (e.g., glass, nitrocellulose, *etc.*) in a two-dimensional matrix or array having bound probes. The probes can be bound to the substrate by either covalent bonds or by non-specific interactions, such as hydrophobic interactions. Samples of nucleic acids can be detectably labeled (e.g., using radioactive or fluorescent labels) and then hybridized to the probes. Double stranded nucleic acids, comprising the labeled sample polynucleotides bound to probe nucleic acids, can be detected once the unbound portion of the sample is washed away. Alternatively, the nucleic acids of the test sample can be immobilized on the array, and the probes detectably labeled.

Techniques for constructing arrays and methods of using these arrays are described in, for example, Schena *et al.* (1996) Proc Natl Acad Sci U S A. **93**(20):10614-9; Schena *et al.* (1995) Science **270**(5235):467-70; Shalon *et al.* (1996) Genome Res. **6**(7):639-45, USPN 5,807,522, EP 799 897; WO 97/29212; WO 97/27317; EP 785 280; WO 97/02357; USPN 5,593,839; USPN 5,578,832; EP 728 520; USPN 5,599,695; EP 721 016; USPN 5,556,752; WO 95/22058; and USPN 5,631,734.

Arrays can be used to, for example, examine differential expression of genes and can be used to determine gene function. For example, arrays can be used to detect differential expression of SEQ ID NOS:1, 3, 5, 7, 9, 11 or 13, where expression is compared between a test cell and control cell (e.g., cancer cells and normal cells). High expression of a particular message in a cancer cell, which is not observed in a corresponding normal cell, indicates a cancer specific gene product. Exemplary uses of arrays are further described in, for example, Pappalardo *et al.* (1998) Sem. Radiation Oncol. **8**:217; and Ramsay. (1998) Nature Biotechnol. **16**:40. Furthermore, many variations on methods of detection using arrays are well within the skill in the art and within the scope of the present invention. For example, rather than immobilizing the probe to a solid support, the test sample can be immobilized on a solid support which is then contacted with the probe.

#### POLYPEPTIDE ANALYSIS

Screening for expression of the subject sequences may be based on the functional or antigenic characteristics of the protein. Protein truncation assays are useful in detecting deletions that may affect the biological activity of the protein. Various immunoassays designed to detect polymorphisms in proteins encoded by SEQ ID NOS:1, 3, 5, 7, 9, 11 or 13 may be used in screening. Where many diverse genetic mutations lead to a particular disease phenotype, functional protein assays have proven to be effective screening tools. The activity of the encoded protein in kinase assays, *etc.*, may be determined by comparison with the wild-type protein.

A sample is taken from a patient with cancer. Samples, as used herein, include biological fluids such as blood; organ or tissue culture derived fluids; *etc.* Biopsy samples or other sources of carcinoma cells are of particular interest, e.g. tumor biopsy, *etc.* Also included in the term are derivatives and fractions of such cells and fluids. The number of cells in a sample will generally be at least about  $10^3$ , usually at least  $10^4$ , and may be about  $10^5$  or more. The cells may be dissociated, in

the case of solid tissues, or tissue sections may be analyzed. Alternatively a lysate of the cells may be prepared.

Detection may utilize staining of cells or histological sections, performed in accordance with conventional methods. The antibodies or other specific binding members of interest are added to the cell sample, and incubated for a period of time sufficient to allow binding to the epitope, usually at least about 10 minutes. The antibody may be labeled with radioisotopes, enzymes, fluorescers, chemiluminescers, or other labels for direct detection. Alternatively, a second stage antibody or reagent is used to amplify the signal. Such reagents are well known in the art. For example, the primary antibody may be conjugated to biotin, with horseradish peroxidase-conjugated avidin added as a second stage reagent. Final detection uses a substrate that undergoes a color change in the presence of the peroxidase. The absence or presence of antibody binding may be determined by various methods, including flow cytometry of dissociated cells, microscopy, radiography, scintillation counting, etc.

An alternative method for diagnosis depends on the *in vitro* detection of binding between antibodies and the cancer associated kinase corresponding to SEQ ID NOS:1, 3, 5, 7, 9, 11 or 13 in a lysate. Measuring the concentration of the target protein in a sample or fraction thereof may be accomplished by a variety of specific assays. A conventional sandwich type assay may be used. For example, a sandwich assay may first attach specific antibodies to an insoluble surface or support. The particular manner of binding is not crucial so long as it is compatible with the reagents and overall methods of the invention. They may be bound to the plates covalently or non-covalently, preferably non-covalently.

The insoluble supports may be any compositions to which polypeptides can be bound, which is readily separated from soluble material, and which is otherwise compatible with the overall method. The surface of such supports may be solid or porous and of any convenient shape. Examples of suitable insoluble supports to which the receptor is bound include beads, e.g. magnetic beads, membranes and microtiter plates. These are typically made of glass, plastic (e.g. polystyrene), polysaccharides, nylon or nitrocellulose. Microtiter plates are especially convenient because a large number of assays can be carried out simultaneously, using small amounts of reagents and samples.

Patient sample lysates are then added to separately assayable supports (for example, separate wells of a microtiter plate) containing antibodies. Preferably, a series of standards, containing known concentrations of the test protein is assayed in parallel with the samples or aliquots thereof to serve as controls. Preferably, each sample and standard will be added to multiple wells so that mean values can be obtained for each. The incubation time should be sufficient for binding, generally, from about 0.1 to 3 hr is sufficient. After incubation, the insoluble support is generally washed of non-bound components. Generally, a dilute non-ionic detergent medium at an appropriate pH, generally 7-8, is used as a wash medium. From one to six washes may be employed, with sufficient volume to thoroughly wash non-specifically bound proteins present in the sample.

After washing, a solution containing a second antibody is applied. The antibody will bind to one of the proteins encoded by SEQ ID NOS:1, 3, 5, 7, 9, 11 or 13 with sufficient specificity such that

it can be distinguished from other components present. The second antibodies may be labeled to facilitate direct, or indirect quantification of binding. Examples of labels that permit direct measurement of second receptor binding include radiolabels, such as  $^3\text{H}$  or  $^{125}\text{I}$ , fluorescers, dyes, beads, chemiluminescers, colloidal particles, and the like. Examples of labels that permit indirect measurement of binding include enzymes where the substrate may provide for a colored or fluorescent product. In a preferred embodiment, the antibodies are labeled with a covalently bound enzyme capable of providing a detectable product signal after addition of suitable substrate. Examples of suitable enzymes for use in conjugates include horseradish peroxidase, alkaline phosphatase, malate dehydrogenase and the like. Where not commercially available, such antibody-enzyme conjugates are readily produced by techniques known to those skilled in the art. The incubation time should be sufficient for the labeled ligand to bind available molecules. Generally, from about 0.1 to 3 hr is sufficient, usually 1 hr sufficing.

After the second binding step, the insoluble support is again washed free of non-specifically bound material, leaving the specific complex formed between the target protein and the specific binding member. The signal produced by the bound conjugate is detected by conventional means. Where an enzyme conjugate is used, an appropriate enzyme substrate is provided so a detectable product is formed.

Other immunoassays are known in the art and may find use as diagnostics. Ouchterlony plates provide a simple determination of antibody binding. Western blots may be performed on protein gels or protein spots on filters, using a detection system specific for the cancer associated kinase corresponding to SEQ ID NOS:1, 3, 5, 7, 9, 11 or 13 as desired, conveniently using a labeling method as described for the sandwich assay.

In some cases, a competitive assay will be used. In addition to the patient sample, a competitor to the targeted protein is added to the reaction mix. The competitor and the cancer associated kinase corresponding to SEQ ID NOS:1, 3, 5, 7, 9, 11 or 13 compete for binding to the specific binding partner. Usually, the competitor molecule will be labeled and detected as previously described, where the amount of competitor binding will be proportional to the amount of target protein present. The concentration of competitor molecule will be from about 10 times the maximum anticipated protein concentration to about equal concentration in order to make the most sensitive and linear range of detection.

In some embodiments, the methods are adapted for use *in vivo*, e.g., to locate or identify sites where cancer cells are present. In these embodiments, a detectably-labeled moiety, e.g., an antibody, which is specific for the protein encoded by one of SEQ ID NOS:1, 3, 5, 7, 9, 11 or 13 is administered to an individual (e.g., by injection), and labeled cells are located using standard imaging techniques, including, but not limited to, magnetic resonance imaging, computed tomography scanning, and the like. In this manner, cancer cells are differentially labeled.

The detection methods can be provided as part of a kit. Thus, the invention further provides kits for detecting the presence of an mRNA corresponding to SEQ ID NOS:1, 3, 5, 7, 9, 11 or 13, and/or a polypeptide encoded thereby, in a biological sample. Procedures using these kits can be performed by clinical laboratories, experimental laboratories, medical practitioners, or private

individuals. The kits of the invention for detecting a polypeptide comprise a moiety that specifically binds the polypeptide, which may be a specific antibody. The kits of the invention for detecting a nucleic acid comprise a moiety that specifically hybridizes to such a nucleic acid. The kit may optionally provide additional components that are useful in the procedure, including, but not limited to, buffers, developing reagents, labels, reacting surfaces, means for detection, control samples, standards, instructions, and interpretive information.

#### SAMPLES FOR ANALYSIS

Sample of interest include tumor tissue, e.g. excisions, biopsies, blood samples where the tumor is metastatic, etc. Of particular interest are solid tumors, e.g. carcinomas, and include, without limitation, tumors of the liver and colon. Liver cancers of interest include hepatocellular carcinoma (primary liver cancer). Also called hepatoma, this is the most common form of primary liver cancer. Chronic infection with hepatitis B and C increases the risk of developing this type of cancer. Other causes include cancer-causing substances, alcoholism, and chronic liver cirrhosis. Other liver cancers of interest for analysis by the subject methods include hepatocellular adenoma, which are benign tumors occurring most often in women of childbearing age; hemangioma, which are a type of benign tumor comprising a mass of abnormal blood vessels, cholangiocarcinoma, which originates in the lining of the bile channels in the liver or in the bile ducts; hepatoblastoma, which is common in infants and children; angiosarcoma, which is a rare cancer that originates in the blood vessels of the liver; and bile duct carcinoma and liver cysts. Cancers originating in the lung, breast, colon, pancreas and stomach and blood cells commonly are found in the liver after they become metastatic.

Also of interest are colon cancers. Types of polyps of the colon and rectum include polyps, which are any mass of tissue that arises from the bowel wall and protrudes into the lumen. Polyps may be sessile or pedunculated and vary considerably in size. Such lesions are classified histologically as tubular adenomas, tubulovillous adenomas (villoglandular polyps), villous (papillary) adenomas (with or without adenocarcinoma), hyperplastic polyps, hamartomas, juvenile polyps, polypoid carcinomas, pseudopolyps, lipomas, leiomyomas, or other rarer tumors.

#### SCREENING METHODS

*Target Screening.* Reagents specific for SEQ ID NOS:1, 3, 5, 7, 9, 11 or 13 are used to identify targets of the encoded protein in tumor cells. For example, one of the nucleic acid coding sequences may be introduced into a tumor cell using an inducible expression system. Suitable positive and negative controls are included. Transient transfection assays, e.g. using adenovirus vectors, may be performed. The cell system allows a comparison of the pattern of gene expression in transformed cells with or without expression of the kinase. Alternatively, phosphorylation patterns after induction of expression are examined. Gene expression of putative target genes may be monitored by Northern blot or by probing microarrays of candidate genes with the test sample and a negative control where gene expression of the kinase is not induced. Patterns of phosphorylation may be monitored by incubation of the cells or lysate with labeled phosphate, followed by 1 or 2

dimensional protein gel analysis, and identification of the targets by MALDI, micro-sequencing, western blot analysis, *etc.*, as known in the art.

Some of the potential target genes of the subject cancer associated kinase corresponding to SEQ ID NOS:1, 3, 5, 7, 9, 11 or 13 identified by this method will be secondary or tertiary in a complex cascade of gene expression or signaling. To identify primary targets of the subject kinase activation, expression or phosphorylation will be examined early after induction of expression (within 1-2 hours) or after blocking later steps in the cascade with cycloheximide.

Target genes or proteins identified by this method may be analyzed for expression in primary patient samples as well. The data for the subject cancer associated kinase corresponding to SEQ ID NOS:1, 3, 5, 7, 9, 11 or 13 and target gene expression may be analyzed using statistical analysis to establish a correlation.

*Compound Screening.* The availability of a number of components in signaling pathways allows *in vitro* reconstruction of the pathway, and/or assessment of kinase action on targets. Two or more of the components may be combined *in vitro*, and the behavior assessed in terms of activation of transcription of specific target sequences; modification of protein components, *e.g.* proteolytic processing, phosphorylation, methylation, *etc.*; ability of different protein components to bind to each other *etc.* The components may be modified by sequence deletion, substitution, *etc.* to determine the functional role of specific domains.

Compound screening may be performed using an *in vitro* model, a genetically altered cell or animal, or purified protein corresponding to any one of SEQ ID NOS:1, 3, 5, 7, 9, 11 or 13. One can identify ligands or substrates that bind to, modulate or mimic the action of the encoded polypeptide. Areas of investigation include the development of treatments for hyper-proliferative disorders, *e.g.* cancer, restenosis, osteoarthritis, metastasis, *etc.*

The polypeptides include those encoded by SEQ ID NOS:1, 3, 5, 7, 9, 11 or 13, as well as nucleic acids that, by virtue of the degeneracy of the genetic code, are not identical in sequence to the disclosed nucleic acids, and variants thereof. Variant polypeptides can include amino acid (aa) substitutions, additions or deletions. The amino acid substitutions can be conservative amino acid substitutions or substitutions to eliminate non-essential amino acids, such as to alter a glycosylation site, a phosphorylation site or an acetylation site, or to minimize misfolding by substitution or deletion of one or more cysteine residues that are not necessary for function. Variants can be designed so as to retain or have enhanced biological activity of a particular region of the protein (*e.g.*, a functional domain and/or, where the polypeptide is a member of a protein family, a region associated with a consensus sequence). Variants also include fragments of the polypeptides disclosed herein, particularly biologically active fragments and/or fragments corresponding to functional domains. Fragments of interest will typically be at least about 10 aa to at least about 15 aa in length, usually at least about 50 aa in length, and can be as long as 300 aa in length or longer, but will usually not exceed about 500 aa in length, where the fragment will have a contiguous stretch of amino acids that is identical to a polypeptide encoded by SEQ ID NOS:1, 3, 5, 7, 9, 11 or 13, or a homolog thereof.



Transgenic animals or cells derived therefrom are also used in compound screening. Transgenic animals may be made through homologous recombination, where the normal locus corresponding to SEQ ID NOS:1, 3, 5, 7, 9, 11 or 13 is altered. Alternatively, a nucleic acid construct is randomly integrated into the genome. Vectors for stable integration include plasmids, retroviruses and other animal viruses, YACs, and the like. A series of small deletions and/or substitutions may be made in the coding sequence to determine the role of different exons in kinase activity, oncogenesis, signal transduction, *etc.* Of interest is the use of SEQ ID NOS:1, 3, 5, 7, 9, 11 or 13 to construct transgenic animal models for cancer, where expression of the corresponding kinase is specifically reduced or absent. Specific constructs of interest include antisense sequences that block expression of the targeted gene and expression of dominant negative mutations. A detectable marker, such as lac Z may be introduced into the locus of interest, where up-regulation of expression will result in an easily detected change in phenotype. One may also provide for expression of the target gene or variants thereof in cells or tissues where it is not normally expressed or at abnormal times of development. By providing expression of the target protein in cells in which it is not normally produced, one can induce changes in cell behavior, *e.g.* in the control of cell growth and tumorigenesis.

Compound screening identifies agents that modulate function of the cancer associated kinase corresponding to SEQ ID NOS:1, 3, 5, 7, 9, 11 or 13. Agents that mimic its function are predicted to activate the process of cell division and growth. Conversely, agents that inhibit function may inhibit transformation. Of particular interest are screening assays for agents that have a low toxicity for human cells. A wide variety of assays may be used for this purpose, including labeled *in vitro* protein-protein binding assays, electrophoretic mobility shift assays, immunoassays for protein binding, and the like. Knowledge of the 3-dimensional structure of the encoded protein, derived from crystallization of purified recombinant protein, could lead to the rational design of small drugs that specifically inhibit activity. These drugs may be directed at specific domains, *e.g.* the kinase catalytic domain, the regulatory domain, the auto-inhibitory domain, *etc.*

The term "agent" as used herein describes any molecule, *e.g.* protein or pharmaceutical, with the capability of altering or mimicking the physiological function of a cancer associated kinase corresponding to SEQ ID NOS:1, 3, 5, 7, 9, 11 or 13. Generally a plurality of assay mixtures are run in parallel with different agent concentrations to obtain a differential response to the various concentrations. Typically one of these concentrations serves as a negative control, *i.e.* at zero concentration or below the level of detection.

Candidate agents encompass numerous chemical classes, though typically they are organic molecules, preferably small organic compounds having a molecular weight of more than 50 and less than about 2,500 daltons. Candidate agents comprise functional groups necessary for structural interaction with proteins, particularly hydrogen bonding, and typically include at least an amine, carbonyl, hydroxyl or carboxyl group, preferably at least two of the functional chemical groups. The candidate agents often comprise cyclical carbon or heterocyclic structures and/or aromatic or polyaromatic structures substituted with one or more of the above functional groups. Candidate

agents are also found among biomolecules including peptides, saccharides, fatty acids, steroids, purines, pyrimidines, derivatives, structural analogs or combinations thereof.

Candidate agents are obtained from a wide variety of sources including libraries of synthetic or natural compounds. For example, numerous means are available for random and directed synthesis of a wide variety of organic compounds and biomolecules, including expression of randomized oligonucleotides and oligopeptides. Alternatively, libraries of natural compounds in the form of bacterial, fungal, plant and animal extracts are available or readily produced. Additionally, natural or synthetically produced libraries and compounds are readily modified through conventional chemical, physical and biochemical means, and may be used to produce combinatorial libraries.

Known pharmacological agents may be subjected to directed or random chemical modifications, such as acylation, alkylation, esterification, amidification, *etc.* to produce structural analogs.

Where the screening assay is a binding assay, one or more of the molecules may be joined to a label, where the label can directly or indirectly provide a detectable signal. Various labels include radioisotopes, fluorescers, chemilumescers, enzymes, specific binding molecules, particles, *e.g.* magnetic particles, and the like. Specific binding molecules include pairs, such as biotin and streptavidin, digoxin and antidigoxin, *etc.* For the specific binding members, the complementary member would normally be labeled with a molecule that provides for detection, in accordance with known procedures.

A variety of other reagents may be included in the screening assay. These include reagents like salts, neutral proteins, *e.g.* albumin, detergents, *etc.* that are used to facilitate optimal protein-protein binding and/or reduce non-specific or background interactions. Reagents that improve the efficiency of the assay, such as protease inhibitors, nuclease inhibitors, anti-microbial agents, *etc.* may be used. The mixture of components are added in any order that provides for the requisite binding. Incubations are performed at any suitable temperature, typically between 4 and 40° C. Incubation periods are selected for optimum activity, but may also be optimized to facilitate rapid high-throughput screening. Typically between 0.1 and 1 hours will be sufficient.

Other assays of interest detect agents that mimic the function of a cancer associated kinase corresponding to SEQ ID NOS:1, 3, 5, 7, 9, 11 or 13. For example, an expression construct comprising the gene may be introduced into a cell line under conditions that allow expression. The level of kinase activity is determined by a functional assay, for example detection of protein phosphorylation. Alternatively, candidate agents are added to a cell that lacks the functional cancer associated kinase corresponding to SEQ ID NOS:1, 3, 5, 7, 9, 11 or 13, and screened for the ability to reproduce the activity in a functional assay.

The compounds having the desired pharmacological activity may be administered in a physiologically acceptable carrier to a host for treatment of cancer, *etc.* The compounds may also be used to enhance function in wound healing, cell growth, *etc.* The inhibitory agents may be administered in a variety of ways, orally, topically, parenterally *e.g.* subcutaneously, intraperitoneally, by viral infection, intravascularly, *etc.* Topical treatments are of particular interest. Depending upon the manner of introduction, the compounds may be formulated in a variety of ways. The

concentration of therapeutically active compound in the formulation may vary from about 0.1-10 wt %.

*Formulations.* The compounds of this invention can be incorporated into a variety of formulations for therapeutic administration. Particularly, agents that modulate activity of a cancer associated kinase corresponding to SEQ ID NOS:1, 3, 5, 7, 9, 11 or 13, or polypeptides and analogs thereof are formulated for administration to patients for the treatment of cells where the target activity is undesirably high or low, e.g. to reduce the level of activity in cancer cells. More particularly, the compounds of the present invention can be formulated into pharmaceutical compositions by combination with appropriate, pharmaceutically acceptable carriers or diluents, and may be formulated into preparations in solid, semi-solid, liquid or gaseous forms, such as tablets, capsules, powders, granules, ointments, solutions, suppositories, injections, inhalants, gels, microspheres, and aerosols. As such, administration of the compounds can be achieved in various ways, including oral, buccal, rectal, parenteral, intraperitoneal, intradermal, transdermal, intra-tracheal, etc., administration. The agent may be systemic after administration or may be localized by the use of an implant that acts to retain the active dose at the site of implantation.

In pharmaceutical dosage forms, the compounds may be administered in the form of their pharmaceutically acceptable salts, or they may also be used alone or in appropriate association, as well as in combination with other pharmaceutically active compounds. The following methods and excipients are merely exemplary and are in no way limiting.

For oral preparations, the compounds can be used alone or in combination with appropriate additives to make tablets, powders, granules or capsules, for example, with conventional additives, such as lactose, mannitol, corn starch or potato starch; with binders, such as crystalline cellulose, cellulose derivatives, acacia, corn starch or gelatins; with disintegrators, such as corn starch, potato starch or sodium carboxymethylcellulose; with lubricants, such as talc or magnesium stearate; and if desired, with diluents, buffering agents, moistening agents, preservatives and flavoring agents.

The compounds can be formulated into preparations for injections by dissolving, suspending or emulsifying them in an aqueous or nonaqueous solvent, such as vegetable or other similar oils, synthetic aliphatic acid glycerides, esters of higher aliphatic acids or propylene glycol; and if desired, with conventional additives such as solubilizers, isotonic agents, suspending agents, emulsifying agents, stabilizers and preservatives.

The compounds can be utilized in aerosol formulation to be administered via inhalation. The compounds of the present invention can be formulated into pressurized acceptable propellants such as dichlorodifluoromethane, propane, nitrogen and the like.

Furthermore, the compounds can be made into suppositories by mixing with a variety of bases such as emulsifying bases or water-soluble bases. The compounds of the present invention can be administered rectally via a suppository. The suppository can include vehicles such as cocoa butter, carbowaxes and polyethylene glycols, which melt at body temperature, yet are solidified at room temperature.

Unit dosage forms for oral or rectal administration such as syrups, elixirs, and suspensions may be provided wherein each dosage unit, for example, teaspoonful, tablespoonful, tablet or suppository, contains a predetermined amount of the composition containing one or more compounds of the present invention. Similarly, unit dosage forms for injection or intravenous administration may comprise the compound of the present invention in a composition as a solution in sterile water, normal saline or another pharmaceutically acceptable carrier.

Implants for sustained release formulations are well-known in the art. Implants are formulated as microspheres, slabs, *etc.* with biodegradable or non-biodegradable polymers. For example, polymers of lactic acid and/or glycolic acid form an erodible polymer that is well-tolerated by the host. The implant is placed in proximity to the site of disease, so that the local concentration of active agent is increased relative to the rest of the body.

The term "unit dosage form," as used herein, refers to physically discrete units suitable as unitary dosages for human and animal subjects, each unit containing a predetermined quantity of compounds of the present invention calculated in an amount sufficient to produce the desired effect in association with a pharmaceutically acceptable diluent, carrier or vehicle. The specifications for the novel unit dosage forms of the present invention depend on the particular compound employed and the effect to be achieved, and the pharmacodynamics associated with each compound in the host.

The pharmaceutically acceptable excipients, such as vehicles, adjuvants, carriers or diluents, are readily available to the public. Moreover, pharmaceutically acceptable auxiliary substances, such as pH adjusting and buffering agents, tonicity adjusting agents, stabilizers, wetting agents and the like, are readily available to the public.

Typical dosages for systemic administration range from 0.1  $\mu\text{g}$  to 100 milligrams per kg weight of subject per administration. A typical dosage may be one tablet taken from two to six times daily, or one time-release capsule or tablet taken once a day and containing a proportionally higher content of active ingredient. The time-release effect may be obtained by capsule materials that dissolve at different pH values, by capsules that release slowly by osmotic pressure, or by any other known means of controlled release.

Those of skill will readily appreciate that dose levels can vary as a function of the specific compound, the severity of the symptoms and the susceptibility of the subject to side effects. Some of the specific compounds are more potent than others. Preferred dosages for a given compound are readily determinable by those of skill in the art by a variety of means. A preferred means is to measure the physiological potency of a given compound.

The use of liposomes as a delivery vehicle is one method of interest. The liposomes fuse with the cells of the target site and deliver the contents of the lumen intracellularly. The liposomes are maintained in contact with the cells for sufficient time for fusion, using various means to maintain contact, such as isolation, binding agents, and the like. In one aspect of the invention, liposomes are designed to be aerosolized for pulmonary administration. Liposomes may be prepared with purified proteins or peptides that mediate fusion of membranes, such as Sendai virus or influenza virus, *etc.* The lipids may be any useful combination of known liposome forming lipids, including cationic lipids,

such as phosphatidylcholine. The remaining lipid will normally be neutral lipids, such as cholesterol, phosphatidyl serine, phosphatidyl glycerol, and the like.

#### MODULATION OF ENZYME ACTIVITY

5 Agents that block activity of cancer associated kinase corresponding to SEQ ID NOS:1, 3, 5, 7, 9, 11 or 13 provide a point of intervention in an important signaling pathway. Numerous agents are useful in reducing this activity, including agents that directly modulate expression as described above, e.g. expression vectors, antisense specific for the targeted kinase; and agents that act on the protein, e.g. specific antibodies and analogs thereof, small organic molecules that block catalytic  
10 activity, etc.

The genes, gene fragments, or the encoded protein or protein fragments are useful in therapy to treat disorders associated with defects in sequence or expression. From a therapeutic point of view, inhibiting activity has a therapeutic effect on a number of proliferative disorders, including inflammation, restenosis, and cancer. Inhibition is achieved in a number of ways.

15 Antisense sequences may be administered to inhibit expression. Pseudo-substrate inhibitors, for example, a peptide that mimics a substrate for the kinase may be used to inhibit activity. Other inhibitors are identified by screening for biological activity in a functional assay, e.g. *in vitro* or *in vivo* kinase activity.

Expression vectors may be used to introduce the target gene into a cell. Such vectors  
20 generally have convenient restriction sites located near the promoter sequence to provide for the insertion of nucleic acid sequences. Transcription cassettes may be prepared comprising a transcription initiation region, the target gene or fragment thereof, and a transcriptional termination region. The transcription cassettes may be introduced into a variety of vectors, e.g. plasmid; retrovirus, e.g. lentivirus; adenovirus; and the like, where the vectors are able to transiently or stably  
25 be maintained in the cells, usually for a period of at least about one day, more usually for a period of at least about several days to several weeks.

The gene or protein may be introduced into tissues or host cells by any number of routes, including viral infection, microinjection, or fusion of vesicles. Jet injection may also be used for intramuscular administration, as described by Furth *et al.* (1992) Anal Biochem **205**:365-368. The  
30 DNA may be coated onto gold microparticles, and delivered intradermally by a particle bombardment device, or "gene gun" as described in the literature (see, for example, Tang *et al.* (1992) Nature **356**:152-154), where gold micro projectiles are coated with the protein or DNA, then bombarded into skin cells.

Antisense molecules can be used to down-regulate expression in cells. The antisense  
35 reagent may be antisense oligonucleotides (ODN), particularly synthetic ODN having chemical modifications from native nucleic acids, or nucleic acid constructs that express such antisense molecules as RNA. The antisense sequence is complementary to the mRNA of the targeted gene, and inhibits expression of the targeted gene products. Antisense molecules inhibit gene expression through various mechanisms, e.g. by reducing the amount of mRNA available for translation, through

activation of RNase H, or steric hindrance. One or a combination of antisense molecules may be administered, where a combination may comprise multiple different sequences.

Antisense molecules may be produced by expression of all or a part of the target gene sequence in an appropriate vector, where the transcriptional initiation is oriented such that an antisense strand is produced as an RNA molecule. Alternatively, the antisense molecule is a synthetic oligonucleotide. Antisense oligonucleotides will generally be at least about 7, usually at least about 12, more usually at least about 20 nucleotides in length, and not more than about 500, usually not more than about 50, more usually not more than about 35 nucleotides in length, where the length is governed by efficiency of inhibition, specificity, including absence of cross-reactivity, and the like. It has been found that short oligonucleotides, of from 7 to 8 bases in length, can be strong and selective inhibitors of gene expression (see Wagner *et al.* (1996) Nature Biotechnology 14:840-844).

A specific region or regions of the endogenous sense strand mRNA sequence is chosen to be complemented by the antisense sequence. Selection of a specific sequence for the oligonucleotide may use an empirical method, where several candidate sequences are assayed for inhibition of expression of the target gene *in vitro* or in an animal model. A combination of sequences may also be used, where several regions of the mRNA sequence are selected for antisense complementation.

Antisense oligonucleotides may be chemically synthesized by methods known in the art (see Wagner *et al.* (1993) *supra.* and Milligan *et al.*, *supra.*) Preferred oligonucleotides are chemically modified from the native phosphodiester structure, in order to increase their intracellular stability and binding affinity. A number of such modifications have been described in the literature, which alter the chemistry of the backbone, sugars or heterocyclic bases.

Among useful changes in the backbone chemistry are phosphorothioates; phosphorodithioates, where both of the non-bridging oxygens are substituted with sulfur; phosphoroamidites; alkyl phosphotriesters and boranophosphates. Achiral phosphate derivatives include 3'-O'-5'-S-phosphorothioate, 3'-S-5'-O-phosphorothioate, 3'-CH<sub>2</sub>-5'-O-phosphonate and 3'-NH-5'-O-phosphoroamidate. Peptide nucleic acids replace the entire ribose phosphodiester backbone with a peptide linkage. Sugar modifications are also used to enhance stability and affinity. The alpha.-anomer of deoxyribose may be used, where the base is inverted with respect to the natural .beta.-anomer. The 2'-OH of the ribose sugar may be altered to form 2'-O-methyl or 2'-O-allyl sugars, which provides resistance to degradation without comprising affinity. Modification of the heterocyclic bases must maintain proper base pairing. Some useful substitutions include deoxyuridine for deoxythymidine; 5-methyl-2'-deoxycytidine and 5-bromo-2'-deoxycytidine for deoxycytidine. 5-propynyl-2'-deoxyuridine and 5-propynyl-2'-deoxycytidine have been shown to increase affinity and biological activity when substituted for deoxythymidine and deoxycytidine, respectively.

## EXAMPLES

The following examples are put forth so as to provide those of ordinary skill in the art with a complete disclosure and description of how to make and use the present invention, and are not intended to limit the scope of what the inventors regard as their invention nor are they intended to represent that the experiments below are all or the only experiments performed. Efforts have been made to ensure accuracy with respect to numbers used (e.g. amounts, temperature, *etc.*) but some experimental errors and deviations should be accounted for. Unless indicated otherwise, parts are parts by weight, molecular weight is weight average molecular weight, temperature is in degrees Centigrade, and pressure is at or near atmospheric.

All publications and patent applications cited in this specification are herein incorporated by reference as if each individual publication or patent application were specifically and individually indicated to be incorporated by reference.

The present invention has been described in terms of particular embodiments found or proposed by the present inventor to comprise preferred modes for the practice of the invention. It will be appreciated by those of skill in the art that, in light of the present disclosure, numerous modifications and changes can be made in the particular embodiments exemplified without departing from the intended scope of the invention. For example, due to codon redundancy, changes can be made in the underlying DNA sequence without affecting the protein sequence. Moreover, due to biological functional equivalency considerations, changes can be made in protein structure without affecting the biological action in kind or amount. All such modifications are intended to be included within the scope of the appended claims.

Example 1MAP3K11

The Genbank database was searched for ESTs showing similarity to known kinase domain-related proteins using the "basic local alignment search tool" program, TBLASTN, with default settings. Human ESTs identified as having similarity to these known kinase domain (defined as  $p < 0.0001$ ) were used in a BLASTN and BLASTX screen of the GenBank non-redundant (NR) database.

ESTs that had top human hits with >95% identity over 100 amino acids were discarded. This was based upon the inventors' experience that these sequences were usually identical to the starting probe sequences, with the differences due to sequence error. The remaining BLASTN and BLASTX outputs for each EST were examined manually, *i.e.*, ESTs were removed from the analysis if the inventors determined that the variation from the known kinase domain -related probe sequence was a result of poor database sequence. Poor database sequence was usually identified as a number of 'N' nucleotides in the database sequence for a BLASTN search and as a base deletion or insertion in the database sequence, resulting in a peptide frameshift, for a BLASTX output. ESTs for which the highest scoring match was to non-kinase domain-related sequences were also discarded at this stage.

Using widely known algorithms, e.g. "Smith/Waterman", "Fasta", "FastP", "Needleman/Wunsch", "Blast", "PSIBlast," homology of the subject nucleic acid to other known nucleic acids was determined. A "Local FastP Search" algorithm was performed in order to

determine the homology of the subject nucleic acid invention to known sequences. Then, a ktup value, typically ranging from 1 to 3 and a segment length value, typically ranging from 20 to 200, were selected as parameters. Next, an array of position for the probe sequence was constructed in which the cells of the array contain a list of positions of that substring of length ktup. For each  
5 subsequence in the position array, the target sequence was matched and augmented the score array cell corresponding to the diagonal defined by the target position and the probe subsequence position. A list was then generated and sorted by score and report. The criterion for perfect matches and for mismatches was based on the statistics properties of that algorithm and that database, typically the values were: 98% or more match over 200 nucleotides would constitute a match; and any mismatch  
10 in 20 nucleotides would constitute a mismatch.

Analysis of the BLASTN and BLASTX outputs identified a EST sequence from IMAGE clone A1803752 that had potential for being associated with a sequence encoding a kinase domain-related protein, e.g., the sequence had homology, but not identity, to known kinase domain-related proteins.

After identification of MAP3K11 ESTs were discovered, the clones were added to Kinetek's  
15 clone bank for analysis of gene expression in tumor samples. Gene expression work involved construction of unigene clusters, which are represented by entries in the "pks" database. A list of accession numbers for members of the clusters were assigned. Subtraction of the clusters already present in the clone bank from the clusters recently added left a list of clusters that had not been previously represented in Kinetek's clone bank. For each of the clusters, a random selection of an  
20 EST IMAGE accession numbers were chosen to keep the clusters. For each of the clusters which did not have an EST IMAGE clone, generation of a report so that clone ordering or construction could be implemented was performed on a case by case basis. A list of accession numbers which were not in clusters was constructed and a report was generated.

The A1803752 IMAGE clone was sequenced using standard ABI dye-primer and  
25 dye-terminator chemistry on a 377 automatic DNA sequencer. Sequencing revealed that the sequence corresponds to SEQ ID NO:1.

#### Rapid Amplification of cDNA Ends (RACE).

The gene specific oligodeoxynucleotide primers SEQ ID NO:15 and 16 were designed and  
30 then used to construct full length MAP3K11 cDNA by 5 prime RACE (rapid amplification of cDNA ends; Frohman *et al.* (1988), Proc. Natl. Acad. Sci. USA 85:8898-9002).

A nested primer strategy was used on human brain cDNA provided with a Marathon-Ready™ RACE kit (Clontech, Palo Alto, CA). Following this, thermal cycling on a PE DNA Thermal Cycler 480 was done. When cycling was completed, the PCR product was analyzed, along  
35 with appropriate DNA size markers, on a 1.0% agarose/EtBr gel.

The product so obtained comprised a MAP3K11 polynucleotide having the sequence of SEQ ID NO:1.



Expression Analysis of MAP3K11

The expression of MAP3K11 was determined by dot blot analysis, and the protein was found to be upregulated in several tumor samples.

*Dot blot preparation.* Total RNA was purified from clinical cancer and control samples taken from the same patient. Samples were used from both liver and colon cancer samples. Using reverse transcriptase, cDNAs were synthesized from these RNAs. Radiolabeled cDNA was synthesized using Strip-EZ™ kit (Ambion, Austin, TX) according to the manufacturer's instructions. These labeled, amplified cDNAs were then used as a probe, to hybridize to human protein kinase arrays comprising human MAP3K11. The amount of radiolabeled probe hybridized to each arrayed EST clone was detected using phosphorimaging.

The expression of MAP3K11 was substantially upregulated in the tumor tissues that were tested. The data is shown in Table 1, expressed as the fold increase over the control non-tumor sample.

Table 1

Target	liver 1	liver 2	liver 3	colon 1	colon 4	colon 5	colon 7	colon 8	colon 9	colon 10
MAP3K11	4.1	1.3	2.3	2.1	1.1	1.9	3.4	1.3	0.9	1.75
beta-actin	2.05	1.07	1.57	0.42	1.28	2.19	1.20	4.60	0.60	0.49
GAPDH	1.30	0.33	1.25	0.76						
K413 (ribosomal protein)					1.72	2.36	2.10	1.00	1.00	1.68

The data displayed in Table 2 provides a brief summary of the pathology report of the patient samples.

Table 2

Patient	Age	Gender	Precursor Adenoma	Site of Involvement	Differentiation	Vascular Invasion	Lymphatic Involvement	Metastasis
Liver 1	49	Female	N/a	Liver	Moderately Differentiated	No	Yes	No
Liver 2	53	Male	N/a	Liver	Moderately Differentiated	Yes	No	No
Liver 3	75	Female	Adenoma	Right Colon	Moderately differentiated	No	No	No
Colon 1	55	Female	No	Rectum	Moderately Differentiated	N/A	Yes	No
Colon 4	91	Female	Adenoma	Cecum	Moderately Differentiated	No	Yes	No
Colon 5	79	Male	No	Ileum and Colon				
Colon 7					Moderately Differentiated	No	No	No
Colon 8	61	Male	Yes		Moderately Differentiated	No	Yes	Yes, Liver
Colon 9	60	Male	No	Recto-Sigmoid	Moderately Differentiated	Yes	No	Yes, Liver
Colon	60	Male	No	Sigmoid	Moderately	Yes	Yes	No

10				Colon	Differentiated			
----	--	--	--	-------	----------------	--	--	--

## Example 2

### CaMK-X1

The Genbank database was searched for ESTs showing similarity to known kinase domain-related proteins using the "basic local alignment search tool" program, TBLASTN, with default settings. Human ESTs identified as having similarity to these known kinase domain (defined as  $p < 0.0001$ ) were used in a BLASTN and BLASTX screen of the GenBank non-redundant (NR) database, searched against the sequence of the catalytic domain of CaMK-I (Genbank hs2721161). Sequence screening was performed as described in Example 1.

Analysis of the BLASTN and BLASTX outputs identified an EST sequence from IMAGE clone AA838372 that had potential for being associated with a sequence encoding a kinase domain-related protein, e.g., the sequence had homology, but not identity, to known kinase domain-related proteins. Further, CaMK-X1 was found to have sequence similarity to members of the calmodulin dependent protein kinase family. The reported nucleotide sequence of the 5' EST of the AA838372 IMAGE clone corresponds approximately to 400 nucleotides of SEQ ID NO:1. A search of the UniGene database revealed that the 5' EST of the AA838372 IMAGE clone represented a novel human gene.

The AA838372 IMAGE clone was sequenced using standard ABI dye-primer and dye-terminator chemistry on a 377 automatic DNA sequencer. Sequencing revealed that the sequence corresponds to nucleotides 1 to 2447 of SEQ ID NO:3. Analysis of this gene fragment revealed that the gene product is a novel kinase domain-related protein, thereafter termed CaMK-X1.

### Rapid Amplification of cDNA Ends (RACE).

The gene specific oligodeoxynucleotide primer 5'-GGAGGGCG AGGAAACTGGGGAAG -3' (SEQ ID NO:17) was designed and then used to construct full length CaMK-X1 cDNA by 5 prime RACE (rapid amplification of cDNA ends; Frohman *et al.* 1988, *Proc. Natl. Acad. Sci. USA* 85:8898-9002). Adaptor primer (AP1) was used as sense primer, and SEQ ID NO:3 was used as antisense primer. A nested primer strategy was used on fetal brain cDNA provided with a Marathon-Ready™ RACE kit (Clontech, Palo Alto, CA). Following this, thermal cycling on a PE DNA Thermal Cycler 480 was done. When cycling was completed, the PCR product was analyzed, along with appropriate DNA size markers, on a 1.0% agarose/EtBr gel.

The product so obtained comprised a CaMK-X1 polynucleotide having the sequence of SEQ ID NO:3. BLASTX analysis indicated that the starting methionine residue was present at nucleotide 10, and that an upstream in-frame stop codon was present at nucleotide 1498, and the longest ORF (SEQ ID NO:3) predicted a protein of 476 amino acids (SEQ ID NO:4).

Homology analysis of the deduced amino acid sequence of CaMK-X1 revealed strong sequence identity with CaMK I from amino acid residues 11 to 333. The corresponding region of CaMK I contains the threonine residue required for activation and the regulatory domain that folds over the active site unless bound by CaM (Matsuchita *et al.* (1998) *Journal of Biological Chemistry*

273, 21473-21481). CaMK-X1 also has a region between residues 23 and 277 that is highly homologous (46% identity) to the highly conserved serine/threonine kinase active site.

#### Expression Analysis

5 The expression of CaMK-X1 was determined by Northern Blot, and dot blot analysis, and the protein was found to be upregulated in several tumor samples. In normal tissue, CaMK-X1 is highly expressed in brain, and at lower levels in kidney and spleen.

10 *Dot blot preparation.* Total RNA was purified from clinical cancer and control samples taken from the same patient. Samples were used from both liver and colon cancer samples. Using reverse transcriptase, cDNAs were synthesized from these RNAs. Radiolabeled cDNA was synthesized using Strip-EZ™ kit (Ambion, Austin, TX) according to the manufacturer's instructions. These labeled, amplified cDNAs were then used as a probe, to hybridize to human protein kinase arrays comprising human CaMK-X1. The amount of radiolabeled probe hybridized to each arrayed EST clone was detected using phosphorimaging.

15 The expression of CaMK-X1 was substantially upregulated in the tumor tissues that were tested. The data is shown in Table 3, expressed at the fold increase over the control non-tumor sample.

Table 3

	liver 1	liver 2	liver 3	colon 1	colon 2	colon 3	colon 4	colon 5	colon 6	colon 7
CaMK-X1	5.0	4.9	5.1	2.3	2.6	1.5	3.3	1.2	1.3	4.05

#### Functional Assays

A deletion mutant clone was created to aid in the characterization of this kinase *in vivo*. In addition, it is shown that CaMK-X1 phosphorylates CREB at Ser 133 in Jurkat cells, and this phosphorylation is controlled by a Calmodulin binding site.

25 CaMK-X1 kinase activity was shown *in vitro* using three different approaches. CaMK-X1 was purified from Hi5 insect cells and HEK293 cells overexpressing CaMK-X1 using GST and Ni2+ affinity chromatography. Furthermore, CaMK-X1 was purified via immunoprecipitation using a monoclonal antibody directed against the X-press fusion protein. CaMK-X1 displays no activity toward exogenous substrates in the absence of Ca2+ and calmodulin. In the presence of Ca2+ and calmodulin, CaMK-X1 phosphorylated Syntide and CREBtide peptides. This is the first experimental demonstration that CaMK-X1 behaves as a calcium/calmodulin-dependent protein kinase.

35 *Cloning and sub-cloning.* Cloning of CaMK-X1 and construction of cDNA expression vectors and the CaMK-X1 deletion mutant: A human brain cDNA library was used with a 5' RACE system. To generate the full-length cDNA of CaMK-X1, a pair of primers were designed and used in the PCR reaction. (SEQ ID NO:24) 5'-GTGGAGGGC GAGGAACTGGGGAAG-3 and (SEQ ID NO:25) 5'-CTCGAGTCACA TAATGAGACAGACTCCAGTC. The coding area of CaMK-X1 was amplified using

the above pair of primers. The amplification product was then cloned into a Promega T/A vector and subsequently cloned into other vectors as necessary. The EcoRI and XhoI fragment of CaMK-X1 was cloned into bacterial expression vector pGEX-4T-3 and mammalian expression vector pcDNA3.1/His B. All constructs were verified by restriction enzyme digestion and DNA sequencing.

*Tissue distribution of CaMK-X1.* CaMK-X1 was used to probe and blot mRNA, using a commercially available poly-A<sup>+</sup> selected blot (Clontech, Palo Alto, CA), and hybridized according to the manufacturer's instructions. The CaMK-X1 clone (corresponding to SEQ ID NO:3) was radiolabeled using Strip-EZ PCR kit (Ambion, Austin, TX) according to the manufacturer's instructions.

It was found that in normal tissues, CaMK-X1 is expressed at high levels only in the brain, hybridizing to an mRNA of approximately 2.8 Kb in length. The mRNA was expressed at low levels in the kidney and spleen. The mRNA in the Northern blot ran at a position consistent with a molecular weight between 2.5-2.7 kb.

*CaMK-X1 increases proliferation of Cos7 cells.* The proliferation rate of Cos7 cells when transfected with CaMK-X1 was examined. To determine whether increased levels of CaMK-X1 had any effect on cell proliferation, Cos7 cells were transfected with increasing concentrations of CaMK-X1 or vector plasmids in the presence of KCl. Cell proliferation was measured by standard protocols. As shown in Fig. 1, transfection of CaMK-X1 increased the rate of proliferation, whereas the same concentration of vector alone decreased the rate of proliferation. The proliferation rate of Cos7 cells transiently transfected with CaMK-X1 is higher in 5% serum than at the 2.5% or 0.5%, suggesting that CaMK-X1 induced proliferation is modulated by serum. This data demonstrates that CaMK-X1 can promote cell proliferation.

*CaMK-X1 phosphorylates CREB in vivo.* cAMP response element-binding protein (CREB) is a DNA binding transcription factor. A number of growth factors and hormones have been shown to stimulate the expression of cellular genes by inducing the phosphorylation of the nuclear factor CREB at Ser 133 (Montminy (1997) Annu.Rev. Biochem. 66:807-822). Originally characterized as a target for PKA-mediated phosphorylation, CREB is also recognized by other kinases including Protein kinase C, calmodulin kinase, microtubule-activated protein kinase activated protein, and protein kinase B/AKT.

It was investigated whether CaMK-X1 could regulate CREB-Ser 133 phosphorylation *in vivo*. To analyze CaMK-X1 *in vivo*, Jurkat cells were utilized. Jurkat cells transfected with various concentrations of plasmids carrying CaMK-X1 or vector were stimulated with KCl. Whole cell protein was prepared from these transfected cells and the phosphorylation status of CREB at Ser 133 was determined. Detection of CREB phosphorylation was carried out using anti-phospho-CREB antibody. Phosphorylation of CREB increased with increasing amounts of the CaMK-X1 gene transfection, but only in the presence of Ca<sup>2+</sup>.

To assess the effects of intracellular  $\text{Ca}^{2+}$  on CaMK-X1, transfected Jurkat cells were treated with 30 mM KCl. KCl depolarizes cell membranes thereby creating an increase in intracellular  $\text{Ca}^{2+}$ . Addition of KCl resulted in significant phosphorylation of CREB only in cells transfected with CaMK-X1. These results show that CaMK-X1 is activated by  $\text{Ca}^{2+}$  and subsequently phosphorylates CREB at Ser 133 in Jurkat cells.

*Calmodulin binding site deletion mutant of CaMK-X1 constitutively phosphorylates CREB in vivo.* It has been shown previously that CaM kinases can be made  $\text{Ca}^{2+}$  independent by truncation of the calmodulin binding site. Similarly, a constitutively active form of CaMK-X1 was created by removing the putative CaM-binding domain via truncation at amino acid Gln 301. This deletion site eliminates the two predicted  $\text{Ca}^{2+}$ /Calmodulin-binding sites in the autoinhibitory domain. The truncated gene was placed in a pcDNA mammalian expression vector for transfection experiments.

To analyze the function of the mutant CaMK-X1 *in vivo*, Jurkat cells were used. Jurkat cells transfected with various concentrations of plasmids carrying CaMK-X1 or vector were stimulated with KCl. Whole cell protein was prepared from these transfected cells and the phosphorylation status of CREB at Ser 133 was determined. Detection of CREB phosphorylation was carried out using anti-phospho-CREB antibody. Mock treatment by the vectors did not have any effect on CREB phosphorylation. The transfection of wild type CaMK-X1 had no effect on CREB phosphorylation; however, addition of KCl to wild type transfected Jurkat cells resulted in significant CREB phosphorylation. Transfection of the deletion mutant had a significant effect on CREB phosphorylation without the addition of KCl. These results demonstrate that truncation of wild type CaMK-X1 at Gln 301 converted the enzyme to a  $\text{Ca}^{2+}$ /CaM-independent state.

*Expression of CaMK-X1 kinase in HEK293 cells.* The availability of the CaMK-X1 clone allows us to reconstruct the signaling pathway. This allows us to identify downstream components such as transcription factors or modification of protein components such as phosphorylation, proteolytic processing, methylation, and the like, which finds use in drug screening.

To characterize CaMK-X1 at the protein level, HEK293 cells were transfected with pcDNA3-Xpress (Invitrogen) containing the CaMK-X1 coding sequence fused to the Xpress epitope; and stable cell lines were created using standard techniques. Five stable cell lines containing the pcDNA-CaMK-X1 plasmid and five containing the vector only control were selected and CaMK-X1 expression levels were determined. Whole cell extracts were prepared from each cell line. The cell lysates were analysed by Western blotting with an anti Xpress monoclonal antibody. These experiments revealed a 53 kDa fusion protein present in the CaMK-X1 transfected cells that was absent in the control cells.

The transfected HEK293 cells stably expressed CaMK-X1 as an Xpress fusion protein. Similarly, we have detected a GST-CaMK-X1 fusion protein expressed in Hi5 cells. Glutathione-sepharose affinity chromatography was used to purify the GST-CaMK-X1 fusion protein. Glutathione-sepharose purified CaMK-X1 and anti-Xpress antibody immunoprecipitated CaMK-X1 were subjected to Western blot analysis. This Western blot indicates that CaMK-X1 can be purified

from both transfected HEK293 cell lysate and Hi5 cell lysate. These methodologies were used to purify CaMK-X1 for further characterization.

A protein with a molecular mass of 53kDa was identified when lysates of HEK293 cells transfected with the Xpress-CaMK-X1 clone were subjected to immunoprecipitation with anti-Xpress antibody followed by anti-Xpress Western blotting, which band was absent with vector alone transfected cells. This data confirms that the anti-Xpress antibody selectively immunoprecipitated the fusion protein (Xpress-CaMK-X1).

These immunoprecipitated materials were assayed for kinase activity, using the peptides (SEQ ID NO:26) CREBtide: Lys Arg Arg Glu Ile Leu Ser Arg Arg Pro Ser Tyr Arg; (SEQ ID NO:27) Syntide 2: Pro Leu Ala Arg Thr Leu Ser Val Ala Gly Leu Pro Gly Lys Lys; and (SEQ ID NO:28) Calmodulin Dependent Protein Kinase Substrate: Pro Leu Ser Arg Thr Leu Ser Val Ser Ser. The immunoprecipitated materials were subjected to an *in vitro* kinase assay as described above. Since it was shown that CaMK-X1 phosphorylates CREB *in vivo*, it was reasoned that CaMK-X1 would phosphorylate CREBtide and Syntide 2 (Colbran *et al.* (1989) *J Biol Chem* 264(9):4800-4804). As predicted, CaMK-X1 phosphorylated CREBtide and Syntide 2 *in vitro*. In contrast, CaMK-X1 could not phosphorylate control peptide. The degree of phosphorylation is augmented in the presence of calmodulin, as shown in Figure 2. In the absence of a substrate, there is no significant incorporation of radioactive material ( $^{32}\text{P}$ ) indicating that CaMK-X1 does not autophosphorylate under these assay conditions. This demonstrates that immunoprecipitated CaMK-X1 possesses a kinase activity and that this kinase activity is capable of phosphorylating peptides *in vitro*. These studies also revealed that CaMK-X1 requires calmodulin for efficient activity.

*Catalytic activity and comparison of substrate specificities of CaMK-X1.* In order to determine if CaMK-X1 is an active kinase *in vitro*, the clone was Histidine tagged, expressed in Sf9 cells and purified with a Ni $^{2+}$  affinity column. For analysis of substrate specificity, we tested the following three peptides; CREBtide, Syntide 2 and CDPK-peptide (control peptide). *In vitro* kinase assays were then performed. As described above, CREBtide and Syntide 2 are phosphorylated by the purified CaMK-X1. The rate of phosphorylation is increased in the presence of Ca $^{2+}$  and calmodulin. Compared to a no substrate control, addition of the peptides resulted in significant  $^{32}\text{P}$  incorporation. These results indicate that CaMK-X1 phosphorylates these peptides *in vitro*. Our studies also revealed Syntide 2 and CREBtide had higher incorporation of  $^{32}\text{P}$  than the control peptide. These observations further confirm the *in vivo* data.

*Summary.* We have demonstrated that CaMK-X1 phosphorylates CREB in cells and *in vitro* at Ser 133. We have also demonstrated CaMK-X1 kinase activity *in vitro*. We were able to purify CaMK-X1 from transfected Hi5 insect cells and from a HEK293 cell line overexpressing CaMK-X1 using glutathione-sepharose and Ni $^{2+}$  affinity chromatography. Furthermore, CaMK-X1 was purified by immunoprecipitation using a monoclonal antibody directed against the Xpress fusion protein. CaMK-X1 displays no activity toward exogenous substrates in the absence of Ca $^{2+}$  and calmodulin.

In the presence of  $\text{Ca}^{2+}$  and calmodulin, CaMK-X1 phosphorylated Syntide 2 and CREBtide. These results indicate that Camk X-1 are involved in human pathology.

### Materials.

Dulbecco's Modified Eagle Medium (DMEM), RPMI Medium 1640, L-glutamine, phosphate buffered solution (PBS), fetal bovine serum (FBS), and restriction enzymes were from GibcoBRL. TOPO cloning kit (including PCR materials and pCR 2.1-Topo vector) were from Invitrogen. Phospho-CREB (Ser133) polyclonal rabbit antibody was from Cell Signaling Technology. 96- and 6-well delta surface plates were from NUNC. QIAprep Spin Miniprep Kit was from Qiagen. Wizard Plus Minipreps DNA Purification System (for gel extractions) (Promega). FuGENE 6 Transfection Reagent was from Boehringer Mannheim. pcDNA3.1 mammalian expression vector (Invitrogen). Western Blotting Luminol Reagent was from Santa Cruz Biotechnology. 2° goat-anti-rabbit IgG (H+L) HRP conjugated antibody was from Bio-Rad Laboratories.

*Cloning of full length CaMK-X1.* To generate the full-length cDNA of CaMK-X1, a pair of primers were designed and used in the PCR reaction. (SEQ ID NO:29) 5'-GAATTCAATGGGTCGAAAGGAAGAAGATGA and (SEQ ID NO:25) 5'-CTCGAGTCACATAATGAGACAGACTCCAGTC. The amplification product was cloned into cloning vectors through restriction sites EcoRI and XhoI. The EcoRI and XhoI fragment was cloned into bacteria expression vector pGEX-4T-3 and mammalian expression vector pcDNA3.1/HisB. All constructs were verified by restriction enzyme digestion and DNA sequencing.

*Construction of deletion mutant CaMK-X1CA.* A deletion mutant was created using these oligonucleotides EcoR1 (SEQ ID NO:30) 5'-GAATTCAATGGGTCGAAAGGAAGAAGATGA-3' forward, and Xho1 (SEQ ID NO:31) 5'-CTCGAGCTGGATCTGGAGGCTGACTGATGG-3' reverse. The resulting PCR fragment was cloned into mammalian expression vector pcDNA 3.1.

*Cell Culture.* Cells were incubated at 37°C in 5% CO<sub>2</sub> (standard conditions). All cells, unless mentioned below, were cultured in DMEM with FBS; the specific amount of FBS varies and is stated in the report for each result. Jurkat cells were cultured in RPMI Medium 1640 with added glucose, L-glutamine, and 10% FBS.

*Cell Transfection.* Cells were seeded to a density of  $2 \times 10^5$  in 6 well plates (in appropriate media for the particular cell line) and incubated for 24 hours under standard conditions. 3 ml of FuGENE 6 transfection reagent was diluted in 97 ml of serum-free media (appropriate for the cell line being transfected) and left for 5 minutes at room temperature; that was then added drop-wise to the desired amount of plasmid DNA (in pcDNA3.1) and left for 10 minutes at room temperature. The finished transfection solution was then added drop-wise to the cells, which were then incubated for 24 hours under standard conditions.

*Proliferation Assay.* The media from 6 well plates was removed and trypsin was added to digest the extracellular matrix holding the cells to the plate; media (appropriate to the cell type) was then added to deactivate the trypsin. The cells and media were transferred into Falcon tubes, centrifuged, and the supernatant was discarded. The cells were resuspended in appropriate media. 3000 cells were seeded in each well of a 96 well plate and appropriate media was added up to 90 ml.

Ten  $\mu$ l of 0.1 Ci/L  $^3$ H-thymidine was added to each well. The plates were then incubated for 24 hours under standard conditions. Twenty-five  $\mu$ l of cold trichloroacetic acid was added to each well and the plates were kept at 4°C for 2 hours. The plates were then washed in cold running water and allowed to dry. Proliferation was determined by incorporation of thymidine as measured via scintillation counting.

*Cell lysis.* Lysis buffer was 50 mM Hepes (pH 7.5), 150 mM NaCl, 1% NP-40, 2 mM NaF, 1mM  $\text{Na}_3\text{VO}_4$ , 1mM PMSF, 1 mg/ml pepstatin, 1 mg/ml leupeptin, 1 mg/ml aprotinin, and 20 mM  $\beta$ -glycerophosphate. For adherent cells, the media was removed from the 6 well plate, the wells were washed with PBS which was then removed, the plates were put on ice and 40 ml of lysis buffer was then added to each well. Crude lysates were collected with a cell scraper and placed in an Eppendorf tube. For non-adherent cells, the media and cells were transferred from a 6-well plate to tubes, centrifuged and the supernatant removed; 40 ml of lysis buffer was then added. All crude lysates were then vortexed and left on ice for 10 minutes. The crude lysates were centrifuged at 14,000 RPM for 10 minutes at 4°C and the supernatant, the final lysate, was transferred to new tubes.

*Western Blotting.* Equal weights of cell lysate proteins were mixed with 4X loading buffer, boiled for five minutes and were then briefly centrifuged. The samples were run on a 10% SDS-PAGE and were then transferred to PVDF membranes which were washed with TTBS and blocked with 2% BSA. They were blotted with primary antibody for 16 hours at 4°C. The membranes were washed with TTBS, blotted with secondary antibody for 1 hour and washed with TTBS. The luminol reagent was added, the blot was placed on film and the autoradiograph developed.

*Expression and purification of CaMK-X1 protein.* The human CaMK-XI gene (K283) was sub-cloned into baculovirus transfer vector pAcG4T3 derived from pAcG2T (BD Biosciences) under the control of the strong AcNPV (*Autographa californica* Nuclear Polyhedrosis Virus) polyhedrin promoter. This was co-transfected with linear BaculoGold DNA in *Spodoptera frugiperda* Sf9 cells following standard procedure (BD Biosciences). The GST-CaMK-X1 recombinant baculovirus was amplified in Sf9 cells in TNM-FH medium (JHR Biosciences) with 10% fetal bovine serum. The GST-CaMK-X1 protein was expressed in approximately  $5 \times 10^8$  Hi-5 cells (Invitrogen) in 500 ml of Excell-400 medium (JHR Biosciences) at a multiplicity of infection (MOI) of five for a period of 72 h in a spinner flask. The cells were harvested at 800Xg for 5 min at 4°C. The pellet was lysed in 40 ml of Lysis Buffer (50 mM Tris-HCl, pH7.5, 2.5 mM EDTA, 150 mM NaCl, 1% NP-40, 0.1%  $\beta$ -mercaptoethanol, 10  $\mu$ g/ml DNase I, 0.5 mM sodium orthovanadate, 50 mM  $\beta$ -glycerophosphate, 0.1 mM PMSF, 1 mM benzamidine, 2  $\mu$ g/ml aprotinin, 2  $\mu$ g/ml leupeptin, 1  $\mu$ g/ml pepstatin) by sonication and centrifuged at 10,000Xg at 4°C for 15 min. The supernatant was loaded on a column containing 2.5 ml of glutathione-sepharose (Sigma). The column was washed with Wash Buffer A (50 mM Tris-HCl, pH 7.5, 1 mM EDTA, 500 mM NaCl, 0.1%  $\beta$ -mercaptoethanol, 0.1% NP-40, 0.1 mM sodium orthovanadate, 50 mM  $\beta$ -glycerophosphate, 0.1 mM PMSF, 1 mM benzamidine) until OD280 returned to baseline, then Wash Buffer B (50 mM Tris-HCl, pH7.5, 1 mM EDTA, 50 mM NaCl, 0.1%  $\beta$ -mercaptoethanol, 0.1 mM PMSF). The GST-CaMK-X1 protein was eluted in Elution Buffer (50 mM



Tris-HCl, pH 7.5, 1 mM EDTA, 50 mM NaCl, 0.1%  $\beta$ -mercaptoethanol, 10 mM glutathione, 10% glycerol). The fraction was aliquoted and stored at  $-70^{\circ}\text{C}$ .

5 *CaMK-XI in vitro assay.* CaMK-X1 was assayed at room temperature for 15 min in 50 mM HEPES, pH 8.0, 10 mM  $\text{MgCl}_2$ , 1 mM dithiothreitol, 0.005% Tween 20, 1 mM  $\text{CaCl}_2$ , 1.5 mM calmodulin (CalBiochem), 50  $\mu\text{M}$   $[\gamma\text{-}^{32}\text{P}]\text{-ATP}$  and 0.2  $\mu\text{g}/\mu\text{l}$  Syntide 2 (American Peptide Company) or CREBtide (CalBiochem) in a final volume of 25  $\mu\text{l}$ . Reactions were initiated by addition of  $[\gamma\text{-}^{32}\text{P}]\text{-ATP}$  and terminated by spotting 10  $\mu\text{l}$  of the reaction mixture onto P81 paper followed by washing in 1% phosphoric acid.

10 *Immunoprecipitation.* For immunoprecipitations, HEK293 cells in 35 mm dishes stably expressing CaMK-X1-X-press plasmid were washed twice in ice-cold PBS and lysed in solution containing 50 mM Tris/HCl, pH 7.6, 2 mM EGTA, 2 mM EDTA, 2 mM dithiothreitol, protease inhibitors aprotinin (10  $\mu\text{g}/\text{ml}$ ) leupeptin (100  $\mu\text{g}/\text{ml}$ ) pepstatin (0.7  $\mu\text{g}/\text{ml}$ ), 1 mM 4-(2-aminoethyl) benzenesulfonyl fluoride hydrochloride, and 1% Triton X-100 (Lysis buffer). Proteins were immunoprecipitated with the anti-X-press antiserum (1:100 dilution) or with control serum. The  
15 immuno complexes were recovered using protein G Sepharose.

*In vitro kinase assay with immunoprecipitated materials.* CaMK-X1 was eluted from the immunocomplexes as described in the previous section and 20  $\mu\text{l}$  of the eluate was mixed with 20  $\mu\text{l}$  of phosphorylation mix containing 100  $\mu\text{M}$   $[\gamma\text{-}^{32}\text{P}]\text{ATP}$  (specific activity, 400-600 cpm/pmol), 30 mM Tris, pH 7.4, 30 mM  $\text{MgCl}_2$ , 1 mM DTT, and 250 nM peptide and incubated for 10-15 minutes at  $30^{\circ}\text{C}$ .

20 *Northern Blot analysis.* Northern blot analysis was performed using an  $[\alpha\text{-}^{32}\text{P}]\text{dCTP}$ -labeled CaMK-X1 cDNA fragment corresponding to bases 1.2 kb of human CaMK-X1 according to standard procedures (Ambion). RNA from several primary human tissues was analyzed with commercially available poly(A) + RNA blots (CLONTECH). The blotted membrane was dried and autoradiographed.

25 *CaMK-X1 activity assay.* Equivalent concentrations of purified CaMK-X1 preparations were incubated using a Beckman Biomek 2000 robotic system. Each well (96 well microtiter plate) contained 15  $\mu\text{l}$  reaction mixture composed of 50 mM HEPES, pH 8.0, 10 mM  $\text{MgCl}_2$ , 1 mM dithiothreitol, 0.005% Tween 20, 1 mM  $\text{CaCl}_2$ , 1.5 mM Calmodulin (CalBiochem) 50  $\mu\text{M}$   $\gamma\text{-}^{32}\text{P}\text{ATP}$  (200 cpm/pmol) and 0.2  $\mu\text{g}/\mu\text{l}$  Syntide 2 (American Peptide Company) or CREBtide (CalBiochem) in  
30 a final volume of 25  $\mu\text{l}$ . The reaction was initiated by addition of  $[\gamma\text{-}^{32}\text{P}]\text{-ATP}$  and terminated by spotting 10  $\mu\text{l}$  of the reaction mixture into a 96 well Millipore Multiscreen plate. The Multiscreen plate was washed in 1% phosphoric acid, dried and counted in a Wallac Microbeta scintillation counter.

### Example 3

#### 35 SGK2 $\alpha$

The Genbank EST database was searched as described in Example 1. Analysis of the BLASTN and BLASTX outputs identified a EST sequence from IMAGE clone AF169034 that had potential for being associated with a sequence encoding a kinase domain-related protein, e.g., the sequence had homology, but not identity, to known kinase domain-related proteins.

The AF169034 IMAGE clone was sequenced using standard ABI dye-primer and dye-terminator chemistry on a 377 automatic DNA sequencer. Sequencing revealed that the sequence corresponds to SEQ ID NO:5, SGK2 $\alpha$ . The expression of SGK2 $\alpha$  was determined by dot blot analysis, and the protein was found to be upregulated in several tumor samples. SEQ ID NO:18 and 19 were used in amplification.

*Dot blot preparation.* Total RNA was purified from clinical cancer and control samples taken from the same patient. Samples were used from both liver and colon cancer samples. Using reverse transcriptase, cDNAs were synthesized from these RNAs. Radiolabeled cDNA was synthesized using Strip-EZ<sup>TM</sup> kit (Ambion, Austin, TX) according to the manufacturer's instructions. These labeled, amplified cDNAs were then used as a probe, to hybridize to human protein kinase arrays comprising human SGK2 $\alpha$ . The amount of radiolabeled probe hybridized to each arrayed EST clone was detected using phosphorimaging.

The expression of SGK2 $\alpha$  was substantially upregulated in the tumor tissues that were tested. The data is shown in Table 4, expressed at the fold increase over the control non-tumor sample.

Table 4

	liver 1	liver 2	liver 3	colon 1	colon 4	colon 5	colon 7	colon 8	colon 9	colon 10
SGK2 $\alpha$	3.6	2.4	1.1	1.1	1.0	3.9	1.8	1.4	0.7	2.55
beta-actin	2.05	1.07	1.57	0.42	1.28	2.19	1.20	4.60	0.60	0.49
GAPDH	1.30	0.33	1.25	0.76	Not done	Not done	Not done	Not done	Not done	Not done
K413 (ribosomal protein)	Not done	Not done	Not done	Not done	1.72	2.36	2.10	1.00	1.00	1.68

The data displayed in Table 5 provides a brief summary of the pathology report of the patient samples.

Table 5

Patient	Age	Gender	Precursor Adenoma	Site of Involvement	Differentiation	Vascular Invasion	Lymphatic Involvement	Metastasis
Liver 1	49	Female	N/a	Liver	Moderately Differentiated	No	Yes	No
Liver 2	53	Male	N/a	Liver	Moderately Differentiated	Yes	No	No
Liver 3	75	Female	Yes	Right Colon	Moderately differentiated	No	No	No
Colon 1	55	Female	No	Rectum	Moderately Differentiated	N/A	Yes	No
Colon 4	91	Female	Yes	Cecum	Moderately Differentiated	No	Yes	No
Colon 5	79	Male	No	Ileum and Colon	Moderately Differentiated	No	No	No
Colon 7	93	Male	No	Recto-Sigmoid	Moderately Differentiated	No	No	No
Colon	61	Male	Yes	Yes	Moderately	No	Yes	Yes,

8					Differentiated			Liver
Colon 9	60	Male	No	Recto-Sigmoid	Moderately Differentiated	Yes	No	Yes, Liver
Colon 10	60	Male	No	Sigmoid Colon	Moderately Differentiated	Yes	Yes	No

*Creation of stable cell lines over expressing SGK2 in HEK293 cells.* We constructed a mammalian expression vector encoding N-terminal Xpress tagged forms of the 45 kDa SGK2 kinase. The ORF of SGK2 was placed in frame with N-terminal Xpress and a Histidine tag in pcDNA 3 mammalian expression vector using standard PCR-based cloning techniques. To characterize SGK2 at the protein level, HEK293 cells were transfected and a stable cell line selected with pcDNA 3 His-Xpress-SGK2 plasmid in the presence of G418. HEK293 cells were stably transfected with mammalian vector incorporating SGK2 to produce clones over expressing wild type SGK2.

Briefly, cells were grown in d-MEM containing 5% FCS, 2mm L-glutamine, glucose (3.6 mg/ml) and G418 (40 µg/ml) was added to transfected cells to maintain selection pressure. The cell lysates were prepared from stable cell lines and subjected to Western blotting with anti-Xpress mAb and anti-His-antibody. A protein with a 45 kDa molecular mass was identified in lysates of HEK293 cells stably expressing SGK2. A similar protein could not be detected in the control HEK293 cells. This analysis suggests that HEK293 cells are overexpressing SGK2 as a fusion protein. To determine whether these cells express higher levels of SGK2 mRNA, we isolated mRNA from stable cell lines as well as control HEK293 cells. Equal amounts of mRNA were immobilized on a nylon membrane and subjected to hybridization with a specific SGK2 probe. Stable cell lines expressed a significantly higher concentration of SGK2 mRNA as compared to control HEK293 cells. These results indicate that stable cell lines are over expressing SGK2 mRNA as well as SGK2 protein. These stable cell lines were used in the subsequent experiments.

*Overexpressed SGK2 can phosphorylate GSK3 in vivo.* We explored the identification of the downstream effectors of SGK2 by using SGK2 overexpressing cells. SGKs have 54 % nucleotide sequence homology to PKB and it has previously been shown that PKB could phosphorylate GSK3 *in vivo* and *in vitro*. In view of this, we wanted to determine whether SGK2 could regulate the activity of GSK3, a kinase that is normally phosphorylates beta catenin. GSK3 phosphorylates beta catenin and targets it for destruction via a ubiquitin-proteasome pathway. To determine whether SGK2 could phosphorylate GSK3, initially, we carried out transient transfection assays in human embryonal kidney epithelial cells (HEK293). Transfection of SGK2 resulted in increased phosphorylation of GSK3. This was monitored by specific anti-GSK3 phospho Ser9 antibody. These results suggest that SGK2 effects the phosphorylation of GSK3 *in vivo*.

As a control, we measured the concentration of GSK3 protein in the assay. The concentration of GSK3 is not affected by SGK2 but the phosphorylation status of GSK3 is affected by the expression of SGK2. This is particularly significant at the lower concentration of serum (0.5%) and 0.1-0.2 µg concentration of SGK2 plasmid. Because GSK3 activity can be inhibited by phosphorylation, it is possible that inhibition of GSK3 by SGK2 could lead to other downstream

effects. To further evaluate the link between SGK2 and GSK3 we measured the phosphorylation status of GSK3 in HEK293 cells and in HEK293 cells stably transfected with SGK2 (named SGK-37A). SGK-37A cells overexpressing SGK2 had significantly higher phospho GSK3 than normal HEK293 cells.

5 This data demonstrates that SGK2 can modulate the phosphorylation status of GSK3 in stably transfected HEK293 cells. It has been shown that GSK3 phosphorylation leads to GSK3 inactivation (Cross *et al.* (1995) Nature 378:785-789). SGK2 may directly phosphorylate GSK3 and inactivate it, thereby abolishing phosphorylation of the cytoplasmic signaling molecule  $\beta$ -catenin and causing its stabilization and nuclear translocation. In the nucleus,  $\beta$ -catenin associates with TCF4 to  
10 induce the transcription of several genes including cyclin D1.

*SGK2 enhances cell proliferation.* Since we have shown that overexpression of SGK2 stimulates GSK3 phosphorylation, it was investigated whether this could lead to cell proliferation. To study the effects of SGK2 on cell proliferation, we used several cells types. These cells were  
15 transiently transfected with SGK2 or control DNA plasmids. The DNA synthesis rate was determined by measuring [<sup>3</sup>H] thymidine incorporation. When HEK293 and 3T3 cells were transfected with SGK2, they exhibited greater amounts of DNA synthesis than the control vector. The rate of proliferation was dependent on the concentration of transfected SGK2 plasmid. This data indicates that SGK2 stimulates cell proliferation in these cell types. Co-expression of PDK1 with SGK further  
20 enhanced the rate of proliferation.

These data reveal that SGK2 promotes proliferation in a variety of cells, and suggest that SGK2 promotes cell proliferation and support tumor progression in these types of cells.

*SGK overexpression stimulates AP1 transactivation.* It has previously been shown that  
25 GSK3 phosphorylates c-Jun at C-terminal sites, resulting in inhibition of DNA binding (Nikolakaki *et al.* (1993) Oncogene 8:833-840) This can lead to the inhibition of AP1 activity in intact cells. It is believed that this keeps the cell's homeostasis in control. Since we have shown that SGK2 phosphorylates GSK3, we wanted to evaluate whether this could modulate the AP1 transactivation in cells overexpressing SGK2.

30 AP1 activity was measured in HEK293 cells and in HEK293 cells stably transfected with SGK2. SGK-37A clones have been shown to overexpress SGK2. AP1 activity was several fold higher in SGK-37A than in control HEK293 cells (Fig. 3). This data suggests that SGK2 can upregulate AP1 promoter activity in HEK293 cells. In the nucleus, AP1 transactivation induces the transcription of several genes involved in proliferation and several MMP genes. Our data suggests  
35 that SGK2 can induce an invasive phenotype via AP1 dependent upregulation of MMP gene expression.

*SGK2 stimulates the translocation of beta catenin into the nucleus.* SGK2 stabilizes beta catenin in HEK293 cells. To determine whether overexpression of SGK2 in HEK293 cells would  
40 induce beta catenin stability, we employed immunocytochemistry analysis. Monoclonal antibody for

beta catenin was used in the analysis. *In vivo* expression of beta catenin was measured by standard protocols. The results indicate that SGK2 expressing cells have a higher concentration of beta catenin than parental cells.  $\beta$  catenin is localized entirely in the nucleus of SGK2 overexpressing cells, suggesting that SGK2 regulates the translocation of beta catenin into the nucleus.

5 Taken together, these results indicate that SGK2 is an important intracellular regulator of signaling via components of the Wnt/wingless pathway, specifically through modulation of GSK3 $\beta$  activity. Beta catenin has a consensus sequence phosphorylation site for GSK3 $\beta$ , and GSK3 $\beta$  acts to cause the degradation of beta catenin. Several studies have shown that GSK3 $\beta$  phosphorylates  $\beta$  catenin and that the phosphorylation of  $\beta$  catenin is essential for its degradation. If  $\beta$  catenin is not  
10 phosphorylated, the stability of  $\beta$  catenin increases in the cytoplasm and subsequently increases the translocation of beta catenin to the nucleus. In the nucleus, beta catenin associates with TCF4 to induce the transcription of several genes including cyclin D1.

*SGK stimulates TCF4 transcriptional activity.* The nuclear translocation of beta catenin is  
15 associated with a complex formation between  $\beta$  catenin and members of the high mobility group transcription factors, LEF1/TCF, which then activate transcription of target genes. LEF1 is a transcription factor that is by itself unable to stimulate transcription from multimerized sites, although in association with  $\beta$  catenin LEF1/TCF proteins can augment promoter activity from multimerized binding sites.

20 We examined the transcriptional activation of a synthetic TCF4/ $\beta$  catenin responsive promoter construct containing TCF4 binding sites in HEK293 cells overexpressing SGK2 and in control HEK293 cells. Higher promoter activity was observed only in SGK2 overexpressing cells. Transient transfection of increasing concentrations of TCF4 reporter gene produced concentration dependent TCF4 transactivation in SGK2 over expressing cells, whereas transient transfection of  
25 TCF4 reporter gene into HEK293 cells did not produce significant transactivation. This result indicates that SGK2 selectively targets GSK3 $\beta$ . Regulated  $\beta$  catenin subsequently increased the TCF4 transactivation in HEK293 cells. These data indicates that SGK2 overexpression overcomes the regulation of TCF4 expression by adhesion /deadhesion, and that it maintains constitutively high levels of TCF4 transactivation. TCF4/ $\beta$  catenin has been shown to induce transcription of genes  
30 encoding homeobox proteins that regulate mesenchymal genes, and this pathway is likely to mediate the epithelial to mesenchymal transformation. Constitutive activation of TCF/ $\beta$  catenin is oncogenic in human colon carcinomas. The data presented here show that SGK2 can modulate  $\beta$  catenin signaling and transactivate TCF4 reporter genes.

35 *SGK2 stimulate NF- $\kappa$ B transcription.* It has previously been shown that PKB/AKT regulate NF- $\kappa$ B mediated transactivation. In view of this, we next asked whether SGK2 could activate the NF- $\kappa$ B reporter assay *in vivo*. To evaluate NF- $\kappa$ B transactivation, the NF- $\kappa$ B promoter containing luciferase plasmid was transiently transfected into HEK293 cells overexpressing SGK2 and control HEK293 cells. As shown in Figure 3, the activity of the NF- $\kappa$ B reporter was several fold higher in

SGK2 overexpressing cells than in control HEK293 cells. Increasing concentration of NF- $\kappa$ B reporter plasmid in the SGK2 overexpressing cells increased luciferase activity, whereas NF- $\kappa$ B mediated transactivation had no significant effect on the control HEK293 cell. This data demonstrates that SGK2 can regulate NF- $\kappa$ B transactivation.

5 NF- $\kappa$ B transactivation occurs in response to the major proapoptotic signals, including TNF- $\alpha$ , anticancer drugs, and ionizing radiation. Several reports have indicated that in some cancer cell types, NF- $\kappa$ B is an important factor for cell survival. Hence, SGK2 may promote cell survival in certain cell types and participate in tumor promotion.

10 NF- $\kappa$ B DNA binding activity coincides with degradation of I $\kappa$ B alpha. To examine the status of I $\kappa$ B alpha in the SGK2 overexpressing cells, we performed the following experiment. Cellular extracts were made from HEK293 cells overexpressing SGK2 and control HEK293 cells. These cell extracts were analyzed against a specific anti-phospho I $\kappa$ B alpha antibody. Increasing concentrations of cell extract produced increasing I $\kappa$ B alpha phospho signal, whereas the same protein concentration of control HEK293 cell extracts did not produce I $\kappa$ B alpha phospho signals.  
15 These results suggest that NF- $\kappa$ B activation by SGK2 is mediated by I $\kappa$ B alpha phosphorylation.

*SGK2 phosphorylation of BAD.* SGK2 phosphorylates some of the proteins phosphorylated by PKB. It has previously been shown that PKB can phosphorylate BAD. It was tested whether SGK2 phosphorylates BAD. Protein was isolated from HEK293 cells overexpressing SGK2 and  
20 control HEK293 cells; and the phosphorylation status of BAD was measured. The cells were lysed and the expression of BAD phosphorylation was determined by anti-BAD phospho antibody. SGK2 overexpressing cells contain higher levels of phospho Bad protein than normal cells, although expression levels of BAD protein were unaffected by SGK2. These finding show that SGK2 increases BAD phosphorylation in HEK293 cells.

25 Phosphorylation of BAD may lead to the prevention of cell death via a mechanism that involves the selective association of phosphorylated forms of BAD with 14-3-3 protein isoforms. The identification of BAD as a SGK2 substrate expands the list of *in vivo* SGK2 targets. Recent studies have revealed that BAD represents a point of convergence of several different signal transduction pathways that are activated by survival factors that inhibit apoptosis in mammalian cells. These data  
30 suggest that SGK2 inhibits apoptosis in mammalian cells through phosphorylation of BAD.

*Phosphorylation of FKHR in HEK293 cells.* The forkhead family of transcription factors is involved in tumorigenesis in rhabdomyosarcoma and acute leukemias. FKHR, FKHL1, and AFX mediate signaling via a pathway involving IGFR1, PI3K and PKB/AKT. Phosphorylation of FKHR  
35 family members by PKB/AKT promotes cell survival and regulates FKHR nuclear translocation and target gene transcription. Insulin stimulation specifically promotes phosphorylation of this threonine site and causes FKHR cytoplasmic retention by 14-3-3 protein binding on the phosphorylated sequence.

To investigate whether FKHR could be phosphorylated by SGK2 in a cellular context, we created HEK293 cells stably expressing SGK2 and then examined FKHR phosphorylation with phospho specific antibodies. These experiments demonstrated that FKHR, Thr24 or Ser 256 were phosphorylated at low levels in normal HEK293 cells whereas HEK293 stable cells had higher levels of FKHR phosphorylation. This data shows that FKHR exhibits higher phosphorylation status in SGK2 overexpressing cells.

It has previously been shown that FKHR phosphorylation leads to FKHR's interaction with 14-3-3 proteins and sequestration in the cytoplasm, away from its transcriptional targets. The unphosphorylated FKHR accumulates in the nucleus where it activates death genes, including Fas ligand gene, and thereby participates in the process of apoptosis. Upon phosphorylation, FKHR interacts with 14-3-3 and is retained in the cytoplasm thereby inhibiting its ability to activate transcription. Therefore, phosphorylation of FKHR by SGK2 can promote cell survival.

*CREB phosphorylation is regulated by SGK2.* To determine whether CREB is a regulatory target for SGK2, we performed the following experiments. Equal amounts of protein were isolated from SGK2 overexpressing cells as well as control HEK293 cells and subjected to phospho CREB analysis. The cells were lysed and the amount of CREB phosphorylation was determined by CREB phospho (Ser133) antibody. SGK2 overexpressing cells contain higher levels of phospho CREB protein than normal cells, showing that SGK2 increases CREB phosphorylation

Studies by have indicated that CREB function is important in promoting cell survival. Cyclin D1 expression is regulated by CREB. The majority of breast cancer cell lines and mammary tumors overexpress cyclin D1, suggesting that induction of cyclin D1 may play an important role in mammary tumorigenesis. These studies further clarify the mechanism by which SGK2 could promote cell survival. CREB function is important in promoting cell survival by responding to growth factor stimulation. These data imply that SGK2 modulates the phosphorylation status of CREB *in vivo*, and therefore is involved in cell survival through the CREB pathway.

*SGK2 is activated by PDK1 and the activation leads to increased kinase activity.* To determine whether cloned and purified SGK2 can phosphorylate specific peptides directly, SGK2 was purified from insect cells. Activation was performed *in vitro* by mixing SGK2 and PDK1. After the activation, the PDK1 was removed from the mixture and purified SGK2 was used for the analysis. The cell extracts were purified by GST affinity column chromatography and the purity was analyzed by SDS- PAGE. Both non-activated and PDK1-activated SGK2 produced similar amounts of protein. SGK2 activated by PKD1 was significantly phosphorylated, while non-activated SGK2 was not. The data is shown in Figure 4.

The kinase activity of SGK2 was evaluated using specific peptides. SGK2 was incubated with two different peptide substrates ((SEQ ID NO: 32) PKB -sub: CKRPRAASFAE; and (SEQ ID NO:33) PDK1: KTFCGTPEYLAPEV RREPRILS EEEQEMFRDFDYI (UBI Catalogue #12401), and *in vitro* kinase assays carried out. Equivalent concentration of purified SGK2 were incubated using a Beckman Biomek 2000 robotic system. Each well containing 25 µl reaction mixture composed of 10

5  $\mu$ l SGK2, 5  $\mu$ l of assay dilution buffer, 5  $\mu$ l of peptide substrate and 5  $\mu$ l of  $\gamma$   $^{32}$ P-ATP. The kinase reaction was carried out for 15 minutes at room temperature (22°C). At the end of the reaction period, 10  $\mu$ l of the reaction mixture was spotted onto 96-well p81 phosphocellulose multiscreen plates from Millipore, washed and the  $^{32}$ P incorporation was counted in a Wallac Microbeta scintillation counter.

10 Peptides incubated with purified SGK 2 gave significant incorporation of  $^{32}$ P, whereas in the absence of peptides no significant incorporation was seen. When comparing the peptides, PKB-sub had significant incorporation of  $^{32}$ P whereas addition of same amount of control peptide (PDK1 peptide) had no significant incorporation. This data demonstrates that purified SGK2 possesses a kinase activity *in vitro*. Moreover, the PDK1 activated SGK2 had significantly higher kinase activity compared to non-activated SGK2. These data clearly demonstrate that activated SGK2 phosphorylates the GSK3 Ser9 (GSK3 $\beta$  consensus) sequence, supporting the previous observation that SGK2 overexpressing cells exhibit higher level of GSK3 Ser9 phosphorylation than control cells.

15 *SGK2 kinase activity is stimulated by Calyculin A and Okadaic acid.* Hi5 insect cells expressing GST-SGK2 were treated with 100 nM microcysteine, 99.8 nM okadaic acid and 49.8 nM calyculin A for four hours at 27°C. The GST-SGK2a fusion protein was purified by GST-agarose affinity column and eluted with 20mM Glutathione/50mM Tris-HCl/50mM NaCl, pH 7.5. Substrates were PKB sub and CapK sub at 1mg/ml, for 15 minutes at room temperature. The results were as follows:

	No-Substrate (CCPM1)	PKB sub (CCPM1)	CapK sub(CCPM1)
Untreated	349	979	1081
Microcysteine	305	217	330
Calyculin A	0	92540	59335
Okadaic Acid	2078	132171	161553

25 These data indicate that okadaic acid and Calyculin A stimulated SGK2 kinase activity, suggesting that okadaic and Calyculin A can stimulate SGK2 activity. It has previously been shown that protein phosphatase inhibitors such as okadaic acid and Calyculin A modulate phosphorylation of several nuclear proteins.

30 These findings demonstrate SGK2 could promote cell survival and cell growth. Overexpression of SGK2 in HEK293 cells increased GSK3 phosphorylation thereby inhibiting the activity of GSK3, and subsequently leading to AP1 transactivation. GSK3 is involved in regulation of several intracellular signaling pathways, of which the Wnt pathway is of particular interest. In mammals, Wnt signaling increases the stability of beta catenin resulting in transcriptional activation of LEF-1/TCF. In SGK2 overexpressing cells we have shown increased LEF-1/TCF transactivation through increasing the stability of the beta catenin pool in the cells, suggesting that SGK2 activates



the Wnt signaling pathway, which can lead to nuclear localization of beta catenin and increased transactivation of LEF-1/TCF.

At least 6 SGK2 substrates have been identified in mammalian cells, and they fall into two main classes: regulators of apoptosis and regulators of cell growth, including protein synthesis and glycogen metabolism. The SGK2 substrates involved in cell/death regulation include Forkhead transcription factors (FKHR), the pro-apoptotic Bcl-2 family member BAD, and the cyclic AMP response element binding protein (CREB).

We have also demonstrated that SGK2 could regulate signaling pathways that lead to induction of the NF- $\kappa$ B family of transcription factors in HEK293 cells. This induction occurs at the level of degradation of the NF- $\kappa$ B inhibitor I $\kappa$ B and is specific for NF- $\kappa$ B. These data suggest that SGK2 appears to be a point of convergence for several different signaling pathways. Taken together, our results suggest that the over expression of SGK2 may therefore play a central role in tumor cell progression.

## **Materials and Methods.**

Buffers, reagents and methods were as described in Example 2, unless otherwise stated.

**Cloning of full length SGK2.** To generate the full length cDNA of SGK2, a pair of primers were designed and used in a PCR reaction. The amplification product was cloned through restriction sites, EcoR I and Xho I, into bacteria expression vector pGEX-4T-3 and mammalian expression vector pcDNA3.1/His B. All constructs were verified by restriction enzyme digestion and DNA sequencing.

**Expression and Purification of SGK2 Protein.** The human SGK2 gene was subcloned into baculovirus transfer vector pAcG2T (BD Pharmingen) under the control of the strong AcNPV (*Autographa californica* Nuclear Polyhedrosis Virus) polyhedrin promoter. This was co-transfected with linear BaculoGold™ DNA in *Spodoptera frugiperda* Sf9 cells following the manufacturer's procedure (BD Pharmingen). The high titer of GST-SGK2 recombinant baculovirus was amplified in Sf9 cells in TNM-FH medium (JHR Biosciences) with 10% fetal bovine serum. The GST-SGK2 protein was expressed in about  $5 \times 10^8$  Hi5 cells (Invitrogen) in 500 ml of Excell-400 medium (JHR Biosciences) with about 5 MOI for a period of 72 h in a spinner flask. The cells were harvested at 800Xg for 5 min at 4°C. The pellet was lysed in 40 ml of Lysis Buffer by sonication and centrifuged at 10,000Xg at 4°C for 15 min. The supernatant was loaded on the column contained 2.5 ml of glutathione-agarose (Sigma). The column was washed with Wash Buffer A until OD280 returned to baseline, then Wash Buffer B. The GST-SGK2 protein was eluted in Elution Buffer. The fraction was aliquoted and stored at -70°C.

**Assay of SGK2.** SGK2 was assayed at room temperature for 15 min with 25  $\mu$ l of reaction mixture containing 5 mM MOPS, pH 7.2, 5 mM MgCl<sub>2</sub>, 5 mM  $\beta$ -glycerophosphate, 50  $\mu$ M dithiothreitol, 1  $\mu$ M  $\beta$ -methyl aspartic acid, 1 mM EGTA, 0.5 mM EDTA, 0.5  $\mu$ M PKI, 50  $\mu$ M [ $\gamma$ -<sup>32</sup>P]-ATP and 0.2  $\mu$ g/ $\mu$ l PKB-sub peptide (UBI) or PDKtide peptide (UBI) as substrates. GSK3 consensus

peptide (SEQ ID NO:34, PKB -sub: CKRPRAASFAE), PDK1 sub- SEQ ID NO:35, KTFCGTPEYLAPEVRREPRILSEEEQEMFRDFDYI. Reactions were initiated by addition of [ $\gamma$ - $^{32}$ P]-ATP and terminated by spotting 10  $\mu$ l of aliquots onto cellulose phosphate paper in 96-well filtration plate (Millipore), followed by washing in 1% phosphoric acid. The dried plate was added 25  $\mu$ l scintillant (Amersham) and counted.

**SGK2 Phosphorylation by PDK1.** SGK2 was incubated with active His-tag PDK1 in the presence of  $Mg^{2+}$ /ATP. His-tag PDK1 was expressed in insect cells and purified on Talon affinity column. SGK2 phosphorylation assay was performed at room temperature for 20 min in 25  $\mu$ l of reaction solution consisting of 10 mM MOPS, PH 7.2, 15 mM  $MgCl_2$ , 5 mM  $\beta$ -glycerophosphate, 1 mM EGTA, 0.2 mM sodium orthovanadate, 0.2 mM dithiothreitol, 0.5  $\mu$ M PKI, 0.2  $\mu$ M Microcystin-LR, 75 ng/ $\mu$ l PtdIns (3,4,5) P3 (PIP3), 156 ng/ $\mu$ l dioleoyl phosphatidylcholine (DOPC), 156 ng/ $\mu$ l dioleoyl phosphatidylserine (DOPS), 50  $\mu$ M [ $\gamma$ - $^{32}$ P]-ATP, ~20 ng His-PDK1 and ~5  $\mu$ g GST-SGK2. The reaction were incubated and terminated by addition of 25  $\mu$ l 2X loading buffer. No PDK1 was added to negative control reaction. 25  $\mu$ l of above loading samples were run on 9% SDS-PAGE. The dried Coomassia blue-stained gel was imaged in GS-525 Molecular Imager<sup>®</sup> System (BIO-RAD).

**SGK2 Activation by PDK1.** About 2.5 mg of GST-SGK2 and 1  $\mu$ g of His-PDK1 were incubated at 4°C for 2 hours in 20 ml of activation solution containing 10 mM MOPS, PH 7.2, 15 mM  $MgCl_2$ , 5 mM  $\beta$ -glycerophosphate, 1 mM EGTA, 0.2 mM sodium orthovanadate, 0.2 mM dithiothreitol, 0.5  $\mu$ M PKI, 0.2  $\mu$ M Microcystin-LR, 75 ng/ $\mu$ l PtdIns (3,4,5) P3 (PIP3), 156 ng/ $\mu$ l dioleoyl phosphatidylcholine (DOPC), 156 ng/ $\mu$ l dioleoyl phosphatidylserine (DOPS), and 10 mM ATP. The glutathione was removed from the activation solution on Q-sepharose column. The activated GST-SGK2 were re-purified from glutathione-agarose column.

**Cell and cell culture.** 293 cells were stably transfected with a mammalian vector incorporating SGK2 to produce overexpressing wild type SGK2. Cells were grown in MEM containing 10 % FCS, 2 mM L-glutamine, glucose (3.6 mg/ml), insulin (10  $\mu$ g/ml), and G418 (40  $\mu$ g/ $\mu$ l) were added to transfected cells to maintain selection pressure.

**Transient transfection:** HEK293 cells were seeded at  $1.5 \times 10^5$  cells/well plate and grown for 24 hr before transfection. Various concentration of plasmid DNA were transfected using Fugene (Roche) according to the manufacture's protocol. DNA content was normalized with appropriate empty expression vectors. Cells were starved for O/N in DMEM containing 0.5 % FBS.

**Western blotting:** Cells were lysed for 10 minutes on ice in NP-40 lysis buffer (1% NP40, 50 mM Hepes, pH 7.4, 150 mM NaCl, 2mM EDTD, 2mM PMSF, 1mM Na-o- vanadate, 1 mM NaF, 10  $\mu$ g/ml aprotinin, 10  $\mu$ g/ml leupeptin). Extracts were centrifuged with the resulting supernatants being the cell lysate used in assays. Lysates were electrophoresed through SDS-PAGE and transferred to Immobilon-P (Millipore Bedford, MD). Antibodies used to probe Western blots were: Anti-Xpresss, Phospho-FKHR (Thr24, Caspase-9, Phospho-IkB $\alpha$  (Ser32/36), Bad, Phospho CREB, Phospho GSK3  $\alpha$  (ser-9), GSK3 monoclonal, (New England Biolab, Mississauga, ON, Canada) Bands were visualized with ECL chemiluminescent substrate (Amersham Pharmacia biotech).

**Reporter assay:** 293 cells were transfected in 6-well plates with Fugene (Roche Diagnostics) according to the manufacture's instructions. To analyse various reporter assay, respective reporter construct were transiently transfected with indicated amount of luciferase reporter gene construct series of LEF-1/TCF binding sites, AP1 binding sites and NF- $\kappa$ B binding sites. Extracts were prepared and assayed 24-48 after transfection and relative luciferase activity was determined using Promega Dual luciferase reporter assay system as described by the manufacture.

**Immunocytochemistry:** 293-cell lines were grown in 8 chamber slides for 2 days, washed with PBS, fixed in absolute cold methanol for 10 minutes, washed with PBS and incubated overnight at 4° C with beta-catenin (#C19220-BD Transduction Laboratories), His -Prob (#Sc-803, Santa Cruz, USA) and anti-Xpress antibody (R910-25, Invitrogen), all diluted 1:100 in PBS with 0.1 % Triton X-100, then washed with PBS. Proceed with immunostaining by using the ABC method (ABC-Elite kit, Vector). According to the amount and intensity of staining, the scale was divided into 2 classes. The slides designated "+" had positive staining intensity, slides designated "-" showed no immunoreactivity. In addition to conventional light microscopic examination, in order to quantitate the amount of reactivity, specimens were also investigated by computerized image analysis using Image pro (Media Cybernetics, MD, USA).

**Expression and Purification of GST-SGK2a from Hi 5 Insect cells.** Human SGK2a was cloned into the Baculovirus vector pAcG2T with the multiple cloning sites in the vector.. This vector contains an N-terminal Glutathione S-transferase tag (GST-tag) which allows for affinity purification on Glutathione agarose beads. The vector was infected into Sf9 insect cells via lipid vesicles. The titer of the baculovirus particles was amplified in Sf9 insect cells. The amplified baculovirus titer was then used to infect four 250 ml volume spinner-flasks (Pyrex) containing Hi 5 cells which were at approximately  $0.8 \times 10^6$  cells/ml. The expression of the fusion protein cells were incubated at 27°C, with spinning at 80 rpm, over 3.5 days. Near the end of this expression period, each of the four 180 ml cultures of Hi 5 cells were stimulated with a 4 hour, 27° C treatment with either 100% DMSO (negative control) or one of three different PP1 and PP2a phosphatase inhibitors: 100 nM Microcystin (Calbiochem), 55.05 nM Calyculin A (Calbiochem), and 96.9 nM Okadaic Acid (Calbiochem). Finally, the cells were collected by centrifugation in Beckman Avant-25 rotor ID 10.500 at 3000 rpm, 5 min, 4°C. After a brief 1xPBS wash, the cells were resuspended in a 50 mM Tris-HCl / 1% NP-40, pH 7.5 lysis buffer supplemented with the following protease inhibitors: 100  $\mu$ M Sodium Vanadate, 1 mM glycerophosphate, and 237  $\mu$ l Protease Inhibitor Cocktail Set III (Calbiochem). The cells were lysed using the small probe of the sonic dismembrator: output 1:3 repetitions of 8 sec on and 5 sec pause. Once the cytosolic proteins are released into the supernatant, the cellular debris is removed by centrifugation in Beckman Avanti-30: 14,000 rpm, 15 min, 4°C. The lysate supernatant is applied to Glutathione-agarose beads (SIGMA) and allowed to batch-bind, rotating end-over-end, at 4°C for 30 mins. Non-specific proteins are washed from the beads 5 times with STEL 500 (50 mM Tris-HCl / 500 mM NaCl, pH 7.5) followed by 5 times with STEL 50 (50 mM Tris-HCl / 50 mM NaCl, pH 7.5). Finally, the GST-tagged fusion protein is eluted from the beads with Elution buffer (20 mM glutathione / 50 mM Tris-HCl / 50 mM NaCl). Purified SGK2a kinase activity is assayed against PKB

peptide SEQ ID NO:36 (CKRPRAASFAE), a universal SRC kinase family substrate and CapK peptide SEQ ID NO:37 (CGRTGRRNSI).

#### Example 4

##### GRK5

Genbank sequences were screened as described in Example 1. Analysis of BLASTN and BLASTX outputs identified a EST sequence from IMAGE clone A1358974 that had potential for being associated with a sequence encoding a kinase domain-related protein, e.g., the sequence had homology, but not identity, to known kinase domain-related proteins.

The A1358974 IMAGE clone was sequenced using standard ABI dye-primer and dye-terminator chemistry on a 377 automatic DNA sequencer. Sequencing revealed that the sequence corresponds to SEQ ID NO:7. SEQ ID NO:20 and 21 were used for amplification.

The expression of GRK5 was determined dot blot analysis, and the protein was found to be upregulated in several tumor samples.

*Dot blot preparation.* Total RNA was purified from clinical cancer and control samples taken from the same patient. Samples were used from both liver and colon cancer samples. Using reverse transcriptase, cDNAs were synthesized from these RNAs. Radiolabeled cDNA was synthesized using Strip-EZ™ kit (Ambion, Austin, TX) according to the manufacturer's instructions. These labeled, amplified cDNAs were then used as a probe, to hybridize to human protein kinase arrays comprising human GRK5. The amount of radiolabeled probe hybridized to each arrayed EST clone was detected using phosphorimaging.

The expression of GRK5 was substantially upregulated in the tumor tissues that were tested. The data is shown in Table 6, expressed at the fold increase over the control non-tumor sample.

Table 6

	liver 1	liver 2	liver 3	colon 1	colon 4	colon 5	colon 7	colon 8	colon 9	colon 10
GRK5	1.5	0.7	2.6	1.8	1.3	4.3	1.9	0.4	0.7	2.00
beta-actin	2.05	1.07	1.57	0.42	1.28	2.19	1.20	4.60	0.60	0.49
GAPDH	1.30	0.33	1.25	0.76	Not done	Not done	Not done	Not done	Not done	Not done
K413 (ribosomal protein)	Not done	Not done	Not Done	Not Done	1.72	2.36	2.10	1.00	1.00	1.68

*Expression of GRK5.* To characterize GRK5 at the protein level, Hi5 cells were transfected with pAcG4T3-GRK5. The ORF was cloned into baculovirus expression vector pAcG2T (BD pharmagen). This construct construct was then co-transfected with linear BaculoGold DNA into Sf9 cells to obtain an isolated recombinant virus. The recombinant virus was amplified and then used to infect sf9 cells. GRK5 expressed in Hi5 cells was purified by glutathione-sepharose column chromatography. Cell lysates were prepared from these cell lines for further analysis. Briefly, the precipitations were performed with ectopically expressed tagged GRK5 from insects cells as described in the method section. This will enable us to perform *in vitro* kinase assays for the identification of specific inhibitors of this kinase.

To characterize GRK5 at the protein level, HEK293 cells were transfected with pcDNA3-X-press-GRK5 by standard methods. The transiently transfected cell lines were used to prepare whole cell lysates which were analysed by Western blotting with an anti-X-press monoclonal antibody. These experiments revealed a fusion protein in the stably transfected cell lines, whereas HEK293 cell lines transfected with the vector only control did not have this protein. Similarly, we also detected GRK5 in transfected Hi5 cells.

The anti-X-press antibody was used to purify the kinase via immunoprecipitation. Anti-X-press antibody precipitated fusion protein was subjected to SDS-PAGE analysis. SDS-PAGE indicated that we could successfully purify the GRK5 from the lysates from transfected cells.

Next, anti-X-press antibody immunoprecipitated materials and glutathione-sepharose chromatography purified materials were used for *in vitro* kinase assays. Casein, MBP and phosvitin were found to be phosphorylated by purified GRK5. In the absence of substrate there was no significant incorporation of radioactive materials ( $^{32}\text{P}$ ) indicating that GRK5 does not autophosphorylate under these conditions. This suggests that glutathione-sepharose and X-press antibody purified materials possess a kinase activity and that this kinase activity is capable of phosphorylating substrates *in vitro*.

*Expression and Purification of GRK5 Protein.* The human GRK5 gene was subcloned into baculovirus transfer vector pAcG4T3 derived from pAcG2T (BD Biosciences) under the control of the strong AcNPV (*Autographa californica* Nuclear Polyhedrosis Virus) polyhedrin promoter. This was co-transfected with linear BaculoGold DNA in *Spodoptera frugiperda* Sf9 cells using standard techniques (BD Biosciences). The GST-GRK5 recombinant baculovirus was amplified in Sf9 cells in TNM-FH medium (JHR Biosciences) with 10% fetal bovine serum. The GST-GRK5 protein was expressed in about  $5 \times 10^8$  Hi5 cells (Invitrogen) in 500 ml of Excell-400 medium (JHR Biosciences) at a multiplicity of infection (MOI) of five for 72 h in a spinner flask. The cells were harvested at 800Xg for 5 min at 4°C. The pellet was lysed in 40 ml of Lysis Buffer by sonication and centrifuged at 10,000Xg at 4°C for 15 min. The supernatant was loaded onto a column containing 2.5 ml of glutathione-sepharose (Sigma). The column was washed with Wash Buffer A until OD280 returned to baseline. The column was then washed with Wash Buffer B. The GST-GRK5 protein was eluted in Elution Buffer. The eluted protein was aliquoted and stored at -70°C.

#### Example 5

##### DM-PK

The Genbank EST database was searched as described in Example 1. Analysis of the BLASTN and BLASTX outputs identified a EST sequence from IMAGE clone A1886007 that had potential for being associated with a sequence encoding a kinase domain-related protein, *e.g.*, the sequence had homology, but not identity, to known kinase domain-related proteins. The A1886007 IMAGE clone was sequenced using standard ABI dye-primer and dye-terminator chemistry on a 377 automatic DNA sequencer. Sequencing revealed that the sequence corresponds to SEQ ID NO:9. SEQ ID NO:22 and 23 were used for amplification. The expression of DM-PK was determined dot

blot analysis, and the protein was found to be upregulated in several tumor samples. As shown in Figure 5, a number of isoforms of DMPK were characterized, including SEQ ID NO:10; SEQ ID NO:38 and SEQ ID NO:39.

- 5 *Dot blot preparation.* Total RNA was purified from clinical cancer and control samples taken from the same patient. Samples were used from both liver and colon cancer samples. Using reverse transcriptase, cDNAs were synthesized from these RNAs. Radiolabeled cDNA was synthesized using Strip-EZ™ kit (Ambion, Austin, TX) according to the manufacturer's instructions. These labeled, amplified cDNAs were then used as a probe, to hybridize to human protein kinase
- 10 arrays comprising human DM-PK. The amount of radiolabeled probe hybridized to each arrayed EST clone was detected using phosphorimaging.

The expression of DM-PK was substantially upregulated in the tumor tissues that were tested. The data is shown in Table 7, expressed at the fold increase over the control non-tumor sample.

15

Table 7

	liver 1	liver 2	liver 3	colon 1	colon 4	colon 5	colon 7	colon 8	colon 9	colon 10
DM-PK	1.8	1.2	2.8	2	2.0	1.7	4.5	0.9	1.2	2.35
beta-actin	2.05	1.07	1.57	0.42	1.28	2.19	1.20	4.60	0.60	0.49
GAPDH	1.30	0.33	1.25	0.76	Not done	Not done	Not done	Not done	Not done	Not done
K413 (ribosomal protein)	Not done	Not done	Not done	Not done	1.72	2.36	2.10	1.00	1.00	1.68

The data displayed in Table 8 provides a brief summary of the pathology report of the patient samples.

Table 8

Patient	Age	Gender	Precu- sor Adeno- ma	Site of Involve- ment	Differentiation	Vascular Invasion	Lymphatic Involvement	Metastasis
Liver 1	49	Femal e	N/a	Liver	Moderately Differentiated	No	Yes	No
Liver 2	53	Male	N/a	Liver	Moderately Differentiated	Yes	No	No
Liver 3	75	Femal e	Yes	Right Colon	Moderately differentiated	No	No	No
Colon 1	55	Femal e	No	Rectum	Moderately Differentiated	N/A	Yes	No
Colon 4	91	Femal e	Yes	Cecum	Moderately Differentiated	No	Yes	No
Colon 5	79	Male	No	Ileum and Colon	Moderately Differentiated	No	No	No
Colon 7	93	Male	No	Rectosi gmoid	Moderately Differentiated	No	No	No
Colon 8	61	Male	Yes	Yes	Moderately Differentiated	No	Yes	Yes, Liver

Colon 9	60	Male	No	Recto-Sigmoid	Moderately Differentiated	Yes	No	Yes, Liver
Colon 10	60	Male	No	Sigmoid Colon	Moderately Differentiated	Yes	Yes	No

5 *Expression of DM-PK in E. coli.* To characterize DM-PK at the protein level, *E. coli* cells were transformed with pGEX-DM-PK. The DM-PK ORF was cloned into a pGEX vector (Pharmacia) that was used to transform *E. coli*. A transformed colony was selected and cultured in order to express the GST-DM-PK fusion protein. The fusion protein was purified via glutathione-sepharose column chromatography. The purified fraction was analysed by SDS-PAGE, and showed a band corresponding to the DM-PK protein.

10 As an alternative expression system, we transfected HEK293 cells with DM-PK. Cell lysates of the transfected cells were prepared. We utilized an anti-X-press antibody to immunoprecipitate the recombinant DM-PK. This data shows successful expression and purification of DM-PK from transfected HEK293 cells.

15 *Kinase Activity.* DM-PK purified from both *E. coli* and transfected HEK293 was used for *in vitro* kinase assays. MBP and Histone H1 were both phosphorylated by purified DM-PK in these assays. In the absence of added substrate, there was no significant incorporation of radioactive materials (<sup>32</sup>P) indicating that DM-PK does not autophosphorylate under these conditions. This data shows that purified DM-PK possesses kinase activity.

20 *Experimental procedures.* DM-PK was subcloned into bacterial expression vector pGEX-4T3 (Pharmacia) using EcoR1 and Not I sites. The GST-DM-PK protein was produced in *E. coli* DH5a cells in 2X YT media in 150 uM IPTG at 37°C overnight. The cells were harvested at 10,000Xg for 10 minutes at 4°C. The pellet was suspended in 50 ml of Lysis Buffer (150 mM Tris-HCl pH 7.5, 2.5 mM EDTA, 150 mM Mg Cl<sub>2</sub>, 1% NP-40, 0.1 % β-mercaptoethanol, 0.1 mM PMSF, 1mM benzamide and 10 µg/ml trypsin inhibitor), sonicated, and centrifuged at 10,000Xg for 15 minutes at 4°C. The supernatant was loaded onto a 3 ml glutathione-sepharose column. The column was washed by wash buffer (50 mM Tris-HCl, pH 7.5, 1mM EDTA, 500 mM NaCl, 0.1% β-mercaptoethanol, 0.1% NP-40, 0.1 mM PMSF and 1 mM benzamide) and eluted with standard elution buffer.

### Example 6

#### PDK2 Sequence

30 The Genbank database was searched for ESTs showing similarity to known kinase domain-related proteins as described in Example 1. Analysis of the BLASTN and BLASTX outputs identified a EST sequence from IMAGE clone Af309082 that had potential for being associated with a sequence encoding a kinase domain-related protein, *e.g.*, the sequence had homology, but not identity, to known kinase domain-related proteins. The Af309082 IMAGE clone was sequenced using standard ABI dye-primer and dye-terminator chemistry on a 377 automatic DNA sequencer. Sequencing revealed that the sequence corresponds to SEQ ID NO:11; and a second sequence corresponds to SEQ ID NO:13.

5 Total RNA was purified from clinical cancer and control samples, and cDNAs synthesized by reverse transcriptase. CDNA corresponding to normal and tumor tissue from the same set were simultaneously amplified and labeled with alpha dCTP. Labeled, amplified cDNAs were then used to hybridize to human protein kinase arrays containing 354 protein kinases. The amount of radiolabeled probe hybridizing to each arrayed EST clone was detected using phosphorimaging. Through this process it was determined the PDK2 was upregulated in both colon and liver tumor tissue as compared to matched control tissue.



## WHAT IS CLAIMED IS:

1. A method of screening for biologically active agents that modulate a cancer associated protein kinase function, the method comprising: combining a candidate biologically active agent with any one of:
  - 5 (a) a polypeptide encoded by any one of SEQ ID NO:1, 3, 5, 7, 9, 11 or 13; or having the amino acid sequence set forth in SEQ ID NO:38 or SEQ ID NO:39;
  - (b) a cell comprising a nucleic acid encoding a polypeptide encoded by any one of SEQ ID NO:1, 3, 5, 7, 9, 11 or 13; or
  - 10 (c) a non-human transgenic animal model for cancer associated kinase gene function comprising one of: (i) a knockout of a gene corresponding any one of SEQ ID NO:1, 3, 5, 7, 9, 11 or 13; (ii) an exogenous and stably transmitted mammalian gene sequence comprising polypeptide encoded by any one of SEQ ID NO:1, 3, 5, 7, 9, 11 or 13; and  
determining the effect of said agent on kinase function.
- 15 2. A method for the diagnosis of cancer, the method comprising:  
determining the upregulation of expression in any one of SEQ ID NO:1, 3, 5, 7, 9, 11, 13, 38 or 39 in said cancer.
3. The method of Claim 2, wherein said cancer is a liver cancer.
- 20 4. The method of Claim 2, wherein said cancer is a colon cancer.
5. The method of Claim 2, wherein said determining comprises detecting the presence of increased amounts of mRNA in said cancer.
- 25 6. The method of Claim 2, wherein said determining comprises detecting the presence of increased amounts of protein in said cancer.
7. A method for inhibiting the growth of a cancer cell, the method comprising  
30 downregulating activity of the polypeptide encoded by any one of SEQ ID NO:1, 3, 5, 7, 9, 11 or 13 or having the amino acid sequence set forth in SEQ ID NO:38 or SEQ ID NO:39; in said cancer cell.
8. The method according to Claim 7, wherein said method comprises introducing antisense sequences specific for any one of SEQ ID NO:1, 3, 5, 7, 9, 11 or 13.
- 35 9. The method according to Claim 7, wherein said method comprises introducing an inhibitor of kinase activity into said cancer cell.
10. The method according to Claim 7, wherein said cancer cell is a liver cancer cell.
- 40

11. The method according to Claim 7, wherein said cancer cell is a colon cancer cell.

12. A method of screening for targets of a cancer associated protein kinase, wherein said targets are associated with signal transduction in cancer cells, the method comprising:

5 comparing the pattern of gene expression in a normal cell, and in a tumor cell characterized by up-regulation of any one of SEQ ID NO:1, 3, 5, 7, 9, 11, 13, 38 or 39.

13. The method according to Claim 12, wherein said comparing the pattern of gene expression comprises quantitating specific mRNAs by hybridization to an array of polynucleotide  
10 probes.

14. A method of screening for targets of a cancer associated protein kinase, wherein said targets are associated with signal transduction in cancer cells, the method comprising:

15 comparing the pattern of protein phosphorylation in a normal cell, and in a tumor cell characterized by up-regulation of any one of SEQ ID NO:1, 3, 5, 7, 9, 11, 13, 38 or 39.

15. The method according to claim 12 or claim 14, wherein said signal transduction involves activation by protein dependent kinase 1.

20 16. An isolated nucleic acid comprising the sequence set forth in any one of SEQ ID NO:1, 3, 5, 7, 9, 11 or 13.

1/5

# Proliferation Assay on Cell Lines Transfected with K283





FIGURE 1

# Kinase Activities of Expressed CaMKXI

A. CaMKXI Expressed in Hi5 Cell



B. CaMKXI Expressed in 293 Cell




FIGURE 2

3/5




FIGURE 3

4/5


**3T3 cells 0.5% Serum**

FIGURE 4

- 1) no DNA
- 2) 1 ug/ml pcDNA HIS 3.1
- 3) 0.005 ug/ml K 25/pcDNA HIS 3.1
- 4) 0.1 ug/ml K 25/pcDNA HIS 3.1
- 5) 0.15 ug/ml K 25/pcDNA HIS 3.1
- 6) 0.2 ug/ml K 25/pcDNA HIS 3.1
- 7) 0.25 ug/ml K 25/pcDNA HIS 3.1
- 8) 0.3 ug/ml K 25/pcDNA HIS 3.1
- 9) 0.25 ug/ml K 25/pcDNA HIS 3.1 + 0.1ug/mlPDK 1
- 10) 0.25 ug/ml K 25/pcDNA HIS 3.1 + 0.2ug/mlPDK 1
- 11) 0.375 ug/ml K25/pcDNA HIS 3.1
- 12) 0.5 ug/ml K 25/pcDNA HIS 3.1
- 13) 1 ug/ml K 25/pcDNA HIS 3.1

# Alignment of Three DMPK Isoforms Amplified from Human Brain cDNA Library

Consensus NM_004409 K216-2 K216-4 K216-5	MSAEVRLRRLLQQLVLDPGFLGLEPLDLLLVGHVQELGASELAQDKYKVVADFLQWAEPIVVRILKEVRLQRDDFEILKVIGRGAFSEVAVVVKMKQTGVYANKIMNKWDM MSAEVRLRRLLQQLVLDPGFLGLEPLDLLLVGHVQELGASELAQDKYKVVADFLQWAEPIVVRILKEVRLQRDDFEILKVIGRGAFSEVAVVVKMKQTGVYANKIMNKWDM MSAEVRLRRLLQQLVLDPGFLGLEPLDLLLVGHVQELGASELAQDKYKVVADFLQWAEPIVVRILKEVRLQRDDFEILKVIGRGAFSEVAVVVKMKQTGVYANKIMNKWDM MSAEVRLRRLLQQLVLDPGFLGLEPLDLLLVGHVQELGASELAQDKYKVVADFLQWAEPIVVRILKEVRLQRDDFEILKVIGRGAFSEVAVVVKMKQTGVYANKIMNKWDM MSAEVRLRRLLQQLVLDPGFLGLEPLDLLLVGHVQELGASELAQDKYKVVADFLQWAEPIVVRILKEVRLQRDDFEILKVIGRGAFSEVAVVVKMKQTGVYANKIMNKWDM
Consensus NM_004409 K216-2 K216-4 K216-5	LKRGEVSCFREERDVLVNGDRRWITQLHFAFQDENLYLVMEYVVGDDLLTLLSKFGERIPAEARFYLAEIVMAIDSVHRLGYVHRDIKPDNILLDRCGHIRLADF LKRGEVSCFREERDVLVNGDRRWITQLHFAFQDENLYLVMEYVVGDDLLTLLSKFGERIPAEARFYLAEIVMAIDSVHRLGYVHRDIKPDNILLDRCGHIRLADF LKRGEVSCFREERDVLVNGDRRWITQLHFAFQDENLYLVMEYVVGDDLLTLLSKFGERIPAEARFYLAEIVMAIDSVHRLGYVHRDIKPDNILLDRCGHIRLADF LKRGEVSCFREERDVLVNGDRRWITQLHFAFQDENLYLVMEYVVGDDLLTLLSKFGERIPAEARFYLAEIVMAIDSVHRLGYVHRDIKPDNILLDRCGHIRLADF LKRGEVSCFREERDVLVNGDRRWITQLHFAFQDENLYLVMEYVVGDDLLTLLSKFGERIPAEARFYLAEIVMAIDSVHRLGYVHRDIKPDNILLDRCGHIRLADF
Consensus NM_004409 K216-2 K216-4 K216-5	GSCCLKLRADGTVRSVLVAVGTPDYLSPILQAVGGPGTSGVGPCECDWALGVAYEMFYQTPFYADSTAETYGKIVHYKEHLSPLVDEGVPEEARDFIQRLLCPP GSCCLKLRADGTVRSVLVAVGTPDYLSPILQAVGGPGTSGVGPCECDWALGVAYEMFYQTPFYADSTAETYGKIVHYKEHLSPLVDEGVPEEARDFIQRLLCPP GSCCLKLRADGTVRSVLVAVGTPDYLSPILQAVGGPGTSGVGPCECDWALGVAYEMFYQTPFYADSTAETYGKIVHYKEHLSPLVDEGVPEEARDFIQRLLCPP GSCCLKLRADGTVRSVLVAVGTPDYLSPILQAVGGPGTSGVGPCECDWALGVAYEMFYQTPFYADSTAETYGKIVHYKEHLSPLVDEGVPEEARDFIQRLLCPP GSCCLKLRADGTVRSVLVAVGTPDYLSPILQAVGGPGTSGVGPCECDWALGVAYEMFYQTPFYADSTAETYGKIVHYKEHLSPLVDEGVPEEARDFIQRLLCPP
Consensus NM_004409 K216-2 K216-4 K216-5	ETRLGRGGAGDFRTHPFFFGLDWDGLRDSVPPFTPDFFEGATDTCNFDLVEDGILTAMVSGGGETLSDIREGAPLGVHLPFVGYSYSCMALRDSVPVGPPTPME-EAEQL ETRLGRGGAGDFRTHPFFFGLDWDGLRDSVPPFTPDFFEGATDTCNFDLVEDGILTAMVSGGGETLSDIREGAPLGVHLPFVGYSYSCMALRDSVPVGPPTPMEVTEAEQL ETRLGRGGAGDFRTHPFFFGLDWDGLRDSVPPFTPDFFEGATDTCNFDLVEDGILTAMVSGGGETLSDIREGAPLGVHLPFVGYSYSCMALRDSVPVGPPTPMELEAEQL ETRLGRGGAGDFRTHPFFFGLDWDGLRDSVPPFTPDFFEGATDTCNFDLVEDGILTAMVSGGGETLSDIREGAPLGVHLPFVGYSYSCMALRDSVPVGPPTPMELEAEQL ETRLGRGGAGDFRTHPFFFGLDWDGLRDSVPPFTPDFFEGATDTCNFDLVEDGILTAMVSGGGETLSDIREGAPLGVHLPFVGYSYSCMALRDSVPVGPPTPMEVTEAEQL
Consensus NM_004409 K216-2 K216-4 K216-5	LEPHVQAPSLSPSPQDETAEVAVPAAPAAEAEAEVTLRELQEALEEEVLTROSLSREMEAIRTDNQNFASQLEAEARNRDLAEHVRLQQLQERMELLQAEGATAV LEPHVQAPSLSPSPQDETAEVAVPAAPAAEAEAEVTLRELQEALEEEVLTROSLSREMEAIRTDNQNFASQLEAEARNRDLAEHVRLQQLQERMELLQAEGATAV LEPHVQAPSLSPSPQDETAEVAVPAAPAAEAEAEVTLRELQEALEEEVLTROSLSREMEAIRTDNQNFASQLEAEARNRDLAEHVRLQQLQERMELLQAEGATAV LEPHVQAPSLSPSPQDETAEVAVPAAPAAEAEAEVTLRELQEALEEEVLTROSLSREMEAIRTDNQNFASQLEAEARNRDLAEHVRLQQLQERMELLQAEGATAV LEPHVQAPSLSPSPQDETAEVAVPAAPAAEAEAEVTLRELQEALEEEVLTROSLSREMEAIRTDNQNFASQLEAEARNRDLAEHVRLQQLQERMELLQAEGATAV
Consensus NM_004409 K216-2 K216-4 K216-5	TGVPSPRATDPPSH-----VPRPGLSEALSLLLFVAVLSR-AALGICGLVAHAGQLTAVWRRPAGAARAP TGVPSPRATDPPSHLDGPPAVAVGQCPLVGPGMHRRHLLLPARVPRPGLSEALSLLLFVAVLSRAAALGICGLVAHAGQLTAVWRRPAGAARAP TGVPSPRATDPPSHMA-PPAVAVGQCPLVGPGMHRRHLLLPARVPRPGLSEALSLLLFVAVLSR-SAAALGICGLVAHAGQLTAVWRRPAGAARAP ----- TGVPSPRATDPPSH-----VPRPGLSEALSLLLFVAVLSRAAALGICGLVAHAGQLTAVWRRPAGAARAP

FIGURE 5

## SEQUENCE LISTING

<110> Yoganathan, Thillainathan  
Delaney, Allen

<120> CANCER ASSOCIATED PROTEIN KINASES AND  
THEIR USES

<130> KINE-023WO

<140> Unassigned  
<141>

<150> 60/290,555  
<151> 2001-05-10

<150> 60/233,999  
<151> 2000-09-20

<150> 60/237,419  
<151> 2000-10-02

<150> 60/237,423  
<151> 2000-10-02

<150> 60/238,558  
<151> 2000-10-04

<160> 39

<170> FastSEQ for Windows Version 4.0

<210> 1  
<211> 3558  
<212> DNA  
<213> Homo sapien

<220>  
<221> CDS  
<222> (482)...(3023)

<400> 1  
ggaagaaggg agcgggggtcg gagccgtcgg ggccaaagga gacgggggcca ggaacaggca 60  
gtctcgggcc aactgcggac gctccctcca ccccctgcgc aaaaagaccc aaccggagtt 120  
gagggcgtgc ccctgaaggc cccaccttac acttggcggg ggccggagcc aggtctccag 180  
gactgctcca gaaccgaggg aagctcgggt ccctccaagc tagccatggt gaggcgccgg 240  
aggccccggg gccccacccc cccggcctga ccacactgcc ctgggtgccc tctccagaa 300  
gcccagatg cgggggggccc ggagacaaca ctctgggtc cccagagagg cgtgggtctg 360  
gggctgaggg ccaggggccc gatgcccagg ttccgggact agggccttg cagccagcgg 420  
gggtggggac cacgggcacc cagagaaggt cctccacaca tcccagcgcc ggctcccggc 480  
c atg gag ccc ttg aag agc ctc ttc ctc aag agc cct cta ggg tca tgg 529  
Met Glu Pro Leu Lys Ser Leu Phe Leu Lys Ser Pro Leu Gly Ser Trp  
1 5 10 15  
  
aat ggc agt ggc agc ggg ggt ggt ggg ggc ggt gga gga ggc cgg cct 577  
Asn Gly Ser Gly Ser Gly Gly Gly Gly Gly Gly Gly Gly Gly Arg Pro  
20 25 30  
  
gag ggg tct cca aag gca gcg ggt tat gcc aac ccg gtg tgg aca gcc 625  
Glu Gly Ser Pro Lys Ala Ala Gly Tyr Ala Asn Pro Val Trp Thr Ala  
35 40 45



ctg ttc gac tac gag ccc agt ggg cag gat gag ctg gcc ctg agg aag Leu Phe Asp Tyr Glu Pro Ser Gly Gln Asp Glu Leu Ala Leu Arg Lys 50 55 60	673
ggt gac cgt gtg gag gtg ctg tcc cgg gac gca gcc atc tca gga gac Gly Asp Arg Val Glu Val Leu Ser Arg Asp Ala Ala Ile Ser Gly Asp 65 70 75 80	721
gag ggc tgg tgg gcg ggc cag gtg ggt ggc cag gtg ggc atc ttc ccg Glu Gly Trp Trp Ala Gly Gln Val Gly Gly Gln Val Gly Ile Phe Pro 85 90 95	769
tcc aac tat gtg tct cgg ggt ggc ggc ccg ccc ccc tgc gag gtg gcc Ser Asn Tyr Val Ser Arg Gly Gly Gly Pro Pro Pro Cys Glu Val Ala 100 105 110	817
agc ttc cag gag ctg cgg ctg gag gag gtg atc ggc att gga ggc ttt Ser Phe Gln Glu Leu Arg Leu Glu Glu Val Ile Gly Ile Gly Gly Phe 115 120 125	865
ggc aag gtg tac agg ggc agc tgg cga ggt gag ctg gtg gct gtg aag Gly Lys Val Tyr Arg Gly Ser Trp Arg Gly Glu Leu Val Ala Val Lys 130 135 140	913
gca gtt cgc cag gac ccc gat gag gac atc agt gtg aca gcc gag agc Ala Ala Arg Gln Asp Pro Asp Glu Asp Ile Ser Val Thr Ala Glu Ser 145 150 155 160	961
gtt cgc cag gag gcc cgg ctc ttc gcc atg ctg gca cac ccc aac atc Val Arg Gln Glu Ala Arg Leu Phe Ala Met Leu Ala His Pro Asn Ile 165 170 175	1009
att gcc ctc aag gct gtg tgc ctg gag gag ccc aac ctg tgc ctg gtg Ile Ala Leu Lys Ala Val Cys Leu Glu Glu Pro Asn Leu Cys Leu Val 180 185 190	1057
atg gag tat gca gcc ggt ggg ccc ctc agc cga gct ctg gcc ggg cgg Met Glu Tyr Ala Ala Gly Gly Pro Leu Ser Arg Ala Leu Ala Gly Arg 195 200 205	1105
cgc gtg cct ccc cat gtg ctg gtc aac tgg gct gtg cag att gcc cgt Arg Val Pro Pro His Val Leu Val Asn Trp Ala Val Gln Ile Ala Arg 210 215 220	1153
ggg atg cac tac ctg cac tgc gag gcc ctg gtg ccc gtc atc cac cgt Gly Met His Tyr Leu His Cys Glu Ala Leu Val Pro Val Ile His Arg 225 230 235 240	1201
gat ctc aag tcc aac aac att ttg ctg ctg cag ccc att gag agt gac Asp Leu Lys Ser Asn Asn Ile Leu Leu Leu Gln Pro Ile Glu Ser Asp 245 250 255	1249
gac atg gag cac aag acc ctg aag atc acc gac ttt ggc ctg gcc cga Asp Met Glu His Lys Thr Leu Lys Ile Thr Asp Phe Gly Leu Ala Arg 260 265 270	1297
gag tgg cac aaa acc aca caa atg agt gcc gcg ggc acc tac gcc tgg Glu Trp His Lys Thr Thr Gln Met Ser Ala Ala Gly Thr Tyr Ala Trp 275 280 285	1345
atg gct cct gag gtt atc aag gcc tcc acc ttc tct aag ggc agt gac	1393

Met	Ala	Pro	Glu	Val	Ile	Lys	Ala	Ser	Thr	Phe	Ser	Lys	Gly	Ser	Asp		
290						295					300						
gtc	tgg	agt	ttt	ggg	gtg	ctg	ctg	tgg	gaa	ctg	ctg	acc	ggg	gag	gtg	1441	
Val	Trp	Ser	Phe	Gly	Val	Leu	Leu	Trp	Glu	Leu	Leu	Thr	Gly	Glu	Val		
305					310				315					320			
cca	tac	cgt	ggc	att	gac	tgc	ctt	gct	gtg	gcc	tat	ggc	gta	gct	gtt	1489	
Pro	Tyr	Arg	Gly	Ile	Asp	Cys	Leu	Ala	Val	Ala	Tyr	Gly	Val	Ala	Val		
				325					330					335			
aac	aag	ctc	aca	ctg	ccc	atc	cca	tcc	acc	tgc	ccc	gag	ccc	ttc	gca	1537	
Asn	Lys	Leu	Thr	Leu	Pro	Ile	Pro	Ser	Thr	Cys	Pro	Glu	Pro	Phe	Ala		
			340					345					350				
cag	ctt	atg	gcc	gac	tgc	tgg	gcg	cag	gac	ccc	cac	cgc	agg	ccc	gac	1585	
Gln	Leu	Met	Ala	Asp	Cys	Trp	Ala	Gln	Asp	Pro	His	Arg	Arg	Pro	Asp		
		355					360					365					
ttc	gcc	tcc	atc	ctg	cag	cag	ttg	gag	gcg	ctg	gag	gca	cag	gtc	cta	1633	
Phe	Ala	Ser	Ile	Leu	Gln	Gln	Leu	Glu	Ala	Leu	Glu	Ala	Gln	Val	Leu		
	370					375					380						
cgg	gaa	atg	ccg	cgg	gac	tcc	ttc	cat	tcc	atg	cag	gaa	ggc	tgg	aag	1681	
Arg	Glu	Met	Pro	Arg	Asp	Ser	Phe	His	Ser	Met	Gln	Glu	Gly	Trp	Lys		
					390				395					400			
cgc	gag	atc	cag	ggt	ctc	ttc	gac	gag	ctg	cga	gcc	aag	gaa	aag	gaa	1729	
Arg	Glu	Ile	Gln	Gly	Leu	Phe	Asp	Glu	Leu	Arg	Ala	Lys	Glu	Lys	Glu		
				405					410					415			
cta	ctg	agc	cgc	gag	gag	gag	ctg	acg	cga	gcg	gcg	cgc	gag	cag	cgg	1777	
Leu	Leu	Ser	Arg	Glu	Glu	Glu	Leu	Thr	Arg	Ala	Ala	Arg	Glu	Gln	Arg		
			420					425					430				
tca	cag	gcg	gag	cag	ctg	cgg	cgg	cgc	gag	cac	ctg	ctg	gcc	cag	tgg	1825	
Ser	Gln	Ala	Glu	Gln	Leu	Arg	Arg	Arg	Glu	His	Leu	Leu	Ala	Gln	Trp		
		435					440					445					
gag	cta	gag	gtg	ttc	gag	cgc	gag	ctg	acg	ctg	ctg	ctg	cag	cag	gtg	1873	
Glu	Leu	Glu	Val	Phe	Glu	Arg	Glu	Leu	Thr	Leu	Leu	Leu	Gln	Gln	Val		
	450					455					460						
gac	cgc	gag	cga	ccg	cac	gtg	cgc	cgc	cgc	cgc	ggg	aca	ttc	aag	cgc	1921	
Asp	Arg	Glu	Arg	Pro	His	Val	Arg	Arg	Arg	Arg	Gly	Thr	Phe	Lys	Arg		
					470				475					480			
agc	aag	ctc	cgg	gcg	cgc	gac	ggc	ggc	gag	cgt	atc	agc	atg	cca	ctc	1969	
Ser	Lys	Leu	Arg	Ala	Arg	Asp	Gly	Gly	Glu	Arg	Ile	Ser	Met	Pro	Leu		
				485					490					495			
gac	ttc	aag	cac	cgc	atc	acc	gtg	cag	gcc	tca	ccc	ggc	ctt	gac	cgg	2017	
Asp	Phe	Lys	His	Arg	Ile	Thr	Val	Gln	Ala	Ser	Pro	Gly	Leu	Asp	Arg		
			500					505					510				
agg	aga	aac	gtc	ttc	gag	gtc	ggg	cct	ggg	gat	tcg	ccc	acc	ttt	ccc	2065	
Arg	Arg	Asn	Val	Phe	Glu	Val	Gly	Pro	Gly	Asp	Ser	Pro	Thr	Phe	Pro		
		515					520					525					
cgg	ttc	cga	gcc	atc	cag	ttg	gag	cct	gca	gag	cca	ggc	cag	gca	tgg	2113	
Arg	Phe	Arg	Ala	Ile	Gln	Leu	Glu	Pro	Ala	Glu	Pro	Gly	Gln	Ala	Trp		
	530					535					540						

ggc cgc cag tcc ccc cga cgt ctg gag gac tca agc aat gga gag cgg Gly Arg Gln Ser Pro Arg Arg Leu Glu Asp Ser Ser Asn Gly Glu Arg 545 550 555 560	2161
cga gca tgc tgg gct tgg ggt ccc agt tcc ccc aag cct ggg gaa gcc Arg Ala Cys Trp Ala Trp Gly Pro Ser Ser Pro Lys Pro Gly Glu Ala 565 570 575	2209
cag aat ggg agg aga agg tcc cgc atg gac gaa gcc aca tgg tac ctg Gln Asn Gly Arg Arg Arg Ser Arg Met Asp Glu Ala Thr Trp Tyr Leu 580 585 590	2257
gat tca gat gac tca tcc ccc tta gga tct cct tcc aca ccc cca gca Asp Ser Asp Asp Ser Ser Pro Leu Gly Ser Pro Ser Thr Pro Pro Ala 595 600 605	2305
ctc aat ggt aac ccc ccg cgg cct agc ctg gag ccc gag gag ccc aag Leu Asn Gly Asn Pro Pro Arg Pro Ser Leu Glu Pro Glu Glu Pro Lys 610 615 620	2353
agg cct gtc ccc gca gag cgc ggt agc agc tct ggg acg ccc aag ctg Arg Pro Val Pro Ala Glu Arg Gly Ser Ser Ser Gly Thr Pro Lys Leu 625 630 635 640	2401
atc cag cgg gcg ctg ctg cgc ggc acc gcc ctg ctc gcc tcg ctg ggc Ile Gln Arg Ala Leu Leu Arg Gly Thr Ala Leu Leu Ala Ser Leu Gly 645 650 655	2449
ctt ggc cgc gac ctg cag ccg ccg gga ggc cca gga cgc gag cgc ggg Leu Gly Arg Asp Leu Gln Pro Pro Gly Gly Pro Gly Arg Glu Arg Gly 660 665 670	2497
gag tcc ccg aca aca ccc ccc acg cca acg ccc gcg ccc tgc ccg acc Glu Ser Pro Thr Thr Pro Pro Thr Pro Thr Pro Ala Pro Cys Pro Thr 675 680 685	2545
gag ccg ccc cct tcc ccg ctc atc tgc ttc tcg ctc aag acg ccc gac Glu Pro Pro Pro Ser Pro Leu Ile Cys Phe Ser Leu Lys Thr Pro Asp 690 695 700	2593
tcc ccg ccc act cct gca ccc ctg ttg ctg gac ctg ggt atc cct gtg Ser Pro Pro Thr Pro Ala Pro Leu Leu Leu Asp Leu Gly Ile Pro Val 705 710 715 720	2641
ggc cag cgg tca gcc aag agc ccc cga cgt gag gag gag ccc cgc gga Gly Gln Arg Ser Ala Lys Ser Pro Arg Arg Glu Glu Glu Pro Arg Gly 725 730 735	2689
ggc act gtc tca ccc cca ccg ggg aca tca cgc tct gct cct ggc acc Gly Thr Val Ser Pro Pro Pro Gly Thr Ser Arg Ser Ala Pro Gly Thr 740 745 750	2737
cca ggc acc cca cgt tca cca ccc ctg ggc ctc atc agc cga cct ccg Pro Gly Thr Pro Arg Ser Pro Pro Leu Gly Leu Ile Ser Arg Pro Arg 755 760 765	2785
ccc tcg ccc ctt cgc agc cgc att gat ccc tgg agc ttt gtg tca gct Pro Ser Pro Leu Arg Ser Arg Ile Asp Pro Trp Ser Phe Val Ser Ala 770 775 780	2833
ggg cca cgg cct tct ccc ctg cca tca cca cag cct gca ccc cgc cga	2881

Gly	Pro	Arg	Pro	Ser	Pro	Leu	Pro	Ser	Pro	Gln	Pro	Ala	Pro	Arg	Arg	
785					790					795					800	
gca	ccc	tgg	acc	ttg	ttc	ccg	gac	tca	gac	ccc	ttc	tgg	gac	tcc	cca	2929
Ala	Pro	Trp	Thr	Leu	Phe	Pro	Asp	Ser	Asp	Pro	Phe	Trp	Asp	Ser	Pro	
				805					810					815		
cct	gcc	aac	ccc	ttc	cag	ggg	ggc	ccc	cag	gac	tgc	agg	gca	cag	acc	2977
Pro	Ala	Asn	Pro	Phe	Gln	Gly	Gly	Pro	Gln	Asp	Cys	Arg	Ala	Gln	Thr	
			820						825				830			
aaa	gac	atg	ggg	gcc	cag	gcc	ccg	tgg	gtg	ccg	gaa	gcg	ggg	cct	t	3023
Lys	Asp	Met	Gly	Ala	Gln	Ala	Pro	Trp	Val	Pro	Glu	Ala	Gly	Pro		
		835					840					845				
gagtggggcca	ggccactccc	ccgagctcca	gctgccttag	gaggagtcac	agcatacact											3083
ggaacaggag	ctgggtcagc	ctctgcagct	gcctcagttt	ccccagggac	cccaccccc											3143
tttgggggtc	aggaacacta	cactgcacag	gaagcettca	cactggaagg	gggacctgcg											3203
ccccacatc	tgaaacctgt	aggtcccccc	agctcacctg	ccctactggg	gcccacact											3263
gtacccagct	ggttgggagg	accagagcct	gtctcagga	attgcctgct	ggggtgatgc											3323
agggaggagg	ggaggtgcag	ggaagagggg	ccggcctcag	ctgtcaccag	cacttttgac											3383
caagtctgc	tactgcggcc	cctgccctag	ggcttagagc	atggacctcc	tgccctgggg											3443
gtcatctggg	gccagggtc	tctggatgcc	ttctgctgc	cccagccagg	gttggagtct											3503
tagcctcggg	atccagtga	gccagaagcc	aaataaactc	aaaagctgtc	tcccc											3558

&lt;210&gt; 2

&lt;211&gt; 847

&lt;212&gt; PRT

&lt;213&gt; Homo sapien

&lt;400&gt; 2

Met	Glu	Pro	Leu	Lys	Ser	Leu	Phe	Leu	Lys	Ser	Pro	Leu	Gly	Ser	Trp	
1				5					10					15		
Asn	Gly	Ser	Gly	Ser	Gly	Gly	Gly	Gly	Gly	Gly	Gly	Gly	Gly	Arg	Pro	
			20					25					30			
Glu	Gly	Ser	Pro	Lys	Ala	Ala	Gly	Tyr	Ala	Asn	Pro	Val	Trp	Thr	Ala	
			35				40					45				
Leu	Phe	Asp	Tyr	Glu	Pro	Ser	Gly	Gln	Asp	Glu	Leu	Ala	Leu	Arg	Lys	
			50			55					60					
Gly	Asp	Arg	Val	Glu	Val	Leu	Ser	Arg	Asp	Ala	Ala	Ile	Ser	Gly	Asp	
65				70					75					80		
Glu	Gly	Trp	Trp	Ala	Gly	Gln	Val	Gly	Gly	Gln	Val	Gly	Ile	Phe	Pro	
				85				90						95		
Ser	Asn	Tyr	Val	Ser	Arg	Gly	Gly	Gly	Pro	Pro	Pro	Cys	Glu	Val	Ala	
			100					105					110			
Ser	Phe	Gln	Glu	Leu	Arg	Leu	Glu	Glu	Val	Ile	Gly	Ile	Gly	Gly	Phe	
			115				120					125				
Gly	Lys	Val	Tyr	Arg	Gly	Ser	Trp	Arg	Gly	Glu	Leu	Val	Ala	Val	Lys	
			130			135					140					
Ala	Ala	Arg	Gln	Asp	Pro	Asp	Glu	Asp	Ile	Ser	Val	Thr	Ala	Glu	Ser	
145				150					155					160		
Val	Arg	Gln	Glu	Ala	Arg	Leu	Phe	Ala	Met	Leu	Ala	His	Pro	Asn	Ile	
				165				170						175		
Ile	Ala	Leu	Lys	Ala	Val	Cys	Leu	Glu	Pro	Asn	Leu	Cys	Leu	Val		
			180				185					190				
Met	Glu	Tyr	Ala	Ala	Gly	Gly	Pro	Leu	Ser	Arg	Ala	Leu	Ala	Gly	Arg	
			195				200					205				
Arg	Val	Pro	Pro	His	Val	Leu	Val	Asn	Trp	Ala	Val	Gln	Ile	Ala	Arg	
			210			215					220					
Gly	Met	His	Tyr	Leu	His	Cys	Glu	Ala	Leu	Val	Pro	Val	Ile	His	Arg	
225					230					235					240	

Asp	Leu	Lys	Ser	Asn	Asn	Ile	Leu	Leu	Leu	Gln	Pro	Ile	Glu	Ser	Asp	
				245					250					255		
Asp	Met	Glu	His	Lys	Thr	Leu	Lys	Ile	Thr	Asp	Phe	Gly	Leu	Ala	Arg	
			260					265					270			
Glu	Trp	His	Lys	Thr	Thr	Gln	Met	Ser	Ala	Ala	Gly	Thr	Tyr	Ala	Trp	
		275					280					285				
Met	Ala	Pro	Glu	Val	Ile	Lys	Ala	Ser	Thr	Phe	Ser	Lys	Gly	Ser	Asp	
	290					295					300					
Val	Trp	Ser	Phe	Gly	Val	Leu	Leu	Trp	Glu	Leu	Leu	Thr	Gly	Glu	Val	
305					310					315					320	
Pro	Tyr	Arg	Gly	Ile	Asp	Cys	Leu	Ala	Val	Ala	Tyr	Gly	Val	Ala	Val	
				325					330					335		
Asn	Lys	Leu	Thr	Leu	Pro	Ile	Pro	Ser	Thr	Cys	Pro	Glu	Pro	Phe	Ala	
			340					345					350			
Gln	Leu	Met	Ala	Asp	Cys	Trp	Ala	Gln	Asp	Pro	His	Arg	Arg	Pro	Asp	
		355					360					365				
Phe	Ala	Ser	Ile	Leu	Gln	Gln	Leu	Glu	Ala	Leu	Glu	Ala	Gln	Val	Leu	
	370					375					380					
Arg	Glu	Met	Pro	Arg	Asp	Ser	Phe	His	Ser	Met	Gln	Glu	Gly	Trp	Lys	
385					390					395					400	
Arg	Glu	Ile	Gln	Gly	Leu	Phe	Asp	Glu	Leu	Arg	Ala	Lys	Glu	Lys	Glu	
				405					410					415		
Leu	Leu	Ser	Arg	Glu	Glu	Glu	Leu	Thr	Arg	Ala	Ala	Arg	Glu	Gln	Arg	
			420					425					430			
Ser	Gln	Ala	Glu	Gln	Leu	Arg	Arg	Arg	Glu	His	Leu	Leu	Ala	Gln	Trp	
		435					440					445				
Glu	Leu	Glu	Val	Phe	Glu	Arg	Glu	Leu	Thr	Leu	Leu	Leu	Gln	Gln	Val	
	450					455					460					
Asp	Arg	Glu	Arg	Pro	His	Val	Arg	Arg	Arg	Arg	Gly	Thr	Phe	Lys	Arg	
465					470					475					480	
Ser	Lys	Leu	Arg	Ala	Arg	Asp	Gly	Gly	Glu	Arg	Ile	Ser	Met	Pro	Leu	
				485					490					495		
Asp	Phe	Lys	His	Arg	Ile	Thr	Val	Gln	Ala	Ser	Pro	Gly	Leu	Asp	Arg	
			500					505					510			
Arg	Arg	Asn	Val	Phe	Glu	Val	Gly	Pro	Gly	Asp	Ser	Pro	Thr	Phe	Pro	
		515					520						525			
Arg	Phe	Arg	Ala	Ile	Gln	Leu	Glu	Pro	Ala	Glu	Pro	Gly	Gln	Ala	Trp	
	530					535						540				
Gly	Arg	Gln	Ser	Pro	Arg	Arg	Leu	Glu	Asp	Ser	Ser	Asn	Gly	Glu	Arg	
545					550					555					560	
Arg	Ala	Cys	Trp	Ala	Trp	Gly	Pro	Ser	Ser	Pro	Lys	Pro	Gly	Glu	Ala	
				565					570					575		
Gln	Asn	Gly	Arg	Arg	Arg	Ser	Arg	Met	Asp	Glu	Ala	Thr	Trp	Tyr	Leu	
			580					585					590			
Asp	Ser	Asp	Asp	Ser	Ser	Pro	Leu	Gly	Ser	Pro	Ser	Thr	Pro	Pro	Ala	
		595					600					605				
Leu	Asn	Gly	Asn	Pro	Pro	Arg	Pro	Ser	Leu	Glu	Pro	Glu	Glu	Pro	Lys	
						615					620					
Arg	Pro	Val	Pro	Ala	Glu	Arg	Gly	Ser	Ser	Ser	Gly	Thr	Pro	Lys	Leu	
625					630					635					640	
Ile	Gln	Arg	Ala	Leu	Leu	Arg	Gly	Thr	Ala	Leu	Leu	Ala	Ser	Leu	Gly	
				645					650					655		
Leu	Gly	Arg	Asp	Leu	Gln	Pro	Pro	Gly	Gly	Pro	Gly	Arg	Glu	Arg	Gly	
			660					665					670			
Glu	Ser	Pro	Thr	Thr	Pro	Pro	Thr	Pro	Thr	Pro	Ala	Pro	Cys	Pro	Thr	
		675					680					685				
Glu	Pro	Pro	Pro	Ser	Pro	Leu	Ile	Cys	Phe	Ser	Leu	Lys	Thr	Pro	Asp	
	690					695					700					
Ser	Pro	Pro	Thr	Pro	Ala	Pro	Leu	Leu	Leu	Asp	Leu	Gly	Ile	Pro	Val	
705					710					715					720	
Gly	Gln	Arg	Ser	Ala	Lys	Ser	Pro	Arg	Arg	Glu	Glu	Glu	Pro	Arg	Gly	
				725					730					735		

Gly	Thr	Val	Ser	Pro	Pro	Pro	Gly	Thr	Ser	Arg	Ser	Ala	Pro	Gly	Thr
			740					745					750		
Pro	Gly	Thr	Pro	Arg	Ser	Pro	Pro	Leu	Gly	Leu	Ile	Ser	Arg	Pro	Arg
		755					760						765		
Pro	Ser	Pro	Leu	Arg	Ser	Arg	Ile	Asp	Pro	Trp	Ser	Phe	Val	Ser	Ala
		770				775						780			
Gly	Pro	Arg	Pro	Ser	Pro	Leu	Pro	Ser	Pro	Gln	Pro	Ala	Pro	Arg	Arg
		785			790					795					800
Ala	Pro	Trp	Thr	Leu	Phe	Pro	Asp	Ser	Asp	Pro	Phe	Trp	Asp	Ser	Pro
				805					810					815	
Pro	Ala	Asn	Pro	Phe	Gln	Gly	Gly	Pro	Gln	Asp	Cys	Arg	Ala	Gln	Thr
			820					825					830		
Lys	Asp	Met	Gly	Ala	Gln	Ala	Pro	Trp	Val	Pro	Glu	Ala	Gly	Pro	
		835					840						845		

&lt;210&gt; 3

&lt;211&gt; 2447

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; CDS

&lt;222&gt; (70)...(1498)

&lt;400&gt; 3

tggagtggga gctcaagcag gattcttccc gagtccctgg catcctcaga agcttcaact 60  
 ctggaggca atg ggt cga aag gaa gaa gat gac tgc agt tcc tgg aag aaa 111  
                   Met Gly Arg Lys Glu Asp Asp Cys Ser Ser Trp Lys Lys  
                   1                                  5                                  10

cag acc acc aac atc cgg aaa acc ttc att ttt atg gaa gtg ctg gga 159  
 Gln Thr Thr Asn Ile Arg Lys Thr Phe Ile Phe Met Glu Val Leu Gly  
   15                                  20                                  25                                  30

tca gga gct ttc tca gaa gtt ttc ctg gtg aag caa aga ctg act ggg 207  
 Ser Gly Ala Phe Ser Glu Val Phe Leu Val Lys Gln Arg Leu Thr Gly  
                                   35                                  40                                  45

aag ctc ttt gct ctg aag tgc atc aag aag tca cct gcc ttc cgg gac 255  
 Lys Leu Phe Ala Leu Lys Cys Ile Lys Lys Ser Pro Ala Phe Arg Asp  
                                   50                                  55                                  60

agc agc ctg gag aat gag att gct gtg ttg aaa aag atc aag cat gaa 303  
 Ser Ser Leu Glu Asn Glu Ile Ala Val Leu Lys Lys Ile Lys His Glu  
                                   65                                  70                                  75

aac att gtg acc ctg gag gac atc tat gag agc acc acc cac tac tac 351  
 Asn Ile Val Thr Leu Glu Asp Ile Tyr Glu Ser Thr Thr His Tyr Tyr  
   80                                  85                                  90

ctg gtc atg cag ctt gtt tct ggt ggg gag ctc ttt gac cgg atc ctg 399  
 Leu Val Met Gln Leu Val Ser Gly Gly Glu Leu Phe Asp Arg Ile Leu  
   95                                  100                                  105                                  110

gag cgg ggt gtc tac aca gag aag gat gcc agt ctg gtg atc cag cag 447  
 Glu Arg Gly Val Tyr Thr Glu Lys Asp Ala Ser Leu Val Ile Gln Gln  
                                   115                                  120                                  125

gtc ttg tcg gca gtg aaa tac cta cat gag aat ggc atc gtc cac aga 495  
 Val Leu Ser Ala Val Lys Tyr Leu His Glu Asn Gly Ile Val His Arg  
                                   130                                  135                                  140

gac tta aag ccc gaa aac ctg ctt tac ctt acc cct gaa gag aac tct	543
Asp Leu Lys Pro Glu Asn Leu Leu Tyr Leu Thr Pro Glu Glu Asn Ser	
145 150 155	
aag atc atg atc act gac ttt ggt ctg tcc aag atg gaa cag aat ggc	591
Lys Ile Met Ile Thr Asp Phe Gly Leu Ser Lys Met Glu Gln Asn Gly	
160 165 170	
atc atg tcc act gcc tgt ggg acc cca gcc tac gtg gct cca gaa gtg	639
Ile Met Ser Thr Ala Cys Gly Thr Pro Gly Tyr Val Ala Pro Glu Val	
175 180 185 190	
ctg gcc cag aaa ccc tac agc aag gct gtg gat tgc tgg tcc atc ggc	687
Leu Ala Gln Lys Pro Tyr Ser Lys Ala Val Asp Cys Trp Ser Ile Gly	
195 200 205	
gtc atc acc tac ata ttg ctc tgt gga tac ccc ccg ttc tat gaa gaa	735
Val Ile Thr Tyr Ile Leu Leu Cys Gly Tyr Pro Pro Phe Tyr Glu Glu	
210 215 220	
acg gag tct aag ctt ttc gag aag atc aag gag ggc tac tat gag ttt	783
Thr Glu Ser Lys Leu Phe Glu Lys Ile Lys Glu Gly Tyr Tyr Glu Phe	
225 230 235	
gag tct cca ttc tgg gat gac att tct gag tca gcc aag gac ttt att	831
Glu Ser Pro Phe Trp Asp Asp Ile Ser Glu Ser Ala Lys Asp Phe Ile	
240 245 250	
tgc cac ttg ctt gag aag gat ccg aac gag cgg tac acc tgt gag aag	879
Cys His Leu Leu Glu Lys Asp Pro Asn Glu Arg Tyr Thr Cys Glu Lys	
255 260 265 270	
gcc ttg agt cat ccc tgg att gac gga aac acg gcc ctc cac cgg gac	927
Ala Leu Ser His Pro Trp Ile Asp Gly Asn Thr Ala Leu His Arg Asp	
275 280 285	
atc tac cca tca gtc agc ctc cag atc cag aag aac ttt gct aag agc	975
Ile Tyr Pro Ser Val Ser Leu Gln Ile Gln Lys Asn Phe Ala Lys Ser	
290 295 300	
aag tgg agg caa gcc ttc aac gca gca gct gtg gtg cac cac atg agg	1023
Lys Trp Arg Gln Ala Phe Asn Ala Ala Ala Val Val His His Met Arg	
305 310 315	
aag cta cac atg aac ctg cac agc ccg ggc gtc cgc cca gag gtg gag	1071
Lys Leu His Met Asn Leu His Ser Pro Gly Val Arg Pro Glu Val Glu	
320 325 330	
aac agg ccg cct gaa act caa gcc tca gaa acc tct aga ccc agc tcc	1119
Asn Arg Pro Pro Glu Thr Gln Ala Ser Glu Thr Ser Arg Pro Ser Ser	
335 340 345 350	
cct gag atc acc atc acc gag gca cct gtc ctg gac cac agt gta gca	1167
Pro Glu Ile Thr Ile Thr Glu Ala Pro Val Leu Asp His Ser Val Ala	
355 360 365	
ctc cct gcc ctg acc caa tta ccc tgc cag cat ggc cgc cgg ccc act	1215
Leu Pro Ala Leu Thr Gln Leu Pro Cys Gln His Gly Arg Arg Pro Thr	
370 375 380	
gcc cct ggt ggc agg tcc ctc aac tgc ctg gtc aat ggc tcc ctc cac	1263
Ala Pro Gly Arg Ser Leu Asn Cys Leu Val Asn Gly Ser Leu His	
385 390 395	

atc agc agc agc ctg gtg ccc atg cat cag ggg tcc ctg gcc gcc ggg 1311  
 Ile Ser Ser Ser Leu Val Pro Met His Gln Gly Ser Leu Ala Ala Gly  
 400 405 410

ccc tgt ggc tgc tgc tcc agc tgc ctg aac att ggg agc aaa gga aag 1359  
 Pro Cys Gly Cys Cys Ser Ser Cys Leu Asn Ile Gly Ser Lys Gly Lys  
 415 420 425 430

tcc tcc tac tgc tct gag ccc aca ctc ctc aaa aag gcc aac aaa aaa 1407  
 Ser Ser Tyr Cys Ser Glu Pro Thr Leu Leu Lys Lys Ala Asn Lys Lys  
 435 440 445

cag aac ttc aag tcg gag gtc atg gta cca gtt aaa gcc agt ggc agc 1455  
 Gln Asn Phe Lys Ser Glu Val Met Val Pro Val Lys Ala Ser Gly Ser  
 450 455 460

tcc cac tgc cgg gca ggg cag act gga gtc tgt ctc att atg t 1498  
 Ser His Cys Arg Ala Gly Gln Thr Gly Val Cys Leu Ile Met  
 465 470 475

gattcctgga gcctgtgcct atgtcactgc aatttttcagg agacatatc aactcctctg 1558  
 ctcttccaaa cctggtgtct atccggcaga gggaggaagg cagagcaagt ggagcagggc 1618  
 ttagcaggag cagtttctgg ccagaagcac cagcctgctg ccagcggggc agcccctcat 1678  
 aggaggccca ggaggagacc ccaaggcgta gaagccttgt tgaagctgtg agcaggagaa 1738  
 gcggtgcccc ccagcttcca ggtctccctg acctgcctgc tctatgcccc acaccctacg 1798  
 tgccgtggct ctgtgcagtg tacgtagata gctctcgcct gggctctgtg tggttgcgt 1858  
 gaaaagctta atgggctggc caggctgtgt cacccttctcc aagcaaagcc atatggagca 1918  
 tctaccacaga ctccactct gcacacactc actcccacct ctcaagcctc caacctcttg 1978  
 gccagattgg gctcattaat gtcgttgct gcccatctgc atgaatgaca ggcagctccc 2038  
 catggtggtc tgccgtgtgag ctcttcaagt tctaatacct aactccagga ttagctccca 2098  
 agtgcgctga gaccagcca gcacacttct ggcccttctc cctgcctcaa tctaaaagca 2158  
 gtgccacacc ctccaaagtg gaatagaaaag aagttcatga gtaagggtg caaggaattc 2218  
 ttatcctggc cacatgtcct ccgtgcacac acccaatgga gtaaaccttg gaagttgact 2278  
 attttaatgt ctgccaggag ttctaatacct gcctctgttc ccttttctct ccttgaaagt 2338  
 ccagcacacc attcttgtcc ttcccagtt tctcgcct ccaccctcc agcttcatgc 2398  
 tcagtgtgtg gcttaataaaa atggacatat ttttctctaa aaaaaaaaaa 2447

<210> 4

<211> 476

<212> PRT

<213> Homo sapiens

<400> 4

Met Gly Arg Lys Glu Glu Asp Asp Cys Ser Ser Trp Lys Lys Gln Thr  
 1 5 10 15  
 Thr Asn Ile Arg Lys Thr Phe Ile Phe Met Glu Val Leu Gly Ser Gly  
 20 25 30  
 Ala Phe Ser Glu Val Phe Leu Val Lys Gln Arg Leu Thr Gly Lys Leu  
 35 40 45  
 Phe Ala Leu Lys Cys Ile Lys Lys Ser Pro Ala Phe Arg Asp Ser Ser  
 50 55 60  
 Leu Glu Asn Glu Ile Ala Val Leu Lys Lys Ile Lys His Glu Asn Ile  
 65 70 75 80  
 Val Thr Leu Glu Asp Ile Tyr Glu Ser Thr Thr His Tyr Tyr Leu Val  
 85 90 95  
 Met Gln Leu Val Ser Gly Gly Glu Leu Phe Asp Arg Ile Leu Glu Arg  
 100 105 110  
 Gly Val Tyr Thr Glu Lys Asp Ala Ser Leu Val Ile Gln Gln Val Leu  
 115 120 125  
 Ser Ala Val Lys Tyr Leu His Glu Asn Gly Ile Val His Arg Asp Leu  
 130 135 140



Lys Pro Glu Asn Leu Leu Tyr Leu Thr Pro Glu Glu Asn Ser Lys Ile  
 145 150 155 160  
 Met Ile Thr Asp Phe Gly Leu Ser Lys Met Glu Gln Asn Gly Ile Met  
 165 170 175  
 Ser Thr Ala Cys Gly Thr Pro Gly Tyr Val Ala Pro Glu Val Leu Ala  
 180 185 190  
 Gln Lys Pro Tyr Ser Lys Ala Val Asp Cys Trp Ser Ile Gly Val Ile  
 195 200 205  
 Thr Tyr Ile Leu Leu Cys Gly Tyr Pro Pro Phe Tyr Glu Glu Thr Glu  
 210 215 220  
 Ser Lys Leu Phe Glu Lys Ile Lys Glu Gly Tyr Tyr Glu Phe Glu Ser  
 225 230 235 240  
 Pro Phe Trp Asp Asp Ile Ser Glu Ser Ala Lys Asp Phe Ile Cys His  
 245 250 255  
 Leu Leu Glu Lys Asp Pro Asn Glu Arg Tyr Thr Cys Glu Lys Ala Leu  
 260 265 270  
 Ser His Pro Trp Ile Asp Gly Asn Thr Ala Leu His Arg Asp Ile Tyr  
 275 280 285  
 Pro Ser Val Ser Leu Gln Ile Gln Lys Asn Phe Ala Lys Ser Lys Trp  
 290 295 300  
 Arg Gln Ala Phe Asn Ala Ala Ala Val Val His His Met Arg Lys Leu  
 305 310 315 320  
 His Met Asn Leu His Ser Pro Gly Val Arg Pro Glu Val Glu Asn Arg  
 325 330 335  
 Pro Pro Glu Thr Gln Ala Ser Glu Thr Ser Arg Pro Ser Ser Pro Glu  
 340 345 350  
 Ile Thr Ile Thr Glu Ala Pro Val Leu Asp His Ser Val Ala Leu Pro  
 355 360 365  
 Ala Leu Thr Gln Leu Pro Cys Gln His Gly Arg Arg Pro Thr Ala Pro  
 370 375 380  
 Gly Gly Arg Ser Leu Asn Cys Leu Val Asn Gly Ser Leu His Ile Ser  
 385 390 395 400  
 Ser Ser Leu Val Pro Met His Gln Gly Ser Leu Ala Ala Gly Pro Cys  
 405 410 415  
 Gly Cys Cys Ser Ser Cys Leu Asn Ile Gly Ser Lys Gly Lys Ser Ser  
 420 425 430  
 Tyr Cys Ser Glu Pro Thr Leu Leu Lys Lys Ala Asn Lys Lys Gln Asn  
 435 440 445  
 Phe Lys Ser Glu Val Met Val Pro Val Lys Ala Ser Gly Ser Ser His  
 450 455 460  
 Cys Arg Ala Gly Gln Thr Gly Val Cys Leu Ile Met  
 465 470 475

&lt;210&gt; 5

&lt;211&gt; 1812

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 5

gaagagggca gagccgtgca tggggctgct ccccaggacc tgagcaggaa cctggagttt 60  
 tcagagctgc ctgatcattg ctacagaatg aactctagcc cagctgggac cccaagtcca 120  
 cagccctcca gggccaatgg gaacatcaac ctggggcctt cagccaaccc aaatgccag 180  
 cccacggact tcgacttcct caaagtcac ggcaaaggga actacgggaa gtcctactg 240  
 gccaaagcgca agtctgatgg ggcgttctat gcagtgaagg tactacagaa aaagtccatc 300  
 ttaaagaaga aagagcagag ccacatcatg gcagagcgca gtgtgcttct gaagaacgtg 360  
 cggcaccctt tcctcgtggg cctgcgctac tccttccaga cacctgagaa gctctacttc 420  
 gtgctcgact atgtcaacgg gggagagctc ttcttccacc tgacgcggga gcgccggttc 480  
 ctggagcccc gggccagggt ctacgctgct gaggtggcca gcgccattgg ctacctgcac 540  
 tccctcaaca tcatttacag ggatctgaaa ccagagaaca ttctcttgga ctgccaggga 600  
 cacgtggtgc tgacggattt tggcctctgc aaggaagggt tagagcctga agacaccaca 660  
 tccacattct gtggtacccc tgagtacttg gcacctgaag tgcttcggaa agagccttat 720

```

gatcgagcag tggactggtg gtgcttgggg gcagtcctct acgagatgct ccatggcctg 780
ccgccccttct acagccaaga tgtatcccag atgtatgaga acattctgca ccagccgcta 840
cagatccccg gaggccggac agtggccgcc tgtgacctcc tgcaaagcct tctccacaag 900
gaccagaggc agcggctggg ctccaaagca gactttcttg agattaagaa ccatgtattc 960
ttcagcccca taaactggga tgacctgtac cacaagaggc taactccacc cttcaaccga 1020
aatgtgacag gacctgctga cttgaagcat tttgacctag agttcaccca ggaagctgtg 1080
tccaagtcca ttggctgtac ccctgacact gtggccagca gctctggggc ctcaagtgca 1140
ttcctgggat tttcttatgc gccagaggat gatgacatct tggattgcta gaagagaagg 1200
acctgtgaaa ctactgaggc cagctggtat tagtaaggaa ttaccttcag ctgctaggaa 1260
gagcgactca aactaacaat ggcttcaacg agaagcaggt ttattttttc cagcacataa 1320
aagaaaaata atgtttcgga gtccaggact ggcaggacag gtcacatgat actcagaggc 1380
tgtatctctg ccctgccaac cttgacaaat ggcttccaat gttagggttg ctacaagatg 1440
gttactggag ctctagctgc ctattttggtg tttagggaag ggaaaatgga ggaaggggga 1500
gaagagcaaa gggcgctttt aaagagcttt cccaaaagct ccccccaatg acttttgctt 1560
ccatctcact aaccacccac ccctacctgg aatggagggt gggaaatgtg gcttattttg 1620
tggtgtacgt actatcccta ataacaaagg ggttttgacc ctaagacatt agggggagaat 1680
gttgggtagg cagccagccc tcttttacca tagggcctcc tgggtgtttg attttgatct 1740
caatgtgtaa aatgacagag atgtaacaag ctcatagggt atcaatatct cttattgttc 1800
tatgttgaaa aa 1812

```

&lt;210&gt; 6

&lt;211&gt; 367

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 6

```

Met Asn Ser Ser Pro Ala Gly Thr Pro Ser Pro Gln Pro Ser Arg Ala
1          5          10          15
Asn Gly Asn Ile Asn Leu Gly Pro Ser Ala Asn Pro Asn Ala Gln Pro
20          25          30
Thr Asp Phe Asp Phe Leu Lys Val Ile Gly Lys Gly Asn Tyr Gly Lys
35          40          45
Val Leu Leu Ala Lys Arg Lys Ser Asp Gly Ala Phe Tyr Ala Val Lys
50          55          60
Val Leu Gln Lys Lys Ser Ile Leu Lys Lys Lys Glu Gln Ser His Ile
65          70          75          80
Met Ala Glu Arg Ser Val Leu Leu Lys Asn Val Arg His Pro Phe Leu
85          90          95
Val Gly Leu Arg Tyr Ser Phe Gln Thr Pro Glu Lys Leu Tyr Phe Val
100         105         110
Leu Asp Tyr Val Asn Gly Gly Glu Leu Phe Phe His Leu Gln Arg Glu
115         120         125
Arg Arg Phe Leu Glu Pro Arg Ala Arg Phe Tyr Ala Ala Glu Val Ala
130         135         140
Ser Ala Ile Gly Tyr Leu His Ser Leu Asn Ile Ile Tyr Arg Asp Leu
145         150         155         160
Lys Pro Glu Asn Ile Leu Leu Asp Cys Gln Gly His Val Val Leu Thr
165         170         175
Asp Phe Gly Leu Cys Lys Glu Gly Val Glu Pro Glu Asp Thr Thr Ser
180         185         190
Thr Phe Cys Gly Thr Pro Glu Tyr Leu Ala Pro Glu Val Leu Arg Lys
195         200         205
Glu Pro Tyr Asp Arg Ala Val Asp Trp Trp Cys Leu Gly Ala Val Leu
210         215         220
Tyr Glu Met Leu His Gly Leu Pro Pro Phe Tyr Ser Gln Asp Val Ser
225         230         235         240
Gln Met Tyr Glu Asn Ile Leu His Gln Pro Leu Gln Ile Pro Gly Gly
245         250         255
Arg Thr Val Ala Cys Asp Leu Leu Gln Ser Leu Leu His Lys Asp
260         265         270
Gln Arg Gln Arg Leu Gly Ser Lys Ala Asp Phe Leu Glu Ile Lys Asn
275         280         285

```

His Val Phe Phe Ser Pro Ile Asn Trp Asp Asp Leu Tyr His Lys Arg  
 290 295 300  
 Leu Thr Pro Pro Phe Asn Pro Asn Val Thr Gly Pro Ala Asp Leu Lys  
 305 310 315 320  
 His Phe Asp Pro Glu Phe Thr Gln Glu Ala Val Ser Lys Ser Ile Gly  
 325 330 335  
 Cys Thr Pro Asp Thr Val Ala Ser Ser Ser Gly Ala Ser Ser Ala Phe  
 340 345 350  
 Leu Gly Phe Ser Tyr Ala Pro Glu Asp Asp Asp Ile Leu Asp Cys  
 355 360 365

&lt;210&gt; 7

&lt;211&gt; 2557

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 7

```

cagagggagg aagaagcggc ggccgcgccg cgccggtccc tctttgcaga gggggaaact 60
cttgggctga gagcaggaac aacgcggtag gcaaggcggg ctgctggctc ccccggtccc 120
ggcagcagcg gcggcagccc gagcagcggc agcagcagcg gcagcagccc aggcgctgac 180
agccccgccg gccggctccg ttgctgaccg ccgactgtca atggagctgg aaaacatcgt 240
ggccaacacg gtcttgctga aagccaggga agggggcgga ggaaagcgca aagggaagag 300
caagaagtgg aaagaaatcc tgaagttccc tcacattagc cagtgtgaag acctccgaag 360
gaccatagac agagattact gcagtttatg tgacaagcag ccaatcgga ggctgctttt 420
ccggcagttt tgtgaaacca ggcctgggct actgggagag aaagggaagg aaattatgac 480
ggcagaatat gaagttactc cagatgaaaa catagcccaa gttggccaag acctggtctc 540
caagtacctc accccaaagt cccctgtttt catagcccaa gttggccaag acctggtctc 600
ccagacggag gagaagctcc tacagaagcc gtgcaaagaa ctcttttctg cctgtgcaca 660
gtctgtccac gagtacctga ggggagaacc attccacgaa tatctggaca gcatgttttt 720
tgaccgcttt ctccagtggg agtggttggg aaggcaaccg gtgacaaaaa acactttcag 780
gcagtatcga gtgctaggaa aagggggcct cggggaggtc tgtgcctgcc aggttcgggc 840
cacgggtaaa atgtatgcct gcaagcgctt ggagaagaag aggatcaaaa agaggaaagg 900
ggagtccatg gccctcaatg agaagcagat cctcgagaag gtcaacagtc agtttgtggt 960
caacctggcc tatgcctacg agaccaagga tgcactgtgc ttggtcctga ccatcatgaa 1020
tgggggtgac ctgaagttcc acatctacaa catgggcaac cctggcttcg aggaggagcg 1080
ggccttggtt tatgcggcag agatcctctg cggcttagaa gacctccacc gtgagaacac 1140
cgtctaccga gatctgaaac ctgaaaacat cctgttagat gattatggcc acattaggat 1200
ctcagacctg ggcttggtg tgaagatccc cgaggagac ctgatccgcg gccgggtggg 1260
cactgttggc tacatggccc ccgaagtcct gaacaaccag aggtacggcc tgagccccga 1320
ctactggggc cttggctgcc tcatctatga gatgatcgag ggccagtcgc cgttcgcggg 1380
ccgtaaggag aaggtgaagc gggaggaggt ggaccgcccg gtccctggaga cggaggaggt 1440
tactctccac aagttctccg aggaggccaa gtccactctg aagatgctgc tcacgaaaga 1500
tgogaagcag aggtcgggct gccaggagga ggggctgca gaggtaaga gacaccctt 1560
cttcaggaac atgaacttca agcgtttaga agccgggatg ttggaccctc ccttcgttcc 1620
agacccccgc gctgtgtact gtaaggacgt gctggacatc gagcagttct cactgtgaa 1680
gggcgtcaat ctggaccaca cagacgacga cttctactcc aagttctcca cgggctctgt 1740
gtccatccca tggcaaaacg agatgataga aacagaatgc tttaaggagc tgaacgtgtt 1800
tggaacctaat ggtaccctcc cgccagatct gaacagaaac caccctccgg aaccgcccac 1860
gaaagggctg ctccagagac tcttcaagcg gcagcatcag aacaattcca agagttcgcc 1920
cagctccaag accagtttta accaccacat aaactcaaac catgtcagct cgaactccac 1980
cggaagcagc tagtttcggc tctggcctcc aagtccacag tggaaccagc ccagaccctt 2040
ctccttagaa gtggaagtag tggagccctt gctctggtgg ggctgccagg cgagaccccg 2100
ggagccggaa ggaggccgtc catcccgtcg acgtagaacc tcgaggtttc tcaaagaaat 2160
ttccactcag gtctgttttc cgaggcggcc ccgggcggtt ggattggatt tgtctttggt 2220
gaacattgca atagaaatcc aattggatac gacaacttgc acgtatttta atagcgtcat 2280
aactagaact gaattttgtc tttatgattt ttaaagaaaa gttttgtaaa tttctctact 2340
gtctcagttt acattttcgg tatatttgta tttaaatgaa gtgagacttt gaggtgtat 2400
attttctgtg cagccactgt taagccatgt gttccaaggc attttagcgg ggagggggtt 2460
atcaaaaaaa aaaaaaatgt gactcaagac ttccagagcc tcaaatgaga aaatgtcttt 2520
attaaatgta gaaagtgtac catacttcaa aaaaaaa 2557

```

<210> 8  
 <211> 590  
 <212> PRT  
 <213> Homo sapiens

<400> 8

Met	Glu	Leu	Glu	Asn	Ile	Val	Ala	Asn	Thr	Val	Leu	Leu	Lys	Ala	Arg
1				5					10					15	
Glu	Gly	Gly	Gly	Gly	Lys	Arg	Lys	Gly	Lys	Ser	Lys	Lys	Trp	Lys	Glu
			20					25					30		
Ile	Leu	Lys	Phe	Pro	His	Ile	Ser	Gln	Cys	Glu	Asp	Leu	Arg	Arg	Thr
		35					40					45			
Ile	Asp	Arg	Asp	Tyr	Cys	Ser	Leu	Cys	Asp	Lys	Gln	Pro	Ile	Gly	Arg
	50					55					60				
Leu	Leu	Phe	Arg	Gln	Phe	Cys	Glu	Thr	Arg	Pro	Gly	Leu	Glu	Cys	Tyr
65					70					75					80
Ile	Gln	Phe	Leu	Asp	Ser	Val	Ala	Glu	Tyr	Glu	Val	Thr	Pro	Asp	Glu
				85				90						95	
Lys	Leu	Gly	Glu	Lys	Gly	Lys	Glu	Ile	Met	Thr	Lys	Tyr	Leu	Thr	Pro
			100					105					110		
Lys	Ser	Pro	Val	Phe	Ile	Ala	Gln	Val	Gly	Gln	Asp	Leu	Val	Ser	Gln
			115				120					125			
Thr	Glu	Glu	Lys	Leu	Leu	Gln	Lys	Pro	Cys	Lys	Glu	Leu	Phe	Ser	Ala
						135					140				
Cys	Ala	Gln	Ser	Val	His	Glu	Tyr	Leu	Arg	Gly	Glu	Pro	Phe	His	Glu
145					150					155					160
Tyr	Leu	Asp	Ser	Met	Phe	Phe	Asp	Arg	Phe	Leu	Gln	Trp	Lys	Trp	Leu
				165				170						175	
Glu	Arg	Gln	Pro	Val	Thr	Lys	Asn	Thr	Phe	Arg	Gln	Tyr	Arg	Val	Leu
			180					185					190		
Gly	Lys	Gly	Gly	Phe	Gly	Glu	Val	Cys	Ala	Cys	Gln	Val	Arg	Ala	Thr
		195					200					205			
Gly	Lys	Met	Tyr	Ala	Cys	Lys	Arg	Leu	Glu	Lys	Lys	Arg	Ile	Lys	Lys
	210					215					220				
Arg	Lys	Gly	Glu	Ser	Met	Ala	Leu	Asn	Glu	Lys	Gln	Ile	Leu	Glu	Lys
225					230					235					240
Val	Asn	Ser	Gln	Phe	Val	Val	Asn	Leu	Ala	Tyr	Ala	Tyr	Glu	Thr	Lys
				245					250					255	
Asp	Ala	Leu	Cys	Leu	Val	Leu	Thr	Ile	Met	Asn	Gly	Gly	Asp	Leu	Lys
			260					265					270		
Phe	His	Ile	Tyr	Asn	Met	Gly	Asn	Pro	Gly	Phe	Glu	Glu	Glu	Arg	Ala
		275					280						285		
Leu	Phe	Tyr	Ala	Ala	Glu	Ile	Leu	Cys	Gly	Leu	Glu	Asp	Leu	His	Arg
		290				295					300				
Glu	Asn	Thr	Val	Tyr	Arg	Asp	Leu	Lys	Pro	Glu	Asn	Ile	Leu	Leu	Asp
305					310					315					320
Asp	Tyr	Gly	His	Ile	Arg	Ile	Ser	Asp	Leu	Gly	Leu	Ala	Val	Lys	Ile
				325				330						335	
Pro	Glu	Gly	Asp	Leu	Ile	Arg	Gly	Arg	Val	Gly	Thr	Val	Gly	Tyr	Met
			340					345					350		
Ala	Pro	Glu	Val	Leu	Asn	Asn	Gln	Arg	Tyr	Gly	Leu	Ser	Pro	Asp	Tyr
			355				360						365		
Trp	Gly	Leu	Gly	Cys	Leu	Ile	Tyr	Glu	Met	Ile	Glu	Gly	Gln	Ser	Pro
	370					375					380				
Phe	Arg	Gly	Arg	Lys	Glu	Lys	Val	Lys	Arg	Glu	Glu	Val	Asp	Arg	Arg
385					390					395					400
Val	Leu	Glu	Thr	Glu	Glu	Val	Tyr	Ser	His	Lys	Phe	Ser	Glu	Glu	Ala
				405					410					415	
Lys	Ser	Ile	Cys	Lys	Met	Leu	Leu	Thr	Lys	Asp	Ala	Lys	Gln	Arg	Leu
			420					425					430		
Gly	Cys	Gln	Glu	Glu	Gly	Ala	Ala	Glu	Val	Lys	Arg	His	Pro	Phe	Phe
		435					440						445		

Arg	Asn	Met	Asn	Phe	Lys	Arg	Leu	Glu	Ala	Gly	Met	Leu	Asp	Pro	Pro
450						455					460				
Phe	Val	Pro	Asp	Pro	Arg	Ala	Val	Tyr	Cys	Lys	Asp	Val	Leu	Asp	Ile
465					470					475					480
Glu	Gln	Phe	Ser	Thr	Val	Lys	Gly	Val	Asn	Leu	Asp	His	Thr	Asp	Asp
				485					490					495	
Asp	Phe	Tyr	Ser	Lys	Phe	Ser	Thr	Gly	Ser	Val	Ser	Ile	Pro	Trp	Gln
			500					505					510		
Asn	Glu	Met	Ile	Glu	Thr	Glu	Cys	Phe	Lys	Glu	Leu	Asn	Val	Phe	Gly
		515					520					525			
Pro	Asn	Gly	Thr	Leu	Pro	Pro	Asp	Leu	Asn	Arg	Asn	His	Pro	Pro	Glu
		530				535					540				
Pro	Pro	Lys	Lys	Gly	Leu	Leu	Gln	Arg	Leu	Phe	Lys	Arg	Gln	His	Gln
545					550					555					560
Asn	Asn	Ser	Lys	Ser	Ser	Pro	Ser	Ser	Lys	Thr	Ser	Phe	Asn	His	His
			565						570					575	
Ile	Asn	Ser	Asn	His	Val	Ser	Ser	Asn	Ser	Thr	Gly	Ser	Ser		
			580					585					590		

&lt;210&gt; 9

&lt;211&gt; 3407

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 9

```

cagggagggc ttggctccac cactttcctc ccccagcctt tgggcagcag gtcacccctg 60
ttcaggctct gaggggtgcc cctcctgggt ctgtcctcac cacccttcc ccacctcctg 120
ggaaaaaaaa aaaaaaaaaa aaaaaagctg gtttaaagca gagagcctga gggctaaatt 180
taactgtccg agtcggaatc catctctgag tcaccaaga agctgccctg gcctcccgtc 240
cccttcccag gcctcaaccc ctttctccca cccagcccca acccccagcc ctcacccctt 300
agcccccagt tctggagctt gtcgggagca aggggggtgt tgctactggg tcaactcagcc 360
tcaattggcc ctgttcagca atgggcaggt tcttcttgaa attcatcaca cctgtggctt 420
cctctgtgct ctaccttttt attgggggtga cagtgtgaca gctgagattc tccatgcatt 480
ccccctactc tagcactgaa gggttctgaa gggccctgga aggaggagc ttgggggggt 540
ggcttgtgag ggggttaaggc tgggaggcgg gaggggggct ggaccaaggg gtggggagaa 600
ggggaggagg cctcgccggg ccgcagagag aagtggccag agaggcccag gggacagcca 660
gggacaggca gacatgcagc cagggctcca gggcctggac aggggctgcc aggcctgtgt 720
acaggaggac cccgagcccc cggcccgggg aggggccatg gtgctgcctg tccaacatgt 780
cagccgaggt gcggtcgagg cggctccagc agctggtgtt ggaccggggc ttcctggggc 840
tggagcccct gctcgacctt ctctggggcg tccaccagga gctgggcgcc tccgaactgg 900
cccaggacaa gtaoctggcc gacttcttgc agtgggcgga gcccatcgtg gtgaggctta 960
aggaggtccg actgcagagg gacgacttcg agattctgaa ggtgatcgga cgcggggcgt 1020
tcagcgaggt agcggtagtg aagatgaagc agacgggcca ggtgtatgcc atgaagatca 1080
tgaacaagtg ggacatgctg aagaggggag aggtgtcgtg cttccgtgag gagaggagc 1140
tggttggtgaa tggggaccgg cggtgatca cgcagctgca cttcgccctt caggatgaga 1200
actacctgta cctggatcat gagtattacg tgggcgggga cctgctgaca ctgctgagca 1260
agtttgggga gcggtatccg gccgagatgg cgcgcttcta cctggcgag attgtcatgg 1320
ccatagactc ggtgcaccgg cttggctacg tgcacaggga catcaaacc gacaacatcc 1380
tgctggaccg ctgtggccac atccgcctgg ccgacttcgg ctcttgctc aagctgcggg 1440
cagatggaac ggtgcggctg ctggtggctg tgggcacccc agactacctg tcccccgaga 1500
tcctgcagcg tgtggcggt gggcctggga caggcagcta cgggcccgag tgtgactggt 1560
gggcgctggg tgtattcgcc tatgaaatgt tctatgggca gacgccctt ctagcggtatt 1620
ccacggcgga gacctatggc aagatcgctc actacaagga gcacctctt ctgccgtgg 1680
tggacgaagg ggtccctgag gaggtcagc acttcattca gcggttgctg tgtcccccg 1740
agacacggct gggccggggg ggagcaggcg acttccggac acatccctt tcttttgcc 1800
tcgactggga tgggtctccg gacagcgtgc ccccttttac accggtttc gaaggtgcca 1860
ccgacacatg caacttcgac ttggtggagg acgggctcac tgccatggtg agcggggggc 1920
gggagacact gtcggacatt cgggaagggt cggcgtagg ggtccacctg ctttttggg 1980
gctactccta ctctgcagc gccctcagg acagtggagt cccaggcccc acacccatgg 2040
aagtggaggc cgagcagctg cttgagccac acgtgcaagc gccagcctg gagccctcgg 2100
tgtcccaca ggatgaaaca gctgaagtgg cagttccagc ggctgtccct gcggcagagg 2160

```

```

ctgaggccga ggtgacgctg cgggagctcc aggaagccct ggaggaggag gtgctcacc 2220
ggcagagcct gagccgggag atggaggcca tccgcacgga caaccagaac ttcgccagtc 2280
aactacgcga ggcagaggct cggaaccggg acctagaggc acacgtccgg cagttgcagg 2340
agcggatgga gttgctgcag gcagaggagg ccacagctgt cacgggggtc cccagtcccc 2400
gggccacgga tccaccttcc catctagatg. gccccccggc cgtggctgtg ggccagtgcc 2460
cgctggtggg gccaggcccc atgcaccgcc gccacctgct gctccctgcc aggggtcccta 2520
ggcctggcct atcggaggcg ctttccctgc tctgttgcg cgttgttctg tctcgtgccg 2580
ccgccctggg ctgcattggg ttggtggccc acgccggcca actcaccgca gtctggcgcc 2640
gccagagc cgcccgcgct ccctgaaccc tagaactgtc ttcgactccg gggccccggt 2700
ggaagactga gtgcccggg caccgcacag aagccgcgcc caccgcctgc cagttcacaa 2760
ccgctccgag cgtgggtctc cgcccagctc cagtcctgtg taccgggccc gccccctagc 2820
ggccggggag ggaggggccc ggtccgcggc cggcgaacgg ggctcgaagg gtcctttag 2880
ccgggaatgc tgcctgctgct gctgctgctg ctgctgctgc tggggggatc acagaccatt 2940
tctttctttc ggccaggctg agggccctgac gtggatgggc aaactgcagg cctgggaagg 3000
cagcaagccg ggccgtccgt gttccatcct ccacgcaccc ccacctatcg ttggttcgca 3060
aagtgcaaag ctttcttctg catgacgccc tgcctggtggg agcgtctggc gcgatctctg 3120
cctgcttact cgggaaattt gcttttgcca aaccgccttt ttcggggatc ccgcgcccc 3180
ctcctcactt gcctgctct cggagcccca gccggctccg cccgcttcgg cggtttggat 3240
atttattgac ctgcctctcc gactcgctga caggctacag gacccccaac aacccaatc 3300
cacgttttgg atgcactgag accccgacat tctcgggtat ttattgtctg tccccaccta 3360
ggacccccac ccccgaccct cgcgataaaa aggccctcca tctgccc 3407

```

&lt;210&gt; 10

&lt;211&gt; 629

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 10

```

Met Ser Ala Glu Val Arg Leu Arg Arg Leu Gln Gln Leu Val Leu Asp
1          5          10          15
Pro Gly Phe Leu Gly Leu Glu Pro Leu Leu Asp Leu Leu Leu Gly Val
20          25          30
His Gln Glu Leu Gly Ala Ser Glu Leu Ala Gln Asp Lys Tyr Val Ala
35          40          45
Asp Phe Leu Gln Trp Ala Glu Pro Ile Val Val Arg Leu Lys Glu Val
50          55          60
Arg Leu Gln Arg Asp Asp Phe Glu Ile Leu Lys Val Ile Gly Arg Gly
65          70          75          80
Ala Phe Ser Glu Val Ala Val Val Lys Met Lys Gln Thr Gly Gln Val
85          90          95
Tyr Ala Met Lys Ile Met Asn Lys Trp Asp Met Leu Lys Arg Gly Glu
100         105         110
Val Ser Cys Phe Arg Glu Glu Arg Asp Val Leu Val Asn Gly Asp Arg
115         120         125
Arg Trp Ile Thr Gln Leu His Phe Ala Phe Gln Asp Glu Asn Tyr Leu
130         135         140
Tyr Leu Val Met Glu Tyr Tyr Val Gly Gly Asp Leu Leu Thr Leu Leu
145         150         155         160
Ser Lys Phe Gly Glu Arg Ile Pro Ala Glu Met Ala Arg Phe Tyr Leu
165         170         175
Ala Glu Ile Val Met Ala Ile Asp Ser Val His Arg Leu Gly Tyr Val
180         185         190
His Arg Asp Ile Lys Pro Asp Asn Ile Leu Leu Asp Arg Cys Gly His
195         200         205
Ile Arg Leu Ala Asp Phe Gly Ser Cys Leu Lys Leu Arg Ala Asp Gly
210         215         220
Thr Val Arg Ser Leu Val Ala Val Gly Thr Pro Asp Tyr Leu Ser Pro
225         230         235         240
Glu Ile Leu Gln Ala Val Gly Gly Gly Pro Gly Thr Gly Ser Tyr Gly
245         250         255
Pro Glu Cys Asp Trp Trp Ala Leu Gly Val Phe Ala Tyr Glu Met Phe
260         265         270

```

Tyr Gly Gln Thr Pro Phe Tyr Ala Asp Ser Thr Ala Glu Thr Tyr Gly  
 275 280 285  
 Lys Ile Val His Tyr Lys Glu His Leu Ser Leu Pro Leu Val Asp Glu  
 290 295 300  
 Gly Val Pro Glu Glu Ala Arg Asp Phe Ile Gln Arg Leu Leu Cys Pro  
 305 310 315 320  
 Pro Glu Thr Arg Leu Gly Arg Gly Gly Ala Gly Asp Phe Arg Thr His  
 325 330 335  
 Pro Phe Phe Phe Gly Leu Asp Trp Asp Gly Leu Arg Asp Ser Val Pro  
 340 345 350  
 Pro Phe Thr Pro Asp Phe Glu Gly Ala Thr Asp Thr Cys Asn Phe Asp  
 355 360 365  
 Leu Val Glu Asp Gly Leu Thr Ala Met Val Ser Gly Gly Gly Glu Thr  
 370 375 380  
 Leu Ser Asp Ile Arg Glu Gly Ala Pro Leu Gly Val His Leu Pro Phe  
 385 390 395 400  
 Val Gly Tyr Ser Tyr Ser Cys Met Ala Leu Arg Asp Ser Glu Val Pro  
 405 410 415  
 Gly Pro Thr Pro Met Glu Val Glu Ala Glu Gln Leu Leu Glu Pro His  
 420 425 430  
 Val Gln Ala Pro Ser Leu Glu Pro Ser Val Ser Pro Gln Asp Glu Thr  
 435 440 445  
 Ala Glu Val Ala Val Pro Ala Ala Val Pro Ala Ala Glu Ala Glu Ala  
 450 455 460  
 Glu Val Thr Leu Arg Glu Leu Gln Glu Ala Leu Glu Glu Glu Val Leu  
 465 470 475 480  
 Thr Arg Gln Ser Leu Ser Arg Glu Met Glu Ala Ile Arg Thr Asp Asn  
 485 490 495  
 Gln Asn Phe Ala Ser Gln Leu Arg Glu Ala Glu Ala Arg Asn Arg Asp  
 500 505 510  
 Leu Glu Ala His Val Arg Gln Leu Gln Glu Arg Met Glu Leu Leu Gln  
 515 520 525  
 Ala Glu Gly Ala Thr Ala Val Thr Gly Val Pro Ser Pro Arg Ala Thr  
 530 535 540  
 Asp Pro Pro Ser His Leu Asp Gly Pro Pro Ala Val Ala Val Gly Gln  
 545 550 555 560  
 Cys Pro Leu Val Gly Pro Gly Pro Met His Arg Arg His Leu Leu Leu  
 565 570 575  
 Pro Ala Arg Val Pro Arg Pro Gly Leu Ser Glu Ala Leu Ser Leu Leu  
 580 585 590  
 Leu Phe Ala Val Val Leu Ser Arg Ala Ala Ala Leu Gly Cys Ile Gly  
 595 600 605  
 Leu Val Ala His Ala Gly Gln Leu Thr Ala Val Trp Arg Arg Pro Gly  
 610 615 620  
 Ala Ala Arg Ala Pro  
 625

&lt;210&gt; 11

&lt;211&gt; 2637

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; CDS

&lt;222&gt; (1)... (2637)

&lt;400&gt; 11

atg gcc acc gcc ccc tct tat ccc gcc ggg ctc cct ggc tct ccc ggg 48  
 Met Ala Thr Ala Pro Ser Tyr Pro Ala Gly Leu Pro Gly Ser Pro Gly  
 1 5 10 15

ccg ggg tct cct ccg ccc ccc ggc ggc cta gag ctg cag tcg ccg cca	96
Pro Gly Ser Pro Pro Pro Pro Gly Gly Leu Glu Leu Gln Ser Pro Pro	
20 25 30	
ccg cta ctg ccc cag atc ccg gcc ccg ggt tcc ggg gtc tcc ttt cac	144
Pro Leu Leu Pro Gln Ile Pro Ala Pro Gly Ser Gly Val Ser Phe His	
35 40 45	
atc cag atc ggg ctg acc cgc gag ttc gtg ctg ttg ccc gcc gcc tcc	192
Ile Gln Ile Gly Leu Thr Arg Glu Phe Val Leu Leu Pro Ala Ala Ser	
50 55 60	
gag ctg gct cat gtg aag cag ctg gcc tgt tcc atc gtg gac cag aag	240
Glu Leu Ala His Val Lys Gln Leu Ala Cys Ser Ile Val Asp Gln Lys	
65 70 75 80	
ttc cct gag tgt ggc ttc tac ggc ctt tac gac aag atc ctg ctt ttc	288
Phe Pro Glu Cys Gly Phe Tyr Gly Leu Tyr Asp Lys Ile Leu Leu Phe	
85 90 95	
aaa cat gac ccc acg tcg gcc aac ctc ctg cag ctg gtg cgc tcg tcc	336
Lys His Asp Pro Thr Ser Ala Asn Leu Leu Gln Leu Val Arg Ser Ser	
100 105 110	
gga gac atc cag gag ggc gac ctg gtg gag gtg gtg ctg tcg gcc tcg	384
Gly Asp Ile Gln Glu Gly Asp Leu Val Glu Val Val Leu Ser Ala Ser	
115 120 125	
gcc acc ttc gag gac ttc cag atc cgc ccg cac gcc ctc acg gtg cac	432
Ala Thr Phe Glu Asp Phe Gln Ile Arg Pro His Ala Leu Thr Val His	
130 135 140	
tcc tat cgg gcg cct gcc ttc tgt gat cac tgc ggg gag atg ctc ttc	480
Ser Tyr Arg Ala Pro Ala Phe Cys Asp His Cys Gly Glu Met Leu Phe	
145 150 155 160	
ggc cta gtg cgc cag ggc ctc aag tgc gat ggc tgc ggg ctg aac tac	528
Gly Leu Val Arg Gln Gly Leu Lys Cys Asp Gly Cys Gly Leu Asn Tyr	
165 170 175	
cac aag cgc tgt gcc ttc agc atc ccc aac aac tgt agt ggg gcc cgc	576
His Lys Arg Cys Ala Phe Ser Ile Pro Asn Asn Cys Ser Gly Ala Arg	
180 185 190	
aaa cgg cgc ctg tca tcc acg tct ctg gcc agt ggc cac tcg gtg cgc	624
Lys Arg Arg Leu Ser Ser Thr Ser Leu Ala Ser Gly His Ser Val Arg	
195 200 205	
ctc ggc acc tcc gag tcc ctg ccc tgc acg gct gaa gag ctg agc cgt	672
Leu Gly Thr Ser Glu Ser Leu Pro Cys Thr Ala Glu Glu Leu Ser Arg	
210 215 220	
agc acc acc gaa ctc ctg cct cgc cgt ccc ccg tca tcc tct tcc tcc	720
Ser Thr Thr Glu Leu Leu Pro Arg Arg Pro Pro Ser Ser Ser Ser Ser	
225 230 235 240	
tct tct gcc tca tcg tat acg ggc cgc ccc att gag ctg gac aag atg	768
Ser Ser Ala Ser Ser Tyr Thr Gly Arg Pro Ile Glu Leu Asp Lys Met	
245 250 255	
ctg ctc tcc aag gtc aag gtg ccg cac acc ttc ctc atc cac agc tat	816



Leu	Leu	Ser	Lys	Val	Lys	Val	Pro	His	Thr	Phe	Leu	Ile	His	Ser	Tyr		
			260					265					270				
aca	cgg	ccc	acc	gtt	tgc	cag	gct	tgc	aag	aaa	ctc	ctc	aag	ggc	ctc	864	
Thr	Arg	Pro	Thr	Val	Cys	Gln	Ala	Cys	Lys	Lys	Leu	Leu	Lys	Gly	Leu		
		275					280					285					
ttc	cgg	cag	ggc	ctg	caa	tgc	aaa	gac	tgc	aag	ttt	aac	tgt	cac	aaa	912	
Phe	Arg	Gln	Gly	Leu	Gln	Cys	Lys	Asp	Cys	Lys	Phe	Asn	Cys	His	Lys		
	290					295					300						
cgc	tgc	gcc	acc	cgc	gtc	cct	aat	gac	tgc	ctg	ggg	gag	gcc	ctt	atc	960	
Arg	Cys	Ala	Thr	Arg	Val	Pro	Asn	Asp	Cys	Leu	Gly	Glu	Ala	Leu	Ile		
305					310					315					320		
aat	gga	gat	gtg	ccg	atg	gag	gag	gcc	acc	gat	ttc	agc	gag	gct	gac	1008	
Asn	Gly	Asp	Val	Pro	Met	Glu	Glu	Ala	Thr	Asp	Phe	Ser	Glu	Ala	Asp		
			325						330					335			
aag	agc	gcc	ctc	atg	gat	gag	tca	gag	gac	tcc	ggt	gtc	atc	cct	ggc	1056	
Lys	Ser	Ala	Leu	Met	Asp	Glu	Ser	Glu	Asp	Ser	Gly	Val	Ile	Pro	Gly		
			340						345				350				
tcc	cac	tca	gag	aat	gcg	ctc	cac	gcc	agt	gag	gag	gag	gaa	ggc	gag	1104	
Ser	His	Ser	Glu	Asn	Ala	Leu	His	Ala	Ser	Glu	Glu	Glu	Glu	Gly	Glu		
		355					360					365					
gga	ggc	aag	gcc	cag	agc	tcc	ctg	ggg	tac	atc	ccc	cta	atg	agg	gtg	1152	
Gly	Gly	Lys	Ala	Gln	Ser	Ser	Leu	Gly	Tyr	Ile	Pro	Leu	Met	Arg	Val		
	370					375					380						
gtg	caa	tcg	gtg	cga	cac	acg	acg	cgg	aaa	tcc	agc	acc	acg	ctg	cgg	1200	
Val	Gln	Ser	Val	Arg	His	Thr	Thr	Arg	Lys	Ser	Ser	Thr	Thr	Leu	Arg		
385					390					395					400		
gag	ggt	tgg	gtg	gtt	cat	tac	agc	aac	aag	gac	acg	ctg	aga	aag	cgg	1248	
Glu	Gly	Trp	Val	Val	His	Tyr	Ser	Asn	Lys	Asp	Thr	Leu	Arg	Lys	Arg		
			405						410					415			
cac	tat	tgg	cgc	ctg	gac	tgc	aag	tgt	atc	acg	ctc	ttc	cag	aac	aac	1296	
His	Tyr	Trp	Arg	Leu	Asp	Cys	Lys	Cys	Ile	Thr	Leu	Phe	Gln	Asn	Asn		
			420					425					430				
acg	acc	aac	aga	tac	tat	aag	gaa	att	ccg	ctg	tca	gaa	atc	ctc	acg	1344	
Thr	Thr	Asn	Arg	Tyr	Tyr	Lys	Glu	Ile	Pro	Leu	Ser	Glu	Ile	Leu	Thr		
		435					440					445					
gtg	gag	tcc	gcc	cag	aac	ttc	agc	ctt	gtg	ccg	ccg	ggc	acc	aac	cca	1392	
Val	Glu	Ser	Ala	Gln	Asn	Phe	Ser	Leu	Val	Pro	Pro	Gly	Thr	Asn	Pro		
	450					455					460						
cac	tgc	ttt	gag	atc	gtc	act	gcc	aat	gcc	acc	tac	ttc	gtg	ggc	gag	1440	
His	Cys	Phe	Glu	Ile	Val	Thr	Ala	Asn	Ala	Thr	Tyr	Phe	Val	Gly	Glu		
	465				470					475					480		
atg	cct	ggc	ggg	act	ccg	ggt	ggg	cca	agt	ggg	cag	ggg	gct	gag	gcc	1488	
Met	Pro	Gly	Gly	Thr	Pro	Gly	Gly	Pro	Ser	Gly	Gln	Gly	Ala	Glu	Ala		
				485				490						495			
gcc	cgg	ggc	tgg	gag	aca	gcc	atc	cgc	cag	gcc	ctg	atg	ccc	gtc	atc	1536	
Ala	Arg	Gly	Trp	Glu	Thr	Ala	Ile	Arg	Gln	Ala	Leu	Met	Pro	Val	Ile		
			500					505					510				

ctt cag gac gca ccc agc gcc cca ggc cac gcg ccc cac aga caa gct	1584
Leu Gln Asp Ala Pro Ser Ala Pro Gly His Ala Pro His Arg Gln Ala	
515 520 525	
tct ctg agc atc tct gtg tcc aac agt cag atc caa gag aat gtg gac	1632
Ser Leu Ser Ser Ile Ser Val Ser Asn Ser Gln Ile Gln Glu Asn Val Asp	
530 535 540	
att gcc act gtc tac cag atc ttc cct gac gaa gtg ctg ggc tca ggg	1680
Ile Ala Thr Val Tyr Gln Ile Phe Pro Asp Glu Val Leu Gly Ser Gly	
545 550 555 560	
cag ttt gga gtg gtc tat gga ggg aaa cac cgg aag aca ggc cgg gac	1728
Gln Phe Gly Val Val Tyr Gly Gly Lys His Arg Lys Thr Gly Arg Asp	
565 570 575	
gtg gca gtt aag gtc att gac aaa ctg cgc ttc cct acc aag cag gag	1776
Val Ala Val Lys Val Ile Asp Lys Leu Arg Phe Pro Thr Lys Gln Glu	
580 585 590	
agc cag ctc cgg aat gaa gtg gcc att ctg cag agc ctg cgg cat ccc	1824
Ser Gln Leu Arg Asn Glu Val Ala Ile Leu Gln Ser Leu Arg His Pro	
595 600 605	
ggg atc gtg aac ctg gag tgc atg ttc gag acg cct gag aaa gtg ttt	1872
Gly Ile Val Asn Leu Glu Cys Met Phe Glu Thr Pro Glu Lys Val Phe	
610 615 620	
gtg gtg atg gag aag ctg cat ggg gac atg ttg gag atg atc ctg tcc	1920
Val Val Met Glu Lys Leu His Gly Asp Met Leu Glu Met Ile Leu Ser	
625 630 635 640	
agt gag aag ggc cgg ctg cct gag cgc ctc acc aag ttc ctc atc acc	1968
Ser Glu Lys Gly Arg Leu Pro Glu Arg Leu Thr Lys Phe Leu Ile Thr	
645 650 655	
cag atc ctg gtg gct ttg aga cac ctt cac ttc aag aac att gtc cac	2016
Gln Ile Leu Val Ala Leu Arg His Leu His Phe Lys Asn Ile Val His	
660 665 670	
tgt gac ttg aaa cca gaa aac gtg ttg ctg gca tca gca gac cca ttt	2064
Cys Asp Leu Lys Pro Glu Asn Val Leu Leu Ala Ser Ala Asp Pro Phe	
675 680 685	
cct cag gtg aag ctg tgt gac ttt ggc ttt gct cgc atc atc ggc gag	2112
Pro Gln Val Lys Leu Cys Asp Phe Gly Phe Ala Arg Ile Ile Gly Glu	
690 695 700	
aag tcg ttc cgc cgc tca gtg gtg ggc acg ccg gcc tac ctg gca ccc	2160
Lys Ser Phe Arg Arg Ser Val Val Gly Thr Pro Ala Tyr Leu Ala Pro	
705 710 715 720	
gag gtg ctg ctc aac cag ggc tac aac cgc tcg ctg gac atg tgg tca	2208
Glu Val Leu Leu Asn Gln Gly Tyr Asn Arg Ser Leu Asp Met Trp Ser	
725 730 735	
gtg ggc gtg atc atg tac gtc agc ctc agc ggc acc ttc cct ttc aac	2256
Val Gly Val Ile Met Tyr Val Ser Leu Ser Gly Thr Phe Pro Phe Asn	
740 745 750	
gag gat gag gac atc aat gac cag atc cag aac gcc gcc ttc atg tac	2304

Glu Asp. Glu Asp Ile Asn Asp Gln Ile Gln Asn Ala Ala Phe Met Tyr	
755	760 765
ccg gcc agc ccc tgg agc cac atc tca gct gga gcc att gac ctc atc	2352
Pro Ala Ser Pro Trp Ser His Ile Ser Ala Gly Ala Ile Asp Leu Ile	
770	775 780
aac aac ctg ctg cag gtg aag atg cgc aaa cgc tac agc gtg gac aaa	2400
Asn Asn Leu Leu Gln Val Lys Met Arg Lys Arg Tyr Ser Val Asp Lys	
785	790 795 800
tct ctc agc cac ccc tgg tta cag gag tac cag acg tgg ctg gac ctc	2448
Ser Leu Ser His Pro Trp Leu Gln Glu Tyr Gln Thr Trp Leu Asp Leu	
805	810 815
cga gag ctg gag ggg aag atg gga gag cga tac atc acg cat gag agt	2496
Arg Glu Leu Glu Gly Lys Met Gly Glu Arg Tyr Ile Thr His Glu Ser	
820	825 830
gac gac gcg cgc tgg gag cag ttt gca gca gag cat ccg ctg cct ggg	2544
Asp Asp Ala Arg Trp Glu Gln Phe Ala Ala Glu His Pro Leu Pro Gly	
835	840 845
tct ggg ctg ccc acg gac agg gat ctc ggt ggg gcc tgt cca cca cag	2592
Ser Gly Leu Pro Thr Asp Arg Asp Leu Gly Gly Ala Cys Pro Pro Gln	
850	855 860
gac cac gac atg cag ggg ctg gcg gag cgc atc agt gtt ctc tga	2637
Asp His Asp Met Gln Gly Leu Ala Glu Arg Ile Ser Val Leu *	
865	870 875

&lt;210&gt; 12

&lt;211&gt; 878

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 12

Met Ala Thr Ala Pro Ser Tyr Pro Ala Gly Leu Pro Gly Ser Pro Gly	
1	5 10 15
Pro Gly Ser Pro Pro Pro Gly Gly Leu Glu Leu Gln Ser Pro Pro	
20	25 30
Pro Leu Leu Pro Gln Ile Pro Ala Pro Gly Ser Gly Val Ser Phe His	
35	40 45
Ile Gln Ile Gly Leu Thr Arg Glu Phe Val Leu Leu Pro Ala Ala Ser	
50	55 60
Glu Leu Ala His Val Lys Gln Leu Ala Cys Ser Ile Val Asp Gln Lys	
65	70 75 80
Phe Pro Glu Cys Gly Phe Tyr Gly Leu Tyr Asp Lys Ile Leu Leu Phe	
85	90 95
Lys His Asp Pro Thr Ser Ala Asn Leu Leu Gln Leu Val Arg Ser Ser	
100	105 110
Gly Asp Ile Gln Glu Gly Asp Leu Val Glu Val Val Leu Ser Ala Ser	
115	120 125
Ala Thr Phe Glu Asp Phe Gln Ile Arg Pro His Ala Leu Thr Val His	
130	135 140
Ser Tyr Arg Ala Pro Ala Phe Cys Asp His Cys Gly Glu Met Leu Phe	
145	150 155 160
Gly Leu Val Arg Gln Gly Leu Lys Cys Asp Gly Cys Gly Leu Asn Tyr	
165	170 175

His	Lys	Arg	Cys	Ala	Phe	Ser	Ile	Pro	Asn	Asn	Cys	Ser	Gly	Ala	Arg	180	185	190
Lys	Arg	Arg	Leu	Ser	Ser	Thr	Ser	Leu	Ala	Ser	Gly	His	Ser	Val	Arg	195	200	205
Leu	Gly	Thr	Ser	Glu	Ser	Leu	Pro	Cys	Thr	Ala	Glu	Glu	Leu	Ser	Arg	210	215	220
Ser	Thr	Thr	Glu	Leu	Leu	Pro	Arg	Arg	Pro	Pro	Ser	Ser	Ser	Ser	Ser	225	230	235
Ser	Ser	Ala	Ser	Ser	Tyr	Thr	Gly	Arg	Pro	Ile	Glu	Leu	Asp	Lys	Met	245	250	255
Leu	Leu	Ser	Lys	Val	Lys	Val	Pro	His	Thr	Phe	Leu	Ile	His	Ser	Tyr	260	265	270
Thr	Arg	Pro	Thr	Val	Cys	Gln	Ala	Cys	Lys	Lys	Leu	Leu	Lys	Gly	Leu	275	280	285
Phe	Arg	Gln	Gly	Leu	Gln	Cys	Lys	Asp	Cys	Lys	Phe	Asn	Cys	His	Lys	290	295	300
Arg	Cys	Ala	Thr	Arg	Val	Pro	Asn	Asp	Cys	Leu	Gly	Glu	Ala	Leu	Ile	305	310	315
Asn	Gly	Asp	Val	Pro	Met	Glu	Glu	Ala	Thr	Asp	Phe	Ser	Glu	Ala	Asp	325	330	335
Lys	Ser	Ala	Leu	Met	Asp	Glu	Ser	Glu	Asp	Ser	Gly	Val	Ile	Pro	Gly	340	345	350
Ser	His	Ser	Glu	Asn	Ala	Leu	His	Ala	Ser	Glu	Glu	Glu	Glu	Gly	Glu	355	360	365
Gly	Gly	Lys	Ala	Gln	Ser	Ser	Leu	Gly	Tyr	Ile	Pro	Leu	Met	Arg	Val	370	375	380
Val	Gln	Ser	Val	Arg	His	Thr	Thr	Arg	Lys	Ser	Ser	Thr	Thr	Leu	Arg	385	390	395
Glu	Gly	Trp	Val	Val	His	Tyr	Ser	Asn	Lys	Asp	Thr	Leu	Arg	Lys	Arg	405	410	415
His	Tyr	Trp	Arg	Leu	Asp	Cys	Lys	Cys	Ile	Thr	Leu	Phe	Gln	Asn	Asn	420	425	430
Thr	Thr	Asn	Arg	Tyr	Tyr	Lys	Glu	Ile	Pro	Leu	Ser	Glu	Ile	Leu	Thr	435	440	445
Val	Glu	Ser	Ala	Gln	Asn	Phe	Ser	Leu	Val	Pro	Pro	Gly	Thr	Asn	Pro	450	455	460
His	Cys	Phe	Glu	Ile	Val	Thr	Ala	Asn	Ala	Thr	Tyr	Phe	Val	Gly	Glu	465	470	475
Met	Pro	Gly	Gly	Thr	Pro	Gly	Gly	Pro	Ser	Gly	Gln	Gly	Ala	Glu	Ala	485	490	495
Ala	Arg	Gly	Trp	Glu	Thr	Ala	Ile	Arg	Gln	Ala	Leu	Met	Pro	Val	Ile	500	505	510
Leu	Gln	Asp	Ala	Pro	Ser	Ala	Pro	Gly	His	Ala	Pro	His	Arg	Gln	Ala	515	520	525
Ser	Leu	Ser	Ile	Ser	Val	Ser	Asn	Ser	Gln	Ile	Gln	Glu	Asn	Val	Asp	530	535	540
Ile	Ala	Thr	Val	Tyr	Gln	Ile	Phe	Pro	Asp	Glu	Val	Leu	Gly	Ser	Gly	545	550	555
Gln	Phe	Gly	Val	Val	Tyr	Gly	Gly	Lys	His	Arg	Lys	Thr	Gly	Arg	Asp	565	570	575
Val	Ala	Val	Lys	Val	Ile	Asp	Lys	Leu	Arg	Phe	Pro	Thr	Lys	Gln	Glu	580	585	590
Ser	Gln	Leu	Arg	Asn	Glu	Val	Ala	Ile	Leu	Gln	Ser	Leu	Arg	His	Pro	595	600	605
Gly	Ile	Val	Asn	Leu	Glu	Cys	Met	Phe	Glu	Thr	Pro	Glu	Lys	Val	Phe	610	615	620
Val	Val	Met	Glu	Lys	Leu	His	Gly	Asp	Met	Leu	Glu	Met	Ile	Leu	Ser	625	630	635
Ser	Glu	Lys	Gly	Arg	Leu	Pro	Glu	Arg	Leu	Thr	Lys	Phe	Leu	Ile	Thr	645	650	655
Gln	Ile	Leu	Val	Ala	Leu	Arg	His	Leu	His	Phe	Lys	Asn	Ile	Val	His	660	665	670

Cys Asp Leu Lys Pro Glu Asn Val Leu Leu Ala Ser Ala Asp Pro Phe  
 675 680 685  
 Pro Gln Val Lys Leu Cys Asp Phe Gly Phe Ala Arg Ile Ile Gly Glu  
 690 695 700  
 Lys Ser Phe Arg Arg Ser Val Val Gly Thr Pro Ala Tyr Leu Ala Pro  
 705 710 715 720  
 Glu Val Leu Leu Asn Gln Gly Tyr Asn Arg Ser Leu Asp Met Trp Ser  
 725 730 735  
 Val Gly Val Ile Met Tyr Val Ser Leu Ser Gly Thr Phe Pro Phe Asn  
 740 745 750  
 Glu Asp Glu Asp Ile Asn Asp Gln Ile Gln Asn Ala Ala Phe Met Tyr  
 755 760 765  
 Pro Ala Ser Pro Trp Ser His Ile Ser Ala Gly Ala Ile Asp Leu Ile  
 770 775 780  
 Asn Asn Leu Leu Gln Val Lys Met Arg Lys Arg Tyr Ser Val Asp Lys  
 785 790 795 800  
 Ser Leu Ser His Pro Trp Leu Gln Glu Tyr Gln Thr Trp Leu Asp Leu  
 805 810 815  
 Arg Glu Leu Glu Gly Lys Met Gly Glu Arg Tyr Ile Thr His Glu Ser  
 820 825 830  
 Asp Asp Ala Arg Trp Glu Gln Phe Ala Ala Glu His Pro Leu Pro Gly  
 835 840 845  
 Ser Gly Leu Pro Thr Asp Arg Asp Leu Gly Gly Ala Cys Pro Pro Gln  
 850 855 860  
 Asp His Asp Met Gln Gly Leu Ala Glu Arg Ile Ser Val Leu  
 865 870 875

&lt;210&gt; 13

&lt;211&gt; 2037

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; CDS

&lt;222&gt; (1)...(2037)

&lt;400&gt; 13

atg gcc acc gcc ccc tct tat ccc gcc ggg ctc cct ggc tct ccc ggg	48
Met Ala Thr Ala Pro Ser Tyr Pro Ala Gly Leu Pro Gly Ser Pro Gly	
1 5 10 15	
ccg ggg tct cct ccg ccc ccc ggc ggc cta gag ctg cag tcg ccg cca	96
Pro Gly Ser Pro Pro Pro Gly Leu Glu Leu Gln Ser Pro Pro	
20 25 30	
ccg cta ctg ccc cag atc ccg gcc ccg ggt tcc ggg gtc tcc ttt cac	144
Pro Leu Leu Pro Gln Ile Pro Ala Pro Gly Ser Gly Val Ser Phe His	
35 40 45	
atc cag atc ggg ctg acc cgc gag ttc gtg ctg ttg ccc gcc gcc tcc	192
Ile Gln Ile Gly Leu Thr Arg Glu Phe Val Leu Pro Ala Ala Ser	
50 55 60	
gag ctg gct cat gtg aag cag ctg gcc tgt tcc atc gtg gac cag aag	240
Glu Leu Ala His Val Lys Gln Leu Ala Cys Ser Ile Val Asp Gln Lys	
65 70 75 80	
ttc cct gag tgt ggc ttc tac ggc ctt tac gac aag atc ctg ctt ttc	288
Phe Pro Glu Cys Gly Phe Tyr Gly Leu Tyr Asp Lys Ile Leu Leu Phe	
85 90 95	

aaa cat gac ccc acg tcg gcc aac ctc ctg cag ctg gtg cgc tcg tcc	336
Lys His Asp Pro Thr Ser Ala Asn Leu Leu Gln Leu Val Arg Ser Ser	
100 105 110	
gga gac atc cag gag ggc gac ctg gtg gag gtg gtg ctg tcg gcc tcg	384
Gly Asp Ile Gln Glu Gly Asp Leu Val Glu Val Val Leu Ser Ala Ser	
115 120 125	
gcc acc ttc gag gac ttc cag atc cgc ccg cac gcc ctc acg gtg cac	432
Ala Thr Phe Glu Asp Phe Gln Ile Arg Pro His Ala Leu Thr Val His	
130 135 140	
tcc tat cgg gcg cct gcc ttc tgt gat cac tgc ggg gag atg ctc ttc	480
Ser Tyr Arg Ala Pro Ala Phe Cys Asp His Cys Gly Glu Met Leu Phe	
145 150 155 160	
ggc cta gtg cgc cag ggc ctc aag tgc gat ggc tgc ggg ctg aac tac	528
Gly Leu Val Arg Gln Gly Leu Lys Cys Asp Gly Cys Gly Leu Asn Tyr	
165 170 175	
cac aag cgc tgt gcc ttc agc atc ccc aac aac tgt agt ggg gcc cgc	576
His Lys Arg Cys Ala Phe Ser Ile Pro Asn Asn Cys Ser Gly Ala Arg	
180 185 190	
aaa cgg cgc ctg tca tcc acg tct ctg gcc agt ggc cac tcg gtg cgc	624
Lys Arg Arg Leu Ser Ser Thr Ser Leu Ala Ser Gly His Ser Val Arg	
195 200 205	
ctc ggc acc tcc gag tcc ctg ccc tgc acg gct gaa gag ctg agc cgt	672
Leu Gly Thr Ser Glu Ser Leu Pro Cys Thr Ala Glu Glu Leu Ser Arg	
210 215 220	
agc acc acc gaa ctc ctg cct cgc cgt ccc ccg tca tcc tct tcc tcc	720
Ser Thr Thr Glu Leu Pro Arg Arg Pro Pro Ser Ser Ser Ser Ser	
225 230 235 240	
tct tct gcc tca tcg tat acg ggc cgc ccc att gag ctg gac aag atg	768
Ser Ser Ala Ser Ser Tyr Thr Gly Arg Pro Ile Glu Leu Asp Lys Met	
245 250 255	
ctg ctc tcc aag gtc aag gtg ccg cac acc ttc ctc atc cac agc tat	816
Leu Leu Ser Lys Val Lys Val Pro His Thr Phe Leu Ile His Ser Tyr	
260 265 270	
aca cgg ccc acc gtt tgc cag gct tgc aag aaa ctc ctc aag ggc ctc	864
Thr Arg Pro Thr Val Cys Gln Ala Cys Lys Lys Leu Leu Lys Gly Leu	
275 280 285	
ttc cgg cag ggc ctg caa tgc aaa gac tgc aag ttt aac tgt cac aaa	912
Phe Arg Gln Gly Leu Gln Cys Lys Asp Cys Lys Phe Asn Cys His Lys	
290 295 300	
cgc tgc gcc acc cgc gtc cct aat gac tgc ctg ggg gag gcc ctt atc	960
Arg Cys Ala Thr Arg Val Pro Asn Asp Cys Leu Gly Glu Ala Leu Ile	
305 310 315 320	
aat gga gat gtg ccg atg gag gag gcc acc gat ttc agc gag gct gac	1008
Asn Gly Asp Val Pro Met Glu Glu Ala Thr Asp Phe Ser Glu Ala Asp	
325 330 335	
aag agc gcc ctc atg gat gag tca gag gac tcc ggt gtc atc cct ggc	1056

Lys	Ser	Ala	Leu	Met	Asp	Glu	Ser	Glu	Asp	Ser	Gly	Val	Ile	Pro	Gly	
			340					345					350			
tcc	cac	tca	gag	aat	gcg	ctc	cac	gcc	agt	gag	gag	gag	gaa	ggc	gag	1104
Ser	His	Ser	Glu	Asn	Ala	Leu	His	Ala	Ser	Glu	Glu	Glu	Glu	Gly	Glu	
		355					360					365				
gga	ggc	aag	gcc	cag	agc	tcc	ctg	ggg	tac	atc	ccc	cta	atg	agg	gtg	1152
Gly	Gly	Lys	Ala	Gln	Ser	Ser	Leu	Gly	Tyr	Ile	Pro	Leu	Met	Arg	Val	
	370					375					380					
gtg	caa	tcg	gtg	cga	cac	acg	acg	cgg	aaa	tcc	agc	acc	acg	ctg	cgg	1200
Val	Gln	Ser	Val	Arg	His	Thr	Thr	Arg	Lys	Ser	Ser	Thr	Thr	Leu	Arg	
385					390				395					400		
gag	ggt	tgg	gtg	gtt	cat	tac	agc	aac	aag	gac	acg	ctg	aga	aag	cgg	1248
Glu	Gly	Trp	Val	His	Tyr	Ser	Asn	Lys	Asp	Thr	Leu	Arg	Lys	Arg		
			405					410					415			
cac	tat	tgg	cgc	ctg	gac	tgc	aag	tgt	atc	acg	ctc	ttc	cag	aac	aac	1296
His	Tyr	Trp	Arg	Leu	Asp	Cys	Lys	Cys	Ile	Thr	Leu	Phe	Gln	Asn	Asn	
		420					425					430				
acg	acc	aac	aga	tac	tat	aag	gaa	att	ccg	ctg	tca	gaa	atc	ctc	acg	1344
Thr	Thr	Asn	Arg	Tyr	Tyr	Lys	Glu	Ile	Pro	Leu	Ser	Glu	Ile	Leu	Thr	
		435					440					445				
gtg	gag	tcc	gcc	cag	aac	ttc	agc	ctt	gtg	ccg	ccg	ggc	acc	aac	cca	1392
Val	Glu	Ser	Ala	Gln	Asn	Phe	Ser	Leu	Val	Pro	Pro	Gly	Thr	Asn	Pro	
	450				455					460						
cac	tgc	ttt	gag	atc	gtc	act	gcc	aat	gcc	acc	tac	ttc	gtg	ggc	gag	1440
His	Cys	Phe	Glu	Ile	Val	Thr	Ala	Asn	Ala	Thr	Tyr	Phe	Val	Gly	Glu	
465					470				475					480		
atg	cct	ggc	ggg	act	ccg	ggt	ggg	cca	agt	ggg	cag	ggg	gct	gag	gcc	1488
Met	Pro	Gly	Gly	Thr	Pro	Gly	Gly	Pro	Ser	Gly	Gln	Gly	Ala	Glu	Ala	
				485				490						495		
gcc	cgg	ggc	tgg	gag	aca	gcc	atc	cgc	cag	gcc	ctg	atg	ccc	gtc	atc	1536
Ala	Arg	Gly	Trp	Glu	Thr	Ala	Ile	Arg	Gln	Ala	Leu	Met	Pro	Val	Ile	
			500					505					510			
ctt	cag	gac	gca	ccc	agc	gcc	cca	ggc	cac	gcg	ccc	cac	aga	caa	gct	1584
Leu	Gln	Asp	Ala	Pro	Ser	Ala	Pro	Gly	His	Ala	Pro	His	Arg	Gln	Ala	
		515					520					525				
tct	ctg	agc	atc	tct	gtg	tcc	aac	agt	cag	atc	caa	gag	aat	gtg	gac	1632
Ser	Leu	Ser	Ile	Ser	Val	Ser	Asn	Ser	Gln	Ile	Gln	Glu	Asn	Val	Asp	
	530					535					540					
att	gcc	act	gtc	tac	cag	atc	ttc	cct	gac	gaa	gtg	ctg	ggc	tca	ggg	1680
Ile	Ala	Thr	Val	Tyr	Gln	Ile	Phe	Pro	Asp	Glu	Val	Leu	Gly	Ser	Gly	
545					550				555					560		
cag	ttt	gga	gtg	gtc	tat	gga	ggg	aaa	cac	cgg	aag	aca	ggc	cgg	gac	1728
Gln	Phe	Gly	Val	Val	Tyr	Gly	Gly	Lys	His	Arg	Lys	Thr	Gly	Arg	Asp	
			565					570					575			
gtg	gca	gtt	aag	gtc	att	gac	aaa	ctg	cgc	ttc	cct	acc	aag	cag	gag	1776
Val	Ala	Val	Lys	Val	Ile	Asp	Lys	Leu	Arg	Phe	Pro	Thr	Lys	Gln	Glu	
			580					585					590			

agc cag ctc cgg aat gaa gtg gcc att ctg cag agc ctg cgg cat ccc 1824  
 Ser Gln Leu Arg Asn Glu Val Ala Ile Leu Gln Ser Leu Arg His Pro  
 595 600 605

ggg atc gtg aac ctg gag tgc atg ttc gag acg cct gag aaa gtg ttt 1872  
 Gly Ile Val Asn Leu Glu Cys Met Phe Glu Thr Pro Glu Lys Val Phe  
 610 615 620

gtg gtg atg gag aag ctg cat ggg gac atg ttg gag atg atc ctg tcc 1920  
 Val Val Met Glu Lys Leu His Gly Asp Met Leu Glu Met Ile Leu Ser  
 625 630 635 640

agt gag aag ggc cgg ctg cct gag cgc ctc acc aag ttc ctc atc acc 1968  
 Ser Glu Lys Gly Arg Leu Pro Glu Arg Leu Thr Lys Phe Leu Ile Thr  
 645 650 655

cag att tct gct ttc tgg gct ctt gcc tgc ccc aca cct aag ccc tgt 2016  
 Gln Ile Ser Ala Phe Trp Ala Leu Ala Cys Pro Thr Pro Lys Pro Cys  
 660 665 670

gct aag ccc ttt acc tcc tga 2037  
 Ala Lys Pro Phe Thr Ser \*  
 675

<210> 14  
 <211> 678  
 <212> PRT  
 <213> Homo sapiens

<400> 14  
 Met Ala Thr Ala Pro Ser Tyr Pro Ala Gly Leu Pro Gly Ser Pro Gly  
 1 5 10 15  
 Pro Gly Ser Pro Pro Pro Gly Gly Leu Glu Leu Gln Ser Pro Pro  
 20 25 30  
 Pro Leu Leu Pro Gln Ile Pro Ala Pro Gly Ser Gly Val Ser Phe His  
 35 40 45  
 Ile Gln Ile Gly Leu Thr Arg Glu Phe Val Leu Leu Pro Ala Ala Ser  
 50 55 60  
 Glu Leu Ala His Val Lys Gln Leu Ala Cys Ser Ile Val Asp Gln Lys  
 65 70 75 80  
 Phe Pro Glu Cys Gly Phe Tyr Gly Leu Tyr Asp Lys Ile Leu Leu Phe  
 85 90 95  
 Lys His Asp Pro Thr Ser Ala Asn Leu Leu Gln Leu Val Arg Ser Ser  
 100 105 110  
 Gly Asp Ile Gln Glu Gly Asp Leu Val Glu Val Val Leu Ser Ala Ser  
 115 120 125  
 Ala Thr Phe Glu Asp Phe Gln Ile Arg Pro His Ala Leu Thr Val His  
 130 135 140  
 Ser Tyr Arg Ala Pro Ala Phe Cys Asp His Cys Gly Glu Met Leu Phe  
 145 150 155 160  
 Gly Leu Val Arg Gln Gly Leu Lys Cys Asp Gly Cys Gly Leu Asn Tyr  
 165 170 175  
 His Lys Arg Cys Ala Phe Ser Ile Pro Asn Asn Cys Ser Gly Ala Arg  
 180 185 190  
 Lys Arg Arg Leu Ser Ser Thr Ser Leu Ala Ser Gly His Ser Val Arg  
 195 200 205  
 Leu Gly Thr Ser Glu Ser Leu Pro Cys Thr Ala Glu Glu Leu Ser Arg  
 210 215 220  
 Ser Thr Thr Glu Leu Leu Pro Arg Arg Pro Pro Ser Ser Ser Ser  
 225 230 235 240



Ser Ser Ala Ser Ser Tyr Thr Gly Arg Pro Ile Glu Leu Asp Lys Met  
 245 250 255  
 Leu Leu Ser Lys Val Lys Val Pro His Thr Phe Leu Ile His Ser Tyr  
 260 265 270  
 Thr Arg Pro Thr Val Cys Gln Ala Cys Lys Lys Leu Leu Lys Gly Leu  
 275 280 285  
 Phe Arg Gln Gly Leu Gln Cys Lys Asp Cys Lys Phe Asn Cys His Lys  
 290 295 300  
 Arg Cys Ala Thr Arg Val Pro Asn Asp Cys Leu Gly Glu Ala Leu Ile  
 305 310 315 320  
 Asn Gly Asp Val Pro Met Glu Glu Ala Thr Asp Phe Ser Glu Ala Asp  
 325 330 335  
 Lys Ser Ala Leu Met Asp Glu Ser Glu Asp Ser Gly Val Ile Pro Gly  
 340 345 350  
 Ser His Ser Glu Asn Ala Leu His Ala Ser Glu Glu Glu Glu Gly Glu  
 355 360 365  
 Gly Gly Lys Ala Gln Ser Ser Leu Gly Tyr Ile Pro Leu Met Arg Val  
 370 375 380  
 Val Gln Ser Val Arg His Thr Thr Arg Lys Ser Ser Thr Thr Leu Arg  
 385 390 395 400  
 Glu Gly Trp Val Val His Tyr Ser Asn Lys Asp Thr Leu Arg Lys Arg  
 405 410 415  
 His Tyr Trp Arg Leu Asp Cys Lys Cys Ile Thr Leu Phe Gln Asn Asn  
 420 425 430  
 Thr Thr Asn Arg Tyr Tyr Lys Glu Ile Pro Leu Ser Glu Ile Leu Thr  
 435 440 445  
 Val Glu Ser Ala Gln Asn Phe Ser Leu Val Pro Pro Gly Thr Asn Pro  
 450 455 460  
 His Cys Phe Glu Ile Val Thr Ala Asn Ala Thr Tyr Phe Val Gly Glu  
 465 470 475 480  
 Met Pro Gly Gly Thr Pro Gly Gly Pro Ser Gly Gln Gly Ala Glu Ala  
 485 490 495  
 Ala Arg Gly Trp Glu Thr Ala Ile Arg Gln Ala Leu Met Pro Val Ile  
 500 505 510  
 Leu Gln Asp Ala Pro Ser Ala Pro Gly His Ala Pro His Arg Gln Ala  
 515 520 525  
 Ser Leu Ser Ile Ser Val Ser Asn Ser Gln Ile Gln Glu Asn Val Asp  
 530 535 540  
 Ile Ala Thr Val Tyr Gln Ile Phe Pro Asp Glu Val Leu Gly Ser Gly  
 545 550 555 560  
 Gln Phe Gly Val Val Tyr Gly Gly Lys His Arg Lys Thr Gly Arg Asp  
 565 570 575  
 Val Ala Val Lys Val Ile Asp Lys Leu Arg Phe Pro Thr Lys Gln Glu  
 580 585 590  
 Ser Gln Leu Arg Asn Glu Val Ala Ile Leu Gln Ser Leu Arg His Pro  
 595 600 605  
 Gly Ile Val Asn Leu Glu Cys Met Phe Glu Thr Pro Glu Lys Val Phe  
 610 615 620  
 Val Val Met Glu Lys Leu His Gly Asp Met Leu Glu Met Ile Leu Ser  
 625 630 635 640  
 Ser Glu Lys Gly Arg Leu Pro Glu Arg Leu Thr Lys Phe Leu Ile Thr  
 645 650 655  
 Gln Ile Ser Ala Phe Trp Ala Leu Ala Cys Pro Thr Pro Lys Pro Cys  
 660 665 670  
 Ala Lys Pro Phe Thr Ser  
 675

&lt;210&gt; 15

&lt;211&gt; 28

&lt;212&gt; DNA

&lt;213&gt; Primer sequence 1

<400> 15  
 gaattccatg gagcccttga agagcctc 28  
  
 <210> 16  
 <211> 28  
 <212> DNA  
 <213> Primer sequence 2  
  
 <400> 16  
 ctcgagtcaa ggccccgctt ccggcacc 28  
  
 <210> 17  
 <211> 25  
 <212> DNA  
 <213> Homo sapiens  
  
 <400> 17  
 gtggagggcg aggaaactgg ggaag 25  
  
 <210> 18  
 <211> 30  
 <212> DNA  
 <213> Homo sapiens  
  
 <400> 18  
 ggatccatga actctagccc agctgggacc 30  
  
 <210> 19  
 <211> 30  
 <212> DNA  
 <213> Homo sapiens  
  
 <400> 19  
 gaattctagc aatccaagat gtcacatcc 30  
  
 <210> 20  
 <211> 30  
 <212> DNA  
 <213> Homo sapiens  
  
 <400> 20  
 ggatccatgg agctggaaaa catcgtggcc 30  
  
 <210> 21  
 <211> 28  
 <212> DNA  
 <213> Homo sapiens  
  
 <400> 21  
 gaattctagc tgcttccggt ggagttcg 28  
  
 <210> 22  
 <211> 28  
 <212> DNA  
 <213> Homo sapiens  
  
 <400> 22  
 gaattccatg tcagccgagg tgcggctg 28  
  
 <210> 23  
 <211> 28

<212> DNA  
 <213> Homo sapiens  
  
 <400> 23  
 gcggccgctc agggagcgcg ggcggctc 28  
  
 <210> 24  
 <211> 25  
 <212> DNA  
 <213> Homo sapiens  
  
 <400> 24  
 gtggagggcg aggaaactgg ggaag 25  
  
 <210> 25  
 <211> 31  
 <212> DNA  
 <213> Homo sapiens  
  
 <400> 25  
 ctcgagtcac ataatgagac agactccagt c 31  
  
 <210> 26  
 <211> 13  
 <212> PRT  
 <213> Homo sapiens  
  
 <400> 26  
 Lys Arg Arg Glu Ile Leu Ser Arg Arg Pro Ser Tyr Arg  
 1 5 10  
  
 <210> 27  
 <211> 15  
 <212> PRT  
 <213> Homo sapiens  
  
 <400> 27  
 Pro Leu Ala Arg Thr Leu Ser Val Ala Gly Leu Pro Gly Lys Lys .  
 1 5 10 15  
  
 <210> 28  
 <211> 10  
 <212> PRT  
 <213> Homo sapiens  
  
 <400> 28  
 Pro Leu Ser Arg Thr Leu Ser Val Ser Ser  
 1 5 10  
  
 <210> 29  
 <211> 30  
 <212> DNA  
 <213> Homo sapiens  
  
 <400> 29  
 gaattcaatg ggtcgaaagg aagaagatga 30  
  
 <210> 30  
 <211> 30

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 30

gaattcaatg ggtcgaaagg aagaagatga

30

&lt;210&gt; 31

&lt;211&gt; 30

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 31

ctcgagctgg atctggaggc tgactgatgg

30

&lt;210&gt; 32

&lt;211&gt; 11

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 32

Cys	Lys	Arg	Pro	Arg	Ala	Ala	Ser	Phe	Ala	Glu
1				5					10	

&lt;210&gt; 33

&lt;211&gt; 35

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 33

Lys	Thr	Phe	Cys	Gly	Thr	Pro	Glu	Tyr	Leu	Ala	Pro	Glu	Val	Arg	Arg
1			5					10					15		
Glu	Pro	Arg	Ile	Leu	Ser	Glu	Glu	Glu	Gln	Glu	Met	Phe	Arg	Asp	Phe
			20				25						30		
Asp	Tyr	Ile													
		35													

&lt;210&gt; 34

&lt;211&gt; 11

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 34

Cys	Lys	Arg	Pro	Arg	Ala	Ala	Ser	Phe	Ala	Glu
1				5					10	

&lt;210&gt; 35

&lt;211&gt; 35

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 35

Lys	Thr	Phe	Cys	Gly	Thr	Pro	Glu	Tyr	Leu	Ala	Pro	Glu	Val	Arg	Arg
1			5					10					15		
Glu	Pro	Arg	Ile	Leu	Ser	Glu	Glu	Glu	Gln	Glu	Met	Phe	Arg	Asp	Phe
			20				25						30		
Asp	Tyr	Ile													
		35													

<210> 36  
 <211> 11  
 <212> PRT  
 <213> Homo sapiens

<400> 36  
 Cys Lys Arg Pro Arg Ala Ala Ser Phe Ala Glu  
 1 5 10

<210> 37  
 <211> 10  
 <212> PRT  
 <213> Homo sapiens

<400> 37  
 Cys Gly Arg Thr Gly Arg Arg Asn Ser Ile  
 1 5 10

<210> 38  
 <211> 530  
 <212> PRT  
 <213> Homo sapiens

<400> 38  
 Met Ser Ala Glu Val Arg Leu Arg Arg Leu Gln Gln Leu Val Leu Asp  
 1 5 10 15  
 Pro Gly Phe Leu Gly Leu Glu Pro Leu Leu Asp Leu Leu Leu Gly Val  
 20 25 30  
 His Gln Glu Leu Gly Ala Ser Glu Leu Ala Gln Asp Lys Tyr Val Ala  
 35 40 45  
 Asp Phe Leu Gln Trp Ala Glu Pro Ile Val Val Arg Leu Lys Glu Val  
 50 55 60  
 Arg Leu Gln Arg Asp Asp Phe Glu Ile Leu Lys Val Ile Gly Arg Gly  
 65 70 75 80  
 Ala Phe Ser Glu Val Ala Val Val Lys Met Lys Gln Thr Gly Gln Val  
 85 90 95  
 Tyr Ala Met Lys Ile Met Asn Lys Trp Asp Met Leu Lys Arg Gly Glu  
 100 105 110  
 Val Ser Cys Phe Arg Glu Glu Arg Asp Val Leu Val Asn Gly Asp Arg  
 115 120 125  
 Arg Trp Ile Thr Gln Leu His Phe Ala Phe Gln Asp Glu Asn Tyr Leu  
 130 135 140  
 Tyr Leu Val Met Glu Tyr Tyr Val Gly Gly Asp Leu Leu Thr Leu Leu  
 145 150 155 160  
 Ser Lys Phe Gly Glu Arg Ile Pro Ala Glu Met Ala Arg Phe Tyr Leu  
 165 170 175  
 Ala Glu Ile Val Met Ala Ile Asp Ser Val His Arg Leu Gly Tyr Val  
 180 185 190  
 His Arg Asp Ile Lys Pro Asp Asn Ile Leu Leu Asp Arg Cys Gly His  
 195 200 205  
 Ile Arg Leu Ala Asp Phe Gly Ser Cys Leu Lys Leu Arg Ala Asp Gly  
 210 215 220  
 Thr Val Arg Ser Leu Val Ala Val Gly Thr Pro Asp Tyr Leu Ser Pro  
 225 230 235 240  
 Glu Ile Leu Gln Ala Val Gly Gly Gly Pro Gly Thr Gly Ser Tyr Gly  
 245 250 255  
 Pro Glu Cys Asp Trp Trp Ala Leu Gly Val Phe Ala Tyr Glu Met Phe  
 260 265 270  
 Tyr Gly Gln Thr Pro Phe Tyr Ala Asp Ser Thr Ala Glu Thr Tyr Gly  
 275 280 285

Lys Ile Val His Tyr Lys Glu His Leu Ser Leu Pro Leu Val Asp Glu  
 290 295 300  
 Gly Val Pro Glu Glu Ala Arg Asp Phe Ile Gln Arg Ser Leu Cys Pro  
 305 310 315 320  
 Pro Glu Thr Arg Leu Gly Arg Gly Gly Ala Gly Asp Phe Arg Thr His  
 325 330 335  
 Pro Phe Phe Phe Gly Leu Asp Trp Asp Gly Leu Arg Asp Ser Val Pro  
 340 345 350  
 Pro Phe Thr Pro Asp Phe Glu Gly Ala Thr Asp Thr Cys Asn Phe Asp  
 355 360 365  
 Leu Val Glu Asp Gly Leu Thr Ala Met Glu Thr Leu Ser Asp Ile Arg  
 370 375 380  
 Glu Gly Ala Pro Leu Gly Val His Leu Pro Phe Val Gly Tyr Ser Tyr  
 385 390 395 400  
 Ser Cys Met Ala Leu Arg Asp Ser Glu Val Pro Gly Pro Thr Pro Met  
 405 410 415  
 Glu Leu Glu Ala Glu Gln Leu Leu Glu Pro His Val Gln Ala Pro Ser  
 420 425 430  
 Leu Glu Pro Ser Val Ser Pro Gln Asp Glu Thr Ala Glu Val Ala Val  
 435 440 445  
 Pro Ala Ala Val Pro Ala Ala Glu Ala Glu Ala Glu Val Thr Leu Arg  
 450 455 460  
 Glu Leu Gln Glu Ala Leu Glu Glu Glu Val Leu Thr Arg Gln Ser Leu  
 465 470 475 480  
 Ser Arg Glu Met Glu Ala Ile Arg Thr Asp Asn Gln Asn Phe Ala Ser  
 485 490 495  
 Gln Leu Arg Glu Ala Glu Ala Arg Asn Arg Asp Leu Glu Ala His Val  
 500 505 510  
 Arg Gln Leu Gln Glu Arg Met Glu Leu Leu Gln Ala Glu Gly Ala Thr  
 515 520 525  
 Gly Pro  
 530

<210> 39  
 <211> 599  
 <212> PRT  
 <213> Homo sapiens

<400> 39  
 Met Ser Ala Glu Val Arg Leu Arg Arg Leu Gln Gln Leu Val Leu Asp  
 1 5 10 15  
 Pro Gly Phe Leu Gly Leu Glu Pro Leu Leu Asp Leu Leu Leu Gly Val  
 20 25 30  
 His Gln Glu Leu Gly Ala Ser Glu Leu Ala Gln Asp Lys Tyr Val Ala  
 35 40 45  
 Asp Phe Leu Gln Trp Ala Glu Pro Ile Val Val Arg Leu Lys Glu Val  
 50 55 60  
 Arg Leu Gln Arg Asp Asp Phe Glu Ile Leu Lys Val Ile Gly Arg Gly  
 65 70 75 80  
 Ala Phe Ser Glu Val Ala Val Val Lys Met Lys Gln Thr Gly Gln Val  
 85 90 95  
 Tyr Ala Met Lys Ile Met Asn Lys Trp Asp Met Leu Lys Arg Gly Glu  
 100 105 110  
 Val Ser Cys Phe Arg Glu Glu Arg Asp Val Leu Val Asn Gly Asp Arg  
 115 120 125  
 Arg Trp Ile Thr Gln Leu His Phe Ala Phe Gln Asp Glu Asn Tyr Leu  
 130 135 140  
 Tyr Leu Val Met Glu Tyr Tyr Val Gly Gly Asp Leu Leu Thr Leu Leu  
 145 150 155 160  
 Ser Lys Phe Gly Glu Arg Ile Pro Ala Glu Met Ala Arg Phe Tyr Leu  
 165 170 175

Ala Glu Ile Val Met Ala Ile Asp Ser Val His Arg Leu Gly Tyr Val  
 180 185 190  
 His Arg Asp Ile Lys Pro Asp Asn Ile Leu Leu Asp Arg Cys Gly His  
 195 200 205  
 Ile Arg Leu Ala Asp Phe Gly Ser Cys Leu Lys Leu Arg Ala Asp Gly  
 210 215 220  
 Thr Val Arg Ser Leu Val Ala Val Gly Thr Pro Asp Tyr Leu Ser Pro  
 225 230 235 240  
 Glu Ile Leu Gln Ala Val Gly Gly Gly Pro Gly Thr Gly Ser Tyr Gly  
 245 250 255  
 Pro Glu Cys Asp Trp Trp Ala Leu Gly Val Phe Ala Tyr Glu Met Phe  
 260 265 270  
 Tyr Gly Gln Thr Pro Phe Tyr Ala Asp Ser Thr Ala Glu Thr Tyr Gly  
 275 280 285  
 Lys Ile Val His Tyr Lys Glu His Leu Ser Leu Pro Leu Val Asp Glu  
 290 295 300  
 Gly Val Pro Glu Glu Ala Arg Asp Phe Ile Gln Arg Leu Leu Cys Pro  
 305 310 315 320  
 Pro Glu Thr Arg Leu Gly Arg Gly Gly Ala Gly Asp Phe Arg Thr His  
 325 330 335  
 Pro Phe Phe Phe Gly Leu Asp Trp Asp Gly Leu Arg Asp Ser Val Pro  
 340 345 350  
 Pro Phe Thr Pro Asp Phe Glu Gly Ala Thr Asp Thr Cys Asn Phe Asp  
 355 360 365  
 Leu Val Glu Asp Gly Leu Thr Ala Met Val Ser Gly Gly Glu Thr  
 370 375 380  
 Leu Ser Asp Ile Arg Glu Gly Ala Pro Leu Gly Val His Leu Pro Phe  
 385 390 395 400  
 Val Gly Tyr Ser Tyr Ser Cys Met Ala Leu Arg Asp Ser Glu Val Pro  
 405 410 415  
 Gly Pro Thr Pro Met Glu Val Glu Ala Glu Gln Leu Leu Glu Pro His  
 420 425 430  
 Val Gln Ala Pro Ser Leu Glu Pro Ser Val Ser Pro Gln Asp Glu Thr  
 435 440 445  
 Ala Glu Val Ala Val Pro Ala Ala Val Pro Ala Ala Glu Ala Glu Ala  
 450 455 460  
 Glu Val Thr Leu Arg Glu Leu Gln Glu Ala Leu Glu Glu Glu Val Leu  
 465 470 475 480  
 Thr Arg Gln Ser Leu Ser Arg Glu Met Glu Ala Ile Arg Thr Asp Asn  
 485 490 495  
 Gln Asn Phe Ala Ser Gln Leu Arg Glu Ala Glu Ala Arg Asn Arg Asp  
 500 505 510  
 Leu Glu Ala His Val Arg Gln Leu Gln Glu Arg Met Glu Leu Leu Gln  
 515 520 525  
 Ala Glu Gly Ala Thr Ala Val Thr Gly Val Pro Ser Pro Arg Ala Thr  
 530 535 540  
 Asp Pro Pro Ser His Val Pro Arg Pro Gly Leu Ser Glu Ala Leu Ser  
 545 550 555 560  
 Leu Leu Leu Phe Ala Val Val Leu Ser Arg Ala Ala Ala Leu Gly Cys  
 565 570 575  
 Ile Gly Leu Val Ala His Ala Gly Gln Leu Thr Ala Val Trp Arg Arg  
 580 585 590  
 Pro Gly Ala Ala Arg Ala Pro  
 595

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(10) International Publication Number  
**WO 02/024947 A3**

(43) International Publication Date  
28 March 2002 (28.03.2002)

PCT

(51) International Patent Classification<sup>7</sup>: **C12Q 1/68**,  
G01N 33/574, A61P 35/00, A61K 31/70, G01N 33/50

Allen, D. [CA/CA]; 1633 West 65th Avenue, Vancouver,  
British Columbia V6P 2R2 (CA).

(21) International Application Number: PCT/IB01/02237

(74) Agents: **ROBINSON, Christopher, J.** et al.; FETHER-  
STONHAUGH & CO, Suite 2200, 650 West Georgia  
Street, Box 11560, Vancouver, British Columbia V6B 4N8  
(CA).

(22) International Filing Date:  
20 September 2001 (20.09.2001)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

60/233,999	20 September 2000 (20.09.2000)	US
60/237,423	2 October 2000 (02.10.2000)	US
60/237,419	2 October 2000 (02.10.2000)	US
60/238,558	4 October 2000 (04.10.2000)	US
60/290,555	10 May 2001 (10.05.2001)	US

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,  
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,  
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,  
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,  
MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI,  
SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU,  
ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian  
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European  
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,  
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,  
CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD,  
TG).

Published:  
— with international search report

(88) Date of publication of the international search report:  
4 December 2003

(71) Applicants (*for all designated States except US*):  
**KINETEK PHARMACEUTICALS, INC.** [CA/CA];  
1200 West 73rd Avenue, Suite 850, Vancouver, British  
Columbia V6P 6G5 (CA). **THE UNIVERSITY OF**  
**BRITISH COLUMBIA** [CA/CA]; The UBC Univer-  
sity-Industry Liaison Office, IRC Room 331, 2194 Health  
Sciences Mail, Vancouver, British Columbia V6T 1Z3  
(CA).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **YOGANATHAN,**  
**Thillainathan** [CA/CA]; 7111 Lynnwood Drive - 5,  
Richmond, British Columbia V7C 5S9 (CA). **DELANEY,**

For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.

WO 02/024947 A3

(54) Title: CANCER ASSOCIATED PROTEIN KINASES AND THEIR USES

(57) Abstract: Detection of expression of the provided protein kinase in cancers is useful as a diagnostic, for determining the effectiveness of drugs, and determining patient prognosis. The encoded polypeptides further provides a target for screening pharmaceutical agents effective in inhibiting the growth or metastasis of tumor cells.



## INTERNATIONAL SEARCH REPORT

In Application No  
PCT/IB 01/02237

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C12Q1/68 G01N33/574 A61P35/00 A61K31/70 G01N33/50

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 G01N C12Q C12N A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, MEDLINE, EMBASE, SCISEARCH, CHEM ABS Data, SEQUENCE SEARCH, BIOSIS, EMBL

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 99 65928 A (SHANKARA SRINIVAS ;GENZYME CORP (US); ROBERTS BRUCE L (US)) 23 December 1999 (1999-12-23) page 100, line 33; claims 1,9-11	1-16
X	ING Y L ET AL: "MLK-3: IDENTIFICATION OF A WIDELY-EXPRESSED PROTEIN KINASE BEARING AN SH3 DOMAIN AND A LEUCINE ZIPPER-BASIC REGION DOMAIN" ONCOGENE, BASINGSTOKE, HANTS, GB, vol. 9, no. 6, June 1994 (1994-06), pages 1745-1750, XP001087926 ISSN: 0950-9232 cited in the application MLK-3 = SEQ ID NO:1	16



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

## \* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "8" document member of the same patent family

Date of the actual completion of the international search

18 February 2003

Date of mailing of the international search report

05. 03. 2003

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Gabriels, J

# INTERNATIONAL SEARCH REPORT

Int. Application No  
PCT/IB 01/02237

C (Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		Relevant to claim No.
Category *	Citation of document, with indication, where appropriate, of the relevant passages	
A	WO 99 53036 A (SUGEN INC ;WHYTE DAVID (US); PLOWMAN GREGORY (US); MARTINEZ RICARD) 21 October 1999 (1999-10-21) page 134, line 25 -page 137, line 19; claims 23,24	1-15
A	--- GIOELI DANIEL ET AL: "Activation of mitogen-activated protein kinase associated with prostate cancer progression." CANCER RESEARCH, vol. 59, no. 2, 15 January 1999 (1999-01-15), pages 279-284, XP002222312 ISSN: 0008-5472 page 280 -page 281	1-15
A	--- SIVARAMAN V S ET AL: "HYPEREXPRESSION OF MITOGEN-ACTIVATED PROTEIN KINASE IN HUMEN BREASTCANCER" JOURNAL OF CLINICAL INVESTIGATION, NEW YORK, NY, US, vol. 99, 1 April 1997 (1997-04-01), pages 1478-1483, XP002070096 ISSN: 0021-9738 figures 1,2	1-15
X	--- DATABASE EMBL 'Online! EBI; 21 April 1999 (1999-04-21) RHODES S: retrieved from EMBL, accession no. HS272L161 Database accession no. AL049688 XP002231579 a part of SEQ ID NO:3 is identical to AL049688 (99,9%) and the protein sequence encoded by AL049688 (Q9Y3J7) is identical to SEQ ID NO:4 of the present application. abstract	16
X	--- WO 00 35946 A (UNIV DUNDEE ;COHEN PHILIP (GB); DEAK MARIA (GB); KOBAYASHI TAKAYAS) 22 June 2000 (2000-06-22) SGK2-alpha (SEQ 7 from Patent W00035946) = SEQ ID NO:5 claims 25-33	1-16
	--- -/--	

Form PCT/ISA/210 (continuation of second sheet) (July 1992)

# INTERNATIONAL SEARCH REPORT

Int. Application No  
PCT/IB 01/02237

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		Relevant to claim No.
Category *	Citation of document, with indication, where appropriate, of the relevant passages	
P, X	WO 00 73469 A (PLOWMAN GREGORY D ;SUGEN INC (US); WHYTE DAVID (US); MARTINEZ RICA) 7 December 2000 (2000-12-07) SEQ ID NO:118 from Patent W00073469 = SEQ ID NO:5 (also describes SEQ ID NO:6 = protein) SEQ ID NO: 130 from Patent W00073469 = is part of in SEQ ID NO: 14 claims 1,33 example 3	1-16
P, X	WO 01 44497 A (UNIV DUNDEE ;ALESSI DARIO (GB); BIONDI RICARDO (GB)) 21 June 2001 (2001-06-21) SGK2 (fig 16) = 317 AA of SEQ ID NO:6 claim 1	1
X	KUNAPULI PRIYA ET AL: "Cloning and expression of GRK5: A member of the G protein-coupled receptor kinase family." PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES, vol. 90, no. 12, 1993, pages 5588-5592, XP002231578 1993 ISSN: 0027-8424 SEQ ID NO 7 = GRK5 SEQ ID NO 8 = GRK5 protein figure 2	16
X	WO 98 53050 A (BEN SASSON SHMUEL A ;YISSUM RES DEV CO (IL); CHILDRENS MEDICAL CEN) 26 November 1998 (1998-11-26) SEQ ID NO 7 = GRK5 SEQ ID NO 8 = GRK5 protein figure 3C	1-16
X	WO 00 18895 A (YISSUM RES DEV CO ;CHILDRENS MEDICAL CENTER (US)) 6 April 2000 (2000-04-06) SEQ ID NO:21 from Patent W09316196 (alpha D peptide) is a part of SEQ ID NO:8 of the present application. claims 61-67	1
X	WO 93 16196 A (KORNELUK ROBERT G ;MAHADEVAN MANI S (CA)) 19 August 1993 (1993-08-19) AAQ53993 (EMBL) = SEQ ID NO:9 AAR38860 (EMBL) = SEQ ID NO:10 (isoform SEQ ID NO:39) page 41 -page 47	16

Form PCT/ISA/210 (continuation of second sheet) (July 1992)

## INTERNATIONAL SEARCH REPORT

Inte Application No

PCT/IB 01/02237

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
E	WO 01 81555 A (INCYTE GENOMICS INC) 1 November 2001 (2001-11-01) SEQ ID NO:23 from WO0181555 = SEQ ID NO:11 (99,9%) SEQ ID NO:5 from WO0181555 = SEQ ID NO:12 claims 1,5 ----	1-16
E	WO 02 22795 A (PE CORP NY) 21 March 2002 (2002-03-21) AAD36021 (EMBL) from WO0222795 = SEQ ID NO:11 (99,9%) SEQ ID NO:2 from WO0222795 = SEQ ID NO:12 claims 1,4 -----	1-16

Form PCT/ISA/210 (continuation of second sheet) (July 1992)

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/IB 01/02237

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
  
2. ☒ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:  
see FURTHER INFORMATION sheet PCT/ISA/210
  
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. ☒ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
  
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
  
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
  
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☒ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Present claim 9 relates to a method using compounds defined by reference to a desirable characteristic or property, namely being an inhibitor of kinase activity.

The claim covers all compounds having this characteristic or property, whereas the application provides support within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT for only a very limited number of such compounds. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Independent of the above reasoning, the claims also lack clarity (Article 6 PCT). An attempt is made to define the product compound by reference to a result as to render a meaningful search over the whole of the claimed scope impossible. Consequently, the search has been carried out for those compounds which appear to be clear, supported and disclosed, namely those parts relating to antisense sequences of SEQ ID NO:1,3,5,7,9,11, and 13 as inhibitor of kinase activity.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

Invention 1: claims 1-16 (all partially)

An isolated nucleic acid comprising the sequence of SEQ ID NO:1 and methods using this sequence or the polypeptide encoded thereby (SEQ ID NO:2) for screening for anticancer agents, diagnosing cancer, and inhibiting the growth of a cancer cell.

Invention 2: claims 1-16 (all partially)

An isolated nucleic acid comprising the sequence of SEQ ID NO:3 and methods using this sequence or the polypeptide encoded thereby (SEQ ID NO:4) for screening for anticancer agents, diagnosing cancer, and inhibiting the growth of a cancer cell.

Invention 3: claims 1-16 (all partially)

An isolated nucleic acid comprising the sequence of SEQ ID NO:5 and methods using this sequence or the polypeptide encoded thereby (SEQ ID NO:6) for screening for anticancer agents, diagnosing cancer, and inhibiting the growth of a cancer cell.

Invention 4: claims 1-16 (all partially)

An isolated nucleic acid comprising the sequence of SEQ ID NO:7 and methods using this sequence or the polypeptide encoded thereby (SEQ ID NO:8) for screening for anticancer agents, diagnosing cancer, and inhibiting the growth of a cancer cell.

Invention 5: claims 1-16 (all partially)

An isolated nucleic acid comprising the sequence of SEQ ID NO:9 and methods using this sequence or the polypeptide encoded thereby (SEQ ID NO:10) or its isoforms (SEQ ID NO:38 and 39) for screening for anticancer agents, diagnosing cancer, and inhibiting the growth of a cancer cell.

Invention 6: claims 1-16 (all partially)

An isolated nucleic acid comprising the sequence of SEQ ID NO:11 and methods using this sequence or the polypeptide encoded thereby (SEQ ID NO:12) for screening for anticancer agents, diagnosing cancer, and inhibiting the growth of a cancer cell.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Invention 7: claims 1-16 (all partially)  
An isolated nucleic acid comprising the sequence of SEQ ID NO:13 and methods using this sequence or the polypeptide encoded thereby (SEQ ID NO:14) for screening for anticancer agents, diagnosing cancer, and inhibiting the growth of a cancer cell.



# INTERNATIONAL SEARCH REPORT

Information on patent family members

Inter al Application No

PCT/IB 01/02237

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9965928	A	23-12-1999	AU 4824199 A AU 4825699 A AU 5204499 A CA 2335452 A1 EP 1086215 A2 JP 2002534056 T WO 9965928 A2 WO 9965924 A2 WO 9966303 A2	05-01-2000 05-01-2000 05-01-2000 23-12-1999 28-03-2001 15-10-2002 23-12-1999 23-12-1999 23-12-1999
WO 9953036	A	21-10-1999	AU 3642499 A EP 1073723 A2 JP 2002522009 T WO 9953036 A2	01-11-1999 07-02-2001 23-07-2002 21-10-1999
WO 0035946	A	22-06-2000	EP 1141003 A1 WO 0035946 A1 JP 2002533063 T	10-10-2001 22-06-2000 08-10-2002
WO 0073469	A	07-12-2000	AU 5173400 A EP 1180151 A2 JP 2003501038 T WO 0073469 A2	18-12-2000 20-02-2002 14-01-2003 07-12-2000
WO 0144497	A	21-06-2001	AU 2187301 A EP 1234188 A2 WO 0144497 A2	25-06-2001 28-08-2002 21-06-2001
WO 9853050	A	26-11-1998	US 6174993 B1 AU 734642 B2 AU 7583398 A CN 1257538 T EP 0983346 A2 JP 2002500649 T US 2003004103 A1 WO 9853050 A2 US 2002028772 A1 US 2002049301 A1	16-01-2001 21-06-2001 11-12-1998 21-06-2000 08-03-2000 08-01-2002 02-01-2003 26-11-1998 07-03-2002 25-04-2002
WO 0018895	A	06-04-2000	AU 6059099 A CA 2343934 A1 CN 1319133 T EP 1115847 A1 JP 2002525382 T US 2002165150 A1 US 2002160478 A1 WO 0018895 A1	17-04-2000 06-04-2000 24-10-2001 18-07-2001 13-08-2002 07-11-2002 31-10-2002 06-04-2000
WO 9316196	A	19-08-1993	AU 3489393 A CA 2129823 A1 WO 9316196 A2 DE 69313829 D1 EP 0627011 A1	03-09-1993 19-08-1993 19-08-1993 16-10-1997 07-12-1994
WO 0181555	A	27-06-2002	AU 5557301 A WO 0181555 A3 US 2002026226 A1	07-11-2001 27-06-2002 28-02-2002

## INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/IB 01/02237

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 0222795	A	21-03-2002	US 6372468 B1	16-04-2002
			AU 9087201 A	26-03-2002
			WO 0222795 A2	21-03-2002
			US 2002132324 A1	19-09-2002
			US 2002055160 A1	09-05-2002
-----				

Form PCT/ISA/210 (patent family annex) (July 1992)